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ABSTRACT
cis-Diamminedichloroplatinum(II) (CDDP) is a chemotherapeutic agent 
widely used in the treatment of various types of cancer. Its mechanism of cytotoxicity is 
unclear although it is believed that DNA is the critical target. CDDP binds to DNA 
forming a variety of adducts including intrastrand adducts, interstrand adducts, 
monofunctional adducts and DNA-protein crosslinks. This thesis presents evidence that 
there are protein(s) present in mammalian cells which recognise CDDP-damaged DNA,
To assay for these DNA damage recognition proteins (DDRPs) conditions for 
two very separate assays were developed. The gel mobility shift assay, which detects 
protein complexes under non-denaturing conditions, identified two retardation complexes 
which bound to CDDP damaged DNA in human, murine and feline tumour cell extracts. 
Binding of these complexes is shown to CDDP treated oligonucleotide of 54 base
pairs but not to a CDDP treated oligonucleotide of 27 base pairs, therefore suggesting 
binding is dependent on having normal DNA duplex.
The other system used in the detection of the DDRPs is the South-Western 
assay. This allowed the detection of proteins of sizes 25, 50, 100KD binding to CDDP 
treated DNA. The proteins in the South-Western system are run under denaturing 
conditions. It is not entirely clear as to whether the proteins detected in both systems are 
the same or whether they represent entirely different species.
CDDP has been reported to bind to DNA and cause areas of single­
strandedness around the adducts. The results presented in this thesis demonstrate that the 
50KD and 100KD DDRP which bind to CDDP treated double-stranded DNA may also 
have an affinity for single-stranded DNA. The 25KD DDRP, however, only recognises 
double-stranded DNA treated with CDDP suggesting that it is recognising the CDDP 
adducts and not the areas of single-strandedness generated around the adducts.
Resistance to CDDP proves a major problem area in treatment regimes. 
Many cell lines resistant to CDDP have been derived in vitro by multiple exposures to 
the drug. Many mechanisms of resistance to CDDP have been suggested from these 
lines. If a role of the DDRPs was to process damage in the DNA then cell lines resistant 
to CDDP may show an increase in expression of the DDRPs. This thesis presents 
evidence that an ovarian tumour cell line resistant to CDDP in comparison to its parental 
line shows an increase in the binding to the 50KD and 100KD DDRPs.
Work in chapter 5 presents the isolation of CDDP resistant cell lines, by 
acute exposure to the drug, with an increase of up to seven fold resistance levels. 
Evidence is presented for the resistant clones being of a mutational origin. Resistant 
variants occur at a frequency of 3.2x10'° per viable cell. This frequency can be 
increased to 3.4xl0-  ^by treatment of the cells with the chemical mutagen ethyl methane 
sulphonate, EMS. The CDDP resistant phenotype is maintained after six months growth 
in drug free medium. This single step selection may provide clones which are more 
clinically relevant than the lines isolated by multiple exposures to CDDP. They may 
therefore provide a superior model for the study of drug resistance mechanisms to CDDP. 
However examination of the DDRPs showed no detectable difference in the resistant 
clones derived from the A2780 human ovarian tumour cell line.
The thesis therefore presents evidence of the existence of DDRPs in 
mammalian cells. The role of these damage recognition proteins will be discussed.
CHAPTER 1
GENERAL INTRODUCTION
l
1.1 DISCOVERY OF CISPLATIN
Chemotherapy has proved curative for some types of advanced cancers and 
useful in compliment with surgery and radiotherapy in others. Unfortunately, many 
cancers still do not respond to chemotherapy, and other cancers that initially do respond 
later become resistant The question of how tumours become resistant to these drugs is 
obviously of major importance. One of the major sets of drugs in the clinic to-day, is the 
platinum coordination complexes which have proved successful in the treatment of 
ovarian, testicular, bladder, head and neck cancers (Loehrer and Einhom, 1984). 
However cellular resistance to these drugs has been suggested as a reason for platinum 
based treatment failure.
The antitumour activity of the platinum complexes was discovered as a result 
of a fortuitous observation by Rosenberg during the study of effects of electric current on 
growing bacteria (Rosenberg et al, 1965). When alternating current was delivered 
through platinum electrodes to a growing culture of Eschericia coli, the E.coli cells 
stopped dividing and grew into long filaments. It was found that a compound was 
formed from the platinum electrodes during electrolysis which inhibited cell division - 
cisP^IIXNHg^C^. This product is now more commonly known as cis- 
diamminedichloroplatinum(II) or cisplatin (CDDP). The stereochemistry of these 
compounds was found to be important for inhibiting cell division since Rosenberg 
deduced that the corresponding trans isomers of those compounds did not inhibit cell 
division but acted only as a bacteriocide (Rosenberg, 1965).
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1.2 HISTORY OF CISDIAMMINEDICHLOROPLATINUM (II) (Cisplatin)
AS AN ANTITUMOUR AGENT
After the initial discovery by Rosenberg in 1965, of the inhibition of bacterial 
cell division by the platinum compounds, interest was stimulated concerning whether 
these compounds can inhibit cell division in other mammalian cells. Two years later, 
Rosenberg demonstrated that platinum coordination compounds cis- 
diamminedichloroplatinum(II) and cis-diamminedichloroplatinum (TV), have potent 
antitumour activity against Sarcoma 180 and leukemia L1210, whereas the trans 
geometrical isomer of these compounds are ineffective (Rosenberg et al, 1969, 1970). 
The importance of steric conformation is therefore highlighted by the fact that the trans 
isomer has virtually no antitumour activity. Other groups showed that these compounds 
were also effective against a virus-induced reticulum cell sarcoma in mice (Talley, 1970), 
the Dunning ascitic leukemia, Walker 256 carcinoma (Kociba, 1970) and a dimethyl 
benzanthracene induced mammary carcinoma (Welsh, 1971). In 1972, the CDDP 
compound was released for clinical trials and generally referred to as the antitumour drug 
cisplatin, abbreviated throughout this thesis as CDDP. Seven years later, FDA approval 
of the drug was passed and to date it has proved to be one of the most successful drugs in 
the treatment of testicular, ovarian, bladder and head and neck carcinomas (Loehrer and 
Einhom, 1984).
1.3 CHEMICAL STRUCTURE OF CDDP
CDDP, is a neutral square planar coordination complex (Figure 1.1).
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Figure 1.1 Chemical structure of CDDP
Cl
Pt Reactive groups
\
h 3n  Cl
It has two reactive chloride groups and two relatively inert ammine, groups. At 
extracellular chloride concentrations, the chloride groups are stable. However the 
intracellular concentration of chloride is lower and once CDDP enters the cell, the two 
chloride groups are exchanged for hydroxyl groups. This exchange leads to a 
bifunctional charged electrophile which can react with nucleophilic sites in the cell e.g. 
DNA, RNA, proteins etc.
extensive evidence in the literature implicating DNA as the critical target for cytotoxicity 
(Pinto and Lippard, 1985), although it should be borne in mind that much of the evidence 
in mammalian cells is circumstantial. The initial observation, of CDDP induced 
filamentous growth, was the first indication of interaction with DNA (Rosenberg, 1965).
E.coli (Reslova 1971). Normally, release of phage DNA to synthesise new DNA is a rare 
event. However upon treatment with low concentrations of CDDP, induction of the lytic 
cycle was found. There was found to be a correlation between the antitumour activity of 
the platinum compounds and their ability to induce lysogenic E.coli to enter the lytic
1.4 DNA AS THE CRITICAL TARGET
It is not entirely clear as to how CDDP is cytotoxic in cells, although there is
Further evidence came from the induction of growth of phage from lysogenic strains of
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cycle. Most of the proposed mechanisms of CDDP induced cytotoxicity involve DNA 
and the following section will introduce each of these.
1.5 MECHANISMS OF CYTOTOXICITY
Various different hypotheses have been suggested as to how CDDP kills the 
cell, these include:
(1) inhibition of DNA synthesis
(2 ) apoptosis
(3) inability to repair specific adducts
(4) mutagenesis
1.5.1 Inhibition of DNA synthesis
There have been many studies since the discovery of CDDP to suggest 
inhibition of DNA synthesis as the pathway for its cytotoxicity. Studies in human AV3  
cells in culture (Harder & Rosenberg, 1970) and Ehlrich cells in vivo (Howie & Gale, 
1970) have demonstrated that CDDP inhibits DNA replication. It has generally been
shown that concentrations at which DNA synthesis is inhibited does not affect either
RNA or protein synthesis (Roberts & Thomson, 1979). It has however been reported that 
superlethal concentrations of CDDP were required before inhibition of DNA synthesis 
was observed (Salles et al, 1983). In this report however, DNA synthesis was only 
measured during 90 minutes after incubation. Reports have previously demonstrated 
progressive slowing of DNA synthesis over several days (Sorenson and Eastman, 1988). 
It has been suggested that DNA synthesis may be inhibited for two main reasons :
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(1) direct inhibition of the polymerases - DNA polymerases have been 
shown to be stopped in vitro by CDDP intrastrand cross-links (Pinto and Lippard, 1985).
(2) synchronization in a phase of the cell cycle in which DNA 
synthesis would not be anticipated - cells have been reported to arrest in G2  upon 
treatment with CDDP, (Sorenson and Eastman, 1988).
1.5.2 Apoptosis
Since the discovery of the G2  arrest, Eastman has presented several 
hypotheses to try to explain this. It was first suggested that the G2  arrest allowed the 
cells time for post replication repair. However gaps in newly synthesised daughter 
strands were unable to be detected (Sorenson and Eastman, 1988). It was then suggested 
that G2  arrest may be due to the inability to produce transcripts needed for mitosis. This 
was then disproved by studying cell lines deficient and proficient in DNA repair, the 
repair proficient cells being expected to circumvent this arrest. They demonstrated that 
in both cell lines the G2  arrest occurred, however in the repair proficient cells a higher 
concentration of CDDP was required before arrest was observed. It is therefore 
presumably the number of adducts present in the DNA that is important.
In the yeast system it has been demonstrated that G2  arrest caused by 
radiation is controlled by RAD9 (Weinert and Hartwell, 1988). Cells deficient in RAD9 
fail to arrest in G2 ; they continue to cycle and then die. Therefore there may be a similar 
system in mammalian systems that prevent the passage of cells into mitosis. The events 
occurring in the G2  arrest are similar to those which occur in programmed cell death - 
apoptosis.
Apoptosis (first defined by Kerr et al 1972) is a phenomenon which is 
morphologically defined by cell shrinkage and especially in epithelial cells, loss of cell to
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cell contact. Double strand breaks are a characteristic of the cell about to undergo 
apoptosis. The cells show a specific pattern of chromatin condensation, giving a dense 
mass close to the nuclear margin (Arrends, 1990). The next stage is the development of 
apoptotic bodies which express new cell surface markers. These are recognised by 
phagocytes and engulfed so that the cell dies without inflicting damage on its nearest 
neighbours. Protein synthesis is required for apoptosis. Apoptosis occurs during 
embryonic development, metamorphosis, differentiation and general cell turnover.
Many of the anticancer agents including CDDP appear to activate apoptosis 
(for review of biochemical and morphological evidence see Eastman, 1990). Many 
unanswered questions on apoptosis may lead to the understanding of toxicity in 
anticancer drugs
(1) what causes G2  arrest in mammalian cells, and is there a 
mammalian homolog to RAD9?
(2 ) how do cells overcome G2  arrest either to survive or die?
(3) what factors discriminate normal from abnormal mitosis?
(4) activation of endonuclease, how and where?
(5) what is the role of endonuclease in normal cell regulation and 
death?
(6 ) how do so many agents activate the same pathway?
1.5.3 CDDP-DNA adducts and the cells ability to repair them
Approximately 1% of the total cellular platinum binds to DNA, inducing 
various types of inter and intra-strand crosslinks (Eastman, 1988). Over the past decade 
the interaction of CDDP with DNA has been studied by a variety of techniques :
7
(1) Alkaline elution (Kohn and Grimek-Ewig, 1973)
(2) DNA renaturation (Eastman, 1982)
(3) DNA sedimentation (Roberts and Pascoe, 1972)
(4) Digestion of platinated DNA to nucleotides and analysis by HPLC 
fractionation (Fichtinger-Schepman, 1982)
(5) Antibodies to specific adducts (Fichtinger-Schepman et al, 1987;
Poirer et al, 1982)
The first three methods however depend upon the capacity of CDDP to form 
either DNA interstrand cross-links or DNA protein cross-links - which have been shown 
to represent less than 1% of platinated DNA (Eastman 1982). All the above techniques 
have subsequently shown that CDDP can form a variety of adducts (Figure 1.2)
Monofunctional
Intrastrand cross-links including 1,2 d(GpG), 1,2 d(ApG), 1,3 
d(GpG)
Interstrand cross-links 
DNA-protein cross-links
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Figure 1.2
M O N O F U N C T I O N A L I N T R A S T R A N D
I N T E R S T R A N D I N T E R M O L E C U L A R
This figure is adapted from Eastman, (1990)
These major adducts have been reported in treatment of DNA in vitro 
(Eastman, 1986), and in DNA of CDDP exposed bacteria (Fichtinger-Schepman et al, 
1986), CHO cells (Plooy et al, 1985a) and human white blood cells (Fichtinger- 
Schepman et al, 1987).
The majority of cross-links formed have been found to be DNA-intrastrand 
crosslinks with 65% of these cross-links between two neighbouring guanine bases at the 
N7 atom 1,2 d(GpG), 25% cross-linking neighbouring adenine and guanine bases 1,2 
d(ApG) and the remaining cross-linking two guanine bases separated by one or more 
bases 1,3 d(GpG). The formation of cross-links at the guanine bases suggests this is a 
site of favoured reaction on the DNA for the CDDP. A small percentage of cross-links 
(less than 1%) are present in the interstrand formation and also as DNA-protein cross­
links.
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In the initial reports on the measurement of adducts, DNA interstrand 
crosslinks were suggested to be the cytotoxic lesion of CDDP. This stems from work 
when only DNA interstrand cross-links were the measurable adducts and so were found 
to correlate with cytotoxicity. There was the general hypothesis that cytotoxicity could 
be due to the persistence of a specific cross-link which was not repaired by the cell. 
Some reports have shown the persistence of the interstrand cross-links (Erickson et al, 
1981; Plooy et al, 1985^). Conflicting reports in other cell lines have shown that a 
defective repair of inter-strand crosslinks is not due to the cytotoxicity of CDDP 
(Rawlings & Roberts, 1986). Even if a correlation did exist between the persistence of 
interstrand cross-links and CDDP, it must be kept in mind that less than 1% of the cross­
links are of the interstrand formation in vivo (Plooy et al, 1984). Thus although the 
number of interstrand cross-links might be proportional to the decrease in cell survival, 
large numbers of other types of adducts are being ignored which may also exhibit the 
same relationship and ultimately be the cause of platinum induced cytotoxicity.
It is now believed that the major intrastrand adduct, the 1,2 d(GG) adduct is 
the cytotoxic lesion of CDDP. Studies have demonstrated that testicular cell lines which 
were five fold more sensitive to CDDP in comparison to bladder lines were deficient in 
the repair of 1,2 d(AG) and 1,2 d(GG) intrastrand cross-links (Bedford et al, 1988). A 
study by Bohr and co-workers demonstrated that inter-strand crosslinks were removed 
more efficiently in specific gene regions than intra-strand adducts (Jones et al, 1991). 
This therefore suggests that the intra-strand adducts, which have shown to be the major 
CDDP adduct, may be the persistent lesion which causes cytotoxicity.
To measure adduct levels in vivo, antibodies have been raised to the CDDP 
adducts by two different groups (Fichtinger-Schepman et al, 1987; Poirer et al, 1982). 
This has allowed the measurement of adduct levels in white blood cells of patients who 
have been treated with CDDP. There is however great debate going on between the two 
groups due to discrepancies occurring when both their assays are directly compared
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(Fichtinger-Schepman et al, 1989; Reed et al, 1990). To measure the adducts Poirer and
co-workers have used a polyclonal rabbit antiserum raised against calf thymus DNA
modified with CDDP (Poirer et al, 1982) whilst Fichtinger-Schepman has used
polyclonal antibodies raised against CDDP containing dinucleotides, as haptens coupled
to proteins (Fichtinger-Schepman et al, 1985). The antiserum raised by Poirer has been
reported to show a high specificity for poly(dG).poly(dC) therefore it recognises the
major adducts (Lippard et al, 1983) formed at the guanine nucleotides. The antibodies
raised by Fichtinger-Schepman have been shown to be specific for platinum attached to
guanine nucleotides. Both sets of antibodies therefore recognise the major CDDP
of
adducts. Comparing both groups^antibodies, Fichtinger-Schepman detect 14-300 fold 
higher adduct levels in identical human blood samples to Poirer (Fichtinger-Schepman, 
1989). It has been suggested that the antibodies recognise different epitopes. Whatever 
the reasoning for the disagreement over the detection of adducts by the antibodies they 
will prove of major importance in the detection of the in vivo adduct forming the 
important lesion.
It is necessary at this point to make a distinction between two not necessarily 
related phenomena: cytotoxicity and antitumour activity. Cytotoxicity is a non-selective 
process of killing whereas when discussing antitumour effects of drugs, the idea of 
selectivity to tumour cells is introduced. Unlike the cis isomer CDDP, the trans isomer 
transplatin (TDDP) has been demonstrated to exhibit cytotoxicity but no antitumour 
activity. Both CDDP and TDDP bind to DNA therefore the differences between the 
CDDP exhibiting antitumour activity and the TDDP, may be related to the differences 
between the two isomers' reactions with the DNA. The following explanations can be 
put forward for the differences in both cytotoxicity and antitumour activity between the 
two:
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(1) TDDP has been shown to form a majority of DNA-protein cross­
links unlike CDDP, where DNA protein cross-links are present in a minority of the 
population. The comparison between the two, may argue against the DNA-protein cross­
links being the important antitumour lesion. This evidence is by no means definitive as 
both CDDP and TDDP may cross-link to different proteins and this could be related to 
both the cytotoxicity and antitumour activity.
(2) CDDP but not TDDP forms intrastrand cross-links between 
neighbouring bases on a single strand. TDDP being in the trans configuration can only 
form cross-links between guanine bases separated by one or more bases 1,3 d(GpG). 
Therefore the cytotoxicity and the antitumour activity may be related to the major 1,2 
d(GpG) adduct observed.
(3) It has been reported that adducts formed by CDDP accumulate in 
the cell over a period of 48 hours whereas those formed by TDDP accumulate for the first 
six hours and then decreased presumably by repair mechanisms. It has therefore been 
suggested that a specific adduct namely the 1,2 d(GpG) adduct formed only by CDDP are 
not efficiently recognised or repaired and hence remain to kill the cell (Ciccarelli et al,
1985).
The above lists three possibilities on the basis of differences between CDDP 
and TDDP for the cytotoxicity and antitumour activity of CDDP. It is however, at this 
stage not definite, as to which, if any, of the DNA adducts are either the cytotoxic lesion, 
antitumour lesion or both, although the general opinion is that the 1,2 d(GpG) adduct is 
the important cytotoxic lesion.
12
1.5.4 Mutagenesis
CDDP has been reported to be mutagenic in E.coli ( Brouwer et al, 1983), 
and Salmonella typhimurium (Leopold et al, 1981) and carcinogenic in mouse and rat 
(Leopold et al, 1979; Leopold et al, 1981). It may therefore induce mutations that lead to 
lethal effects in the cell.
In bacteria it has been shown that chemical mutagenesis requires the 
involvement of an inducible cellular system leading to increased mutation rates. This 
type of system has been described as SOS processing or error prone repair (review, Little 
and Mount 1982; Walker, 1984). SOS repair generally involves the activation of a 
protease, Rec A, which cleaves a repressor Lex A which normally acts to inhibit the 
function of different genes. On the proteolytic cleavage of Lex A, the products of the 
SOS target genes are expressed at much higher levels and the secondary functions of the 
SOS pathway are expressed, e.g
Prophage induction
Enhanced DNA repair capacity, both excision repair and post­
replication repair 
Filamentous growth 
Enhanced mutagenesis
A signal must activate the Rec A before the SOS processing can occur: 
signals include DNA damage and inhibition of replication.
The contribution of the different CDDP adducts to the mutagenic potency is 
unknown. Studies in E.coli have demonstrated 5'Gs in GAG and GCG sequences to be 
hotspots for base substitution by CDDP (Brouwer et al, 1981). Base substitution has 
been suggested to be SOS-dependent. Mutants in Rec A (Rec A') do not show base
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substitutions (Brouwer et al, 1981). Studies in E.coli also demonstrated the requirement 
for the SOS pathway for the full mutagenic effects of CDDP (Bumouf et al, 1987). 
Evidence is emerging from the mammalian system to suggest that inducible pathways are 
involved in how the cell responds to DNA damage. Studies in cells exposed to 
carcinogens or tumour promoters suggest an inducible pathway is present in mammalian 
cells (Elespuru, 1987).
The suggestion of the GCG and GAG being hot-spots for mutations 
occurring by CDDP treatment of E.coli has been questioned by Bumouf and co-workers, 
1987. Using an assay which is not limited to the detection of nonsense mutations they 
have shown most mutagenic lesions in E.coli occurs at the ApG sites, giving 
predominantly A.T - T.A transversions. They also demonstrated that the GpG site is also 
prone to mutagenesis (Bumouf et al, 1987). Using this forward mutation assay, it is 
however not possible to determine the effects of individual adducts in the mutagenesis 
events. This is now beginning to be overcome by the transfection of vectors containing 
synthetic oligodeoxyribonucleotides with defined adducts into cells. Bumouf and co­
workers have used such a system to examine the mutagenic effects of the d(ApG) site 
(Bumouf et al, 1990). They have described these sites as exhibiting a high mutation 
specificity. These sites have previously been reported to be potential sites for CDDP 
adducts (Eastman, 1986). Studies in Saccharomyces Cerevisiae have shown the 5'GG 
and 5’GA sequences to be hot-spots for mutation (Mis and Kunz, 1990) and other studies 
in the aprt gene of CHO cells have demonstrated mutations to occur at or near to the 
5'AGG and 5'GAG sequences (Boer and Glickman, 1989). Evidence in the literature has 
therefore implicated the major intra-strand crosslink as a pre-mutagenic lesion.
The introduction so far has discussed how CDDP was first discovered and the 
way in which it is thought to kill cells. The following section of the introduction will 
focus on how tumour cells become resistant to CDDP. The following chapters in the
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thesis will attempt to investigate how tumour cells may become resistant to CDDP in 
vitro. It is therefore apt at this point to introduce the phenomenon of drug resistance and 
the studies to date of reported mechanisms of resistance to CDDP.
1.6 RESISTANCE OF TUMOURS TO CHEMOTHERAPEUTIC DRUGS
Although chemotherapy has proved successful in the treatment of various 
forms of cancer, resistance of the tumours to the drug is still a main cause of treatment 
failure. The phenomenon of resistance was encountered in the first documented case of 
cancer chemotherapy (Gilman, 1963).
Resistance has been viewed as either temporary or permanent. Temporary 
resistance can be explained by a variety of factors. If a tumour mass is large, only a 
certain fraction will be killed leaving the remaining tumour cells behind to divide and 
grow again. It may also show resistance due to cell kinetics. If cells in the tumour are 
slow growing then it may not respond as well to drugs acting on dividing cells as will a 
fast growing tumour. Permanent resistance however, will occur even before a tumour 
cell population is subjected to chemotherapeutic drugs. Goldie and Coldman 
hypothesised that the best explanation for treatment failure in the clinic is that drug 
resistant mutants exist or are induced in the tumour cell population (Goldie and Coldman, 
1984). This model is based upon the principles of the Luria-Delbruck fluctuation 
analysis (Luria and Delbruck, 1943), refer to chapter 6 , section 6.1 for further 
introduction. Resistance is therefore the topic of study for many groups for two main 
reasons :
( 1) in an attempt to prevent resistant cells occurring
(2 ) if resistance occurs, the understanding of the mechanisms leading 
to this resistance may allow the development of treatments to circumvent these.
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Goldie and Coldman proposed that at the time of detection of a large tumour 
mass, there is a high probability of resistant cells being present. In terms of treatment of 
the tumour, this leads to the question of how to circumvent resistance in these cells. 
Successful circumvention of resistance has been reported experimentally in cells which 
are resistant to multiple drugs. These cells are referred to as exhibiting pleiotropic drug 
resistance or expressing the MDR phenotype and are found to contain an increase in a 
protein known as P-glycoprotein. This protein has been reported to be a membrane 
protein which actively pumps drug out of the cell (Kartner and Ling, 1989). The 
resistance phenotype described here can be overcome by the calcium channel blocker 
verapamil (Tsuro et al, 1981). For CDDP however, the mechanisms of resistance are 
only beginning to unfold and rational approaches to circumventing resistance are still in 
their early stages, although it has been demonstrated that resistance to CDDP is not 
mediated by increased P-glycoprotein expression.
1.7 MODELS FOR STUDY OF RESISTANCE MECHANISMS
Cell culture model systems have been useful in allowing an understanding of 
the mechanisms of resistance to various drugs, although there limitations must be bore in 
mind. Cell culture model systems, unlike in vivo studies are maniputable and factors 
within them can be controlled. Many studies on mechanisms of resistance to various 
drugs have been carried out in this type of cell model system. Cells can be made resistant 
to a drug by exposing them to increasing concentrations of drug over a period of months, 
even years. After each exposure, the cells exhibiting a resistance to the drug are selected 
for. Upon each increasing concentration of drug, cells with an increased resistant 
phenotype will be selected for. Many resistant cell lines have been isolated in this way 
(e.g Behrens et al, 1987). The disadvantage of studying mechanisms of resistance in cell
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lines isolated in this way, is that cells present are bound to show different mechanisms of 
resistance because they have been isolated in multiple steps.
Cell lines resistant to drugs have also been isolated by a single exposure of 
the cell line to a predetermined concentration of drug which has been shown to give only 
one or two surviving mutants. Cell lines isolated in this way are more likely to exhibit a 
single mechanism of resistance and are less likely to show as great a resistance as those 
cell lines isolated by multiple exposures. These cell lines should make the unravelling of 
mechanisms of resistance to certain drugs much easier (for review see Thomson & Baker, 
1973), (refer to chapter 6 , section 6.1 for further information).
The key question is, which of the mechanisms of resistance characterised in 
these in vitro models contribute to the drug resistance that emerges in patients during the 
treatment of tumours in patients.
1.8 SUGGESTED MECHANISM OF RESISTANCE TO CDDP
The mechanism(s) by which a tumour becomes resistant to the treatment of 
CDDP is a vigorously ongoing area of research. Most of the following suggested 
mechanisms have been characterised in cell lines derived from tumours which have been 
selected for resistance to CDDP by stepwise increasing exposure to the drug. The 
following list presents suggested mechanisms of resistance to CDDP reported in the 
literature from in vitro studies.
(1) Accumulation Decreased CDDP accumulation has been 
reported in several cell lines resistant to CDDP (Andrews and Howell, 1990). It is 
however not entirely clear whether this is due to a decreased influx or increased efflux. 
Increased expression in a membrane protein of size 200KD has been observed in a 
murine lymphoma cell line resistant to CDDP, (Kawai et al, 1990). This is different
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from the multi-drug resistance associated P-glycoprotein with a molecular weight of 
approximately 170KD.
(2) Glutathione The reactive electrophilic CDDP species
will readily react with nucleophilic sites, such as GSH. Suggested mechanisms of 
resistance to CDDP include inactivation of the drug by glutathione (GSH). Many studies 
have demonstrated increased levels of GSH in CDDP resistant cell lines, although little 
correlation has been found between GSH levels and CDDP cytotoxicity (for review, 
Andrews and Howell, 1990). Elevated levels of GSH have been observed as part of the 
resistant phenotype, only when cells were selected for CDDP resistance by continuous 
exposure to CDDP in vitro. There is no clear evidence as to whether the increased levels 
of GSH are involved in CDDP resistance or whether they are part of a general stress 
response to CDDP.
(3) Metal loth ioneins Metallothioneins, like the GSHs,
may act as a nucleophile towards CDDP. The metallothioneins comprise of a family of 
proteins involved in Zn++ homeostasis and are also involved in the detoxification of 
other heavy metals. Metallothioneins have been shown to act as a sink and soak up any 
incoming CDDP. Studies have shown elevation of metallothioneins in some CDDP 
resistant cell lines (Kelley et al, 1988). These cell lines have been made resistant to 
CDDP in vitro by exposing to high concentrations of CDDP for long periods of time. It 
is not entirely clear whether metallothioneins are important in clinical specimens. The 
involvement of metallothioneins at this point in time is controversial.
(4) Signal transduction pathways Patient studies and cultured 
cell line studies have suggested amplification of oncogenes such as c-fos and c-Ha-ras 
occurs in CDDP resistance (for review, Scanlon et al, 1989a). There is however
18
considerable genetic variability among patients and cultured cell lines therefore it may be 
argued that increased expression of a gene may not be responsible for the CDDP 
resistance phenotype. Transfection studies where transfection of a single oncogene e.g 
ras, in cell lines have demonstrated that the ras oncogenes may be important in the CDDP 
resistant phenotype. Transfection of NIH3T3 with H-ras, activated by a mis sense 
mutation are 4-8 fold more resistant to CDDP than the control NIH3T3 lines (Sklar, 
1988). More detailed studies are required to define the role, if any, of the oncogenes in 
CDDP resistance.
abundant supply of deoxythymidylate for the synthesis of DNA, (refer to Figure 1.3). 
The enzymes producing this have therefore become a choice target in cancer 
chemotherapy by drugs such as methotrexate, 5-flourouracil.
Figure 1.3 Synthesis of deoxythymidylate
(5) Folate metabolism Rapidly dividing cells require an
'Thymidylate
Thymidine
Kinase
►TTP DNA synthesis 
DNA repair
FOLATE METABOLISM dUMP
Methyl group donated from 
10-methylenetetrahydrofolate 
pool CH2 FH4
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dUMP = deoxyuridine monophosphate 
dTMP = deoxythymidine monophosphate 
T IP  = thymidine triphosphate
Reports have suggested that the initial response of cells to CDDP is to 
enhance the 10-methylenetetrahydrofolate pool (Scanlon et al, 1986). CDDP resistant 
A2780 cells have shown a 2.5 fold increase in thymidine kinase, thymidylate synthase 
and dihydrofolate reductase activities (Scanlon et al, 1989^). Other reports have reported 
increases in other cell lines. The stimulated folate metabolism may be one of the first 
changes to occur during development of resistance, since it is detected in cells with low 
level CDDP resistance.
(6 ) DNA repair DNA has been reported to be the critical target in 
the mechanism of cytotoxicity of CDDP. On reaction of CDDP with DNA, both in vitro 
and in vivo, various adducts have been reported. Indirect evidence has shown that CDDP 
resistance in human cell cultures is associated with enhanced DNA repair (Ozols et al, 
1988; Lai et al, 1988; Eastman, 1988). Evidence in the literature for enhanced DNA 
repair in the CDDP resistance phenotype will be presented in greater detail in the next 
sections of this introduction as it may play an important role in the results of this thesis.
The list presented above is by no means exhaustive, with evidence for new 
mechanisms being added continually. It has not been presented in any order of 
importance. As to date there is no evidence to support any of the above as the main 
mechanism of resistance to CDDP.
The next section of the introduction will present evidence for DNA repair 
being important in CDDP resistance and an introduction to the DNA repair pathway(s) 
which may be involved.
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1.9 INVOLVEMENT OF DNA REPAIR IN CDDP RESISTANCE
A role of increased DNA repair capacity as a mechanism of CDDP resistance 
has been reported throughout the literature (for review, Andrews and Howell, 1990). In 
these studies DNA repair has been measured by different systems ;
(1) unscheduled DNA synthesis - this is a measure of the stimulation 
of DNA repair in vivo after exposure of cells to chemicals or drugs such as CDDP 
(Bianchi et al, 1982).
(2 ) repair synthesis - this in vitro assay system measures the 
incorporation of radio-labelled nucleotides into damaged DNA (Wood et al, 1988^
(3) CAT reactivation - involves transfection of a CDDP damaged 
plasmid containing the CAT gene into cells. The expression of CAT enzymatic activity 
in transfected cells is then used as a measure of repair of the CDDP adducts in the gene 
(Chu and Chang, 1991).
(4) measure of DNA repair enzymes - levels of mRNA enzymes 
thought to be important in DNA repair and DNA replicative synthesis are measured 
(Scanlon et al, 1989).
(5) adduct removal - use of systems to measure adducts investigates 
the removal rates of adducts in different cell lines (Plooy et al, 1985^, Dijt et al, 1988).
With these various methods listed above there are advantages and 
disadvantages to each. In summary the in vivo assays tend to be less manipulatable an 
the in vitro assays. They do however, represent the cell as a whole and therefore unlike 
the in vitro assays, will have all constituents necessary for repair processes which may be 
rate limiting in the in vitro systems.
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In the in vivo assays, the analysis of DNA repair by 
directly exposing cells to CDDP may be affected by not only damaging the DNA, but 
also damaging the cellular repair machinery itself. The in vitro systems, such as the 
repair synthesis and CAT reactivation assays, will allow the measure of DNA repair 
without effects from other damaged systems. DNA in vivo is normally in the form of 
chromatin, however in the in vitro assay systems the DNA is introduced as a "naked" 
form. This may affect the cellular repair machinery if the chromatin structure proves to 
be important It has been reported that the initial formation and repair processes are 
heterogeneous in different areas of the genome, (Bohr et al, 1987). Studies on the 
formation and repair of CDDP adducts have measured adducts only over the entire 
genome. Bohr has reported, however that the DNA intrastrand is preferentially repaired 
in transcribed regions of the gene (Jones et al, 1991). Among these assays there are 
various advantages and disadvantages to each and therefore it will probably take the 
uniting of results from the various assays to draw conclusions on the importance of DNA 
repair in CDDP resistance.
The table shown below, Table 1.1, provides a summary of evidence in 
different cell lines for enhanced DNA repair as a mechanism of resistance.
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Table 1.1 Summary of evidence for DNA repair as a mechanism 
of CDDP resistance
CELL LINE TUMOUR TYPE
A2780 human ovarian
carcinoma
PE04 human ovarian
carcinoma
L 1 2 1 0 /  mouse leukemia
DDP5
P388 mouse leukemia
HCT8 human colon
carcinoma
ROT6 8  rat ovarian
/C l carcinoma
Hela human
UDS = unscheduled DNA synthesis
(1 ) Ozols et al, 1988
(2 ) Lai et al, 1988
(3) Eastman and Schulte, 1988
(4) Sheibani et al, 1989
(5) Kraker and Moore, 1987
(6 ) Kraker and Moore, 1988
(7) Scanlon et al, 1989^
(8 ) Scanlon et al, 1989a
(9) Chao et al, 1990
FOLD RES EVIDENCE FOR REF
ENHANCED DNA 
REPAIR
20 UDS, repair (1,2)
synthesis
3 repair (2)
synthesis
50 CAT (3,4)
reactivation, 
adduct removal
47 UDS, DNA polp (5,6)
4.3 DNA pola and p (7)
mRNA activity
20 UDS (8 )
15-20 CAT (9)
reactivation
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Evidence in Table 1.1 suggests that levels of enhanced DNA repair may be 
an important factor in the CDDP resistant phenotype in the human ovarian carcinoma cell 
line A2780 (Lai et al, 1988, Ozols et al, 1988). Studies on the L1210 mouse leukemia 
cells and human Hela cells have shown enhanced DNA repair in the CDDP resistant 
phenotype by reactivation of a damaged plasmid DNA more readily in the CDDP 
resistant subline in comparison to the sensitive parental cell line (Sheibani et al, 1989, 
Chao et al, 1991^). There has also been evidence presented from this cell line that the 
GG intrastrand cross-link, which is the predominant lesion, is removed more rapidly in 
resistant cells than in the sensitive parental cell lines (Eastman and Schulte , 1988).
Several polymerases have been shown to be involved in the gap filling step in 
the excision repair pathway of E.coli (review, Van Houten, 1990). If mammalian 
systems follow a similar excision pathway, mammalian polymerases may also be 
involved. There at least five mammalian DNA polymerases, (review, Linn, 1991). Pol a  
and 5 are mainly involved in DNA replication, but may also play a role in DNA repair. 
Pol y is specific for mitochondria and is involved in mitochondrial DNA replication. Pol 
(3 has been implicated to be involved in DNA repair only. Evidence from the P388 
leukemia cell line resistant to CDDP have shown polymerase a  and p activities to be 
increased in comparison to the sensitive parental cell line. This line has also shown an 
increase in unscheduled DNA synthesis (Kraker and Moore, 1987, Kraker and Moore, 
1988). Scanlon and co-workers observed an overexpression in mRNA levels of DNA 
polymerase a  and polymerase p in a human colon carcinoma cell line HCT8  and A2780 
cells (Scanlon et al, 1989^). Many workers have tried to modulate the DNA repair 
pathways in an attempt to modulate resistance to CDDP. Many studies have focused on 
the inhibition of polymerases by aphidicolin . Aphidicolin. is an inhibitor of DNA 
polymerase a  (for further discussion on aphidicolin refer to chapter 6 ). Treatment of 
A2780 cells resistant to CDDP has shown to increase the cytotoxicity of this cell line to
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CDDP (Masuda et al, 1988). As another means of modulation Scanlon and co-workers 
have targeted the biochemical events which they thought may occur in their CDDP 
resistant cell lines. The CDDP resistant cell lines they used were shown to have an 
increase in mRNA levels of dihydrofolate reductase, thymidine kinase, thymidine 5'- 
monophosphate which are believed to be involved in DNA repair and DNA replicative 
synthesis. Deoxyribonucleotides which are essential for DNA repair were therefore 
targeted in an attempt to increase the cytotoxicity of CDDP in these CDDP resistant cell 
lines, (Scanlon et al, 1989^).
Evidence therefore exists in the literature suggesting DNA repair as a
mechanism of resistance to CDDP. Work is progressing in the modulation of CDDP
resistance and pathways of DNA repair are being targeted. DNA repair can be classified 
into three major classes. The following section will introduce each, followed by 
evidence suggesting that CDDP adducts are repaired by the different pathways.
1.10 CLASSES OF DNA REPAIR PATHWAYS
DNA repair falls classically into three major classes :
(1) Direct repair
(2) Recombinational repair
(3) Excision repair
1.10.1 Direct Repair
Direct repair involves reversal of covalent modifications- it does not involve 
either removal or replacement of nucleotides. Examples of direct repair include O^- 
methylguanine DNA methyl transferase and photoreactivation mediated by DNA
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photolyase. Alkylating agents, of which methylating agents appear to be widespread 
environmental mutagens, act through covalent modification of the cellular genome to 
generate miscoding base derivatives and lesions that block DNA replication. These 
covalent modifications can be reversed by enzymes such as the O^-methylguanine DNA 
methyl transferase. This enzyme corrects O^-methylguanine, which can produce a 
miscoding of bases, by direct reversal of damage. This is accomplished by transfer of the 
methyl group to a cysteine residue in the repair enzyme itself, with an unmodified 
guanine simultaneously regenerated in the DNA sequence (for review, Lindahl and 
Sedgwick, 1988). The photoreactivation system, another example of direct DNA repair, 
has been extensively characterised in E.coli and two different strains of yeast, 
Saccharomyces cerevisiae and Streptomyces gresius. DNA photolyases repair 
pyrimidine dimers in DNA by breaking the cyclobutane ring joining the pyrimidines (for 
review, Sancar & Sancar, 1988).
1.10.2 Recombinational repair
Polymerases are involved in the elongation step of replication. If the 
polymerases when working their way along the DNA come in contact with certain 
nucleotide adducts e.g pyrimidine dimers, they will stop replicating and initiate again 
about 1 0 0 0  base pairs beyond the adduct, thus generating a single-stranded gap that 
contains a modified nucleotide on the opposing strand. In E.coli this discontinuity is 
filled in by a process involving recombination controlled by the Rec genes (Rupp et al, 
1971). Rec A protein fills in the gap by transfer of the complementary strand ffom the 
sister duplex (Cox and Lehman, 1987).
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1.10.3 Excision repair
The best characterised systems of DNA repair involve pathways of excision 
repair. It can be classified into two types - the excision of incorrect nucleotides from 
DNA by hydrolysis of the N-glycosylic bond between the deoxyribose and the base by a 
DNA glycosylase (Lindahl, 1974), Figure 1.4, or the removal of damaged bases as a 
short oligonucleotide sequence with the resulting gap being patched by repair synthesis, 
Figure 1.5, for further detail refer to section 1.12.
1.11 EVIDENCE FOR REMOVAL OF CDDP ADDUCTS BY DIFFERENT
PATHWAYS OF REPAIR
Beck and co-workers demonstrated that the recombination-repair deficient 
E.coli mutant rec A13 and the double mutant uvrA6  lexl (mutation in excision repair 
pathway as well as recombination pathway) are very sensitive to CDDP (Beck and 
Brubaker, 1973). This suggests recombinational repair may be involved in the removal 
of CDDP adducts. The Rec A protein has been reported to be inducible by CDDP (Salles 
et al, 1982). This therefore suggests that an SOS type of response may be increasing cell 
survival by inducing a recombinational type of repair of the CDDP adducts. Interruption 
of replication or damage to the DNA generates an induction signal, which activates the 
constitutive level of rec A which in turn promotes cleavage of lex A and the generation of 
the secondary SOS responses. As a consequence the products of the SOS target genes 
are expressed at much higher levels. A number of the target genes are involved in either
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Figure 1.4 Removal of incorrect bases
5 '
Glycosylase- hydrolysis of N-glycosylic bond
Removal of uracil base - AP endonuclease
©
T
OH
Polymerase and ligase
Figure 1.5 A hypothetical model of nucleotide excision repair. The main steps are 
depicted : formation of uvrA2 B complex, damage recognition, incision, repair synthesis. 
Hydrolysis of ATP is shown where it is thought to occur. The diagram is adapted from a 
figure from Van Houten, 1990.
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excision or recombinational repair. The SOS response is therefore the E.coli's way to 
deal with conditions that damage or inhibit DNA replication.
Another repair pathway, which occurs at the replication fork is known as 
mismatch repair. Evidence exists to suggest that mutants in E.coli which are defective in 
mismatch repair show a 2-15 fold increase in sensitivity to CDDP compared to wild-type 
(Fram et al, 1985). This demonstrates that mismatch repair is important in CDDP 
induced DNA damage.
Nucleotide excision repair is one of the best characterised repair pathways in 
E.coli. Many studies on CDDP cytotoxicity have focused on this particular pathway. The 
following section presented will therefore report on evidence in the literature implicating 
nucleotide excision repair to be involved in CDDP cytotoxicity.
1.11.2 EVIDENCE FOR EXCISION REPAIR IN REMOVAL OF CDDP
ADDUCTS
Evidence exists to suggest that CDDP adducts are removed by the nucleotide 
excision repair pathway in E.coli. Mutants of E.coli which are blocked in excision repair 
are extremely sensitive to CDDP. This same study also reported that plasmid DNA 
damaged with CDDP but not TDDP is a substrate for the uvrABC excinuclease (Beck et 
al, 1985). Popoff has reported that upon transformation of various DNA repair proficient 
and deficient strains of E.coli with CDDP and TDDP damaged DNA, that excision repair 
plays an important role in the removal of CDDP adducts (Popoff et al, 1987).
Evidence is now beginning to emerge that nucleotide excision repair is 
important in the repair of CDDP adducts in mammalian systems. A system which was 
first defined by Wood and Lindahl in 1988 to measure the ability of excision repair by 
human cell extracts, was used by Hansson to measure the removal of CDDP adducts, 
(Hansson and Wood, 1989). It was shown that nucleotide patches were introduced into
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plasmid DNA damaged with CDDP when incubated with soluble human cell extracts, in 
an ATP dependent reaction. This suggests that CDDP adducts in mammalian cells are 
removed by a pathway similar to that in E.coli. Further evidence from mammalian 
systems comes from studies on cell lines derived from XP patients and from CHO 
mutants. Cell lines derived from XP patients are normally deficient in the incision step 
of the excision repair pathway. They are extremely sensitive to UV and also show 
hypersensitivity to CDDP therefore suggesting that both types of adducts may be repaired 
by the same pathway.
It is therefore of interest to study the pathway of excision repair in the 
removal of CDDP adducts, as this may be involved in the cytotoxicity of CDDP. The 
excision repair pathway has been well characterised in the E.coli system therefore the 
following section will give an introduction to this system as a lead into excision repair in 
mammalian cells.
1.12 NUCLEOTIDE EXCISION REPAIR IN E.COU
Nucleotide excision repair involves the removal of a damaged DNA adduct 
in a short oligonucleotide sequence and the resynthesis and religation of this patch within 
the duplex DNA. Nucleotide excision repair has been well studied in E.coli therefore a 
review of steps involved will be presented.
Studies in E.coli have isolated at least six proteins involved in this pathway; 
uvr A, uvr B, uvr C, uvr D, polymerase I and DNA ligase. Seeberg and co-workers in 
1976, initiated the research into characterisation and partial purification of the proteins by 
complementation assays with cell extracts from uvr mutants (Seeberg, 1976). By 1981 
the gene products of uvr A, uvrB and uvrC were partially purified and shown to interact to
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produce strand cleavage at pyrimidine dimers, base adducts and interstrand cross-links in 
DNA (Seeberg, 1978, Seeberg, 1981).
Since these observations and the partial purification of the different subunits, 
several groups have gone on to clone each of the uvr genes. To date the uvr genes have 
now been cloned and sequenced, and detailed studies of the properties of the uvr proteins 
are described in the literature (for review, Van Houten, 1990). Due to the cloning of the 
uvr proteins in vectors designed for overexpression, large amounts can be purified to 
homogeneity therefore leading to a hypothetical description of the pathway for the 
removal of damage by nucleotide excision repair (Figure 1.5). There are five major 
steps described;
Damage recognition
Formation of the preincision complex
Incision of the phosphate backbone
Excision, repair synthesis and release of the post­
incision complex
DNA ligation
1.12.1 Damage recognition, formation of preincision complex & incision
In the presence of ATP two molecules of uvrA form a dimer, A2  (refer to 
Figure 1.5). This dimer then interacts with uvrB forming a complex, uvr A2 B. The uvr 
A2 B complex binds to DNA non-specifically and since it has been demonstrated to have
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an ATP-dependent helicase activity, is believed to move along the DNA scanning for 
any changes in conformation of the DNA (Grossman and Yeung, 1990). If the uvr A2 B 
complex encounters a damaged site, the helicase activity is inhibited and the uvr A 
protein dissociates from the complex, leaving uvr B behind at the site of damage. The 
uvr A protein is therefore in this model acting as a shuttle for uvr B to find DNA. Once 
the uvr A2 B is bound, the uvr A dissociates and therefore is likely to become available to 
participate in another loading of uvr B to a damaged site. The uvr B at the site of damage 
has been proposed to allow complexing of uvr C and this complex is then suggested to 
yield an active endonuclease that introduces two cuts in the damaged strand (Orren & 
Sancar, 1989).
1.12.2 Excision, repair synthesis and release of postincision complex
uvr D (helicase II) and polymerase I then becomes involved, presumably by 
allowing the post-incision complex to convert back to the proteins required for 
recognising new damage and refilling in the sequence of nucleotides removed around the 
DNA damage (Caron et al, 1985). It has normally been found that, in the majority of 
repair patches, DNA polymerase appears to fill the excised region with nucleotides. 
Although other polymerases have been shown to perform the gap-filling step and allow 
turn-over of the complex, only pol I will add sufficient nucleotides that the patch is 
repairable with DNA ligase.
1.12.3 Steps at which ATP are required
In Figure 1.5, it can be seen that the model shows, that in various steps, 
hydrolysis of ATP is required. At which points it is required in the pathways has not 
been fully established. Using nucleotide analogues it has been demonstrated that it is
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absolutely necessary for incision to occur (Caron and Grossman, 1988a). ATP has been 
shown to cause an increase in the binding affinity of the uvr A protein to damaged DNA 
(Oh et al, 1989). Formation of the uvr A2 B complex results in a decrease in the uvr A 
ATPase and a stimulation of the uvrB complex which will only hydrolyse ATP. ATP is 
required for the unwinding activity of the uvr A2 B complex of DNA (Oh et al, 1989). 
Maintenance of the DNA in the unwound state does not seem to rely on the presence of 
ATP (Caron & Grossman, 1988^).
1.12.4 Damage recognised by the uvrABC excinuclease
The uvrABC excinuclease works on a large variety of DNA damage. It can
recognise
(1) DNA containing large chemical modifications
(2) Linked bases e.g CDDP guanine-guanine adducts (Popoff, 1987)
(3) Minor modifications e.g O^ alkylguanine (Voigt et al, 1989)
It has been shown however not to recognise mismatches (Thomas et al,
1986). The ability to recognise the above modifications described and not mismatches 
was suggested to be due to the substrates having a kinked DNA structure i.e a distortion 
in the DNA duplex. Many types of damage that are recognised by uvrABC excinuclease 
do cause a kink in the structure e.g CDDP has been reported to distort the DNA double 
helix 40^ towards the major groove (Rice et al, 1988). However some damage which 
does not cause kinks are recognised substrates of the uvrABC excinuclease e.g thymine 
glycols, apurinic sites and O^- methylguanine, (review, Van Houten, 1990).
The distortions that could be recognised by uvrABC can be split into at least 
six separate categories:
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(1) covalent modifications
(2) bulky adducts
(3) localized unwinding of the two DNA strands
(4) site specific bend or kink
(5) charge distribution around the site of damage
(6) any changes in structural dynamics of the DNA helix
In summary the nucleotide excision repair in E.coli is a well characterised 
pathway in which a large spectrum of damage is recognised and repaired by a complex of 
proteins. These proteins have been purified and cloned and the properties of these 
proteins is an intensive research area.
1.13 NUCLEOTIDE EXCISION REPAIR IN EUKARYOTIC MODEL
SYSTEMS
1.13.1 Studies in Saccharomyces Cerevisiae
The yeast system is an attractive model for the study of eukaryotic excision 
repair for three main reasons:
(1) low genome complexity
(2 ) can genetically manipulate the system with ease
(3 ) large numbers of repair mutants available for analysis
Many studies in mutant strains, abnormally sensitive to ultra-violet radiation 
and ionising radiation, have identified large numbers of genes involved in the repair of
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these lesions (for review, Friedberg, 1988). A systematic nomenclature for radiation 
sensitive mutants was established at the International Conference on Yeast Genetics held 
in Chalk River, Ontario in 1970. It was decided that mutants abnormally sensitive to 
killing by radiation should be designated as rad, with identifying locus and allele 
numbers. Locus numbers 1-49 refer to genes which primarily affect sensitivity to ultra­
violet radiation or to both UV and ionising radiation. Locus numbers greater than 50 
designate genes which primarily affect sensitivity to ionising radiation.
Studies on the relative sensitivity of single and double mutants to killing by 
DNA damaging agents have separated the yeast mutants into separate epistasis groups 
(Cox and Game, 1974). In cases where a double mutant is no more sensitive than a 
single mutant, the two genes in question are considered to be epistatic. On the other 
hand, genes are placed in different epistasis groups if double mutants show synergistic 
sensitivity compared to single mutants (Haynes and Kunz, 1981).
Approximately 30 mutant loci have been analysed for mutant effects and 
have been placed into three separate epistasis groups referred to as :
INVOLVEMENT
RAD 3 nucleotide excision repair
RAD 52 recombination repair
RAD 6 mutagenesis and post replication repair
The RAD 3 epistasis group therefore identifies the genes in Saccharomyces 
Cerevisiae involved in excision repair. The model for removal of damage has been 
suggested to be similar to that hypothesized in E.coli with proteins cloned which have
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homologous function to those in E.coli. Table 1.2 summarises the cloned genes of the 
RAD 3 epistasis group.
A high proportion of the predicted gene products harbour acidic regions that 
are thought to confer ability to bind chromatin, mediated by electrostatic interaction with 
basically charged histones. For a review of the genes involved in excision repair for 
Saccharomyces Cerevisiae refer to Friedberg, (1988).
1.13.2 Excision repair in mammals
In comparison to the E.coli system relatively little is known about nucleotide 
excision repair in eukaryotes. The previous section introduced the initiation of studies in 
the simplified eukaryotic system. Within mammals the study of the excision repair 
pathway has been carried out using two classes of excision repair defective cell lines :
(1) cell lines from patients suffering from Xeroderma Pigmentosum.
(2) Laboratory induced UV-sensitive rodent lines (mainly Chinese 
hamster ovary cell lines, CHO).
Xeroderma Pigmentosum is an autosomal recessive human repair disorder. 
This rare, cancer prone syndrome is clinically characterised by the extreme sensitivity of 
the skin to sunlight (UV) exposure, pigmentation abnormalities, predisposition to skin 
cancer, and frequently neurological degeneration (Cleaver and Kramer, 1989). The 
molecular defect in most XP patients occurs in the early steps of the excision-repair 
pathway - mainly defective in the incision step (Setlow et al, 1969, Hansson et al, 1990).
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Table 1.2 Summary of cloned genes of RAD3 epistasis group
GENE 
RAD 1
RAD 2 
RAD 3
RAD 4
RAD 7
RADIO
ERCC-3sc
HOMOLOGIES REMARKS 
TO HUMAN GENES
None
None
ERCC-2
Acidic carboxy 
terminus. May 
be involved in 
recombination.
Transcription 
inducible by UV 
light
Nucleotide and 
DNA binding. 
Contains a 
region
which resembles 
an ATPase.
5'-3' helicase 
activity.
Acidic carboxyl 
terminus.
Unknown
Unknown
Acidic carboxyl 
terminus. From 
amino acid 
sequence shows 
homology to 
known 
functional 
domains in DNA 
thought to be 
involved in DNA 
binding.
Acidic stretches, 
membrane 
association? Partial 
excision defect.
ERCC-1 DNA binding? 
Involved in 
recombination.
ERCC-3 Nucleotide DNA 
binding, DNA 
helicase?
Acidic stretches,
essential
function.
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Cell fusion studies have demonstrated so far eight different complementation groups 
ranging from XP-A through to XP-G and XP-V. A few years prior XP-H was designated 
to be a complementation group, however this has now been reassigned to XP-D (Johnson 
et al, 1989).
Cellular studies have demonstrated XP-A and XP-F to be hypersensitive to 
CDDP induced damage (Dijt et al, 1988; Plooy et al, 1985). Evidence is accumulating 
for deficient repair of CDDP damage by XP cells. XP-A cells are deficient in 
reactivating SV40 DNA damaged by CDDP (Poll et al, 1984) and cells from XP-A, XP- 
C, XP-F are less efficient at restoring expression of a marker gene after transfection of 
CDDP damaged plasmids (Chu and Berg, 1987). Dijt and co-workers reported that cells 
from XP-A remove CDDP adducts at a slower rate than normal repair proficient cells 
(Dijt et al, 1988). Recently in vitro studies have demonstrated that XP-A, XP-C, XP-D 
and XP-G are defective in the repair of plasmid DNA damaged with either CDDP or 
TDDP. This defective repair has been shown to be overcome by the addition of uvrABC 
into the system (Hansson et al, 1990).
The UV sensitive rodent lines possess a similar phenotype to the XP cell 
lines in being defective in the incision step of excision repair (Thompson et al, 1982). 
They are also characterised by their reduced ability for UDS (Thompson et al, 1980). 
These mutants can be classified into at least five complementation groups. There is 
however a UV mutant which shows a normal capacity for UDS (Busch et al, 1989). This 
has been placed into a complementation group of its own, Group 6 . It is likely that this 
mutant does excise UV lesions successfully (for review of CHO mutants, Hickson and 
Harris, 1988).
Mutants from complementation group 1, but not group 2 have been shown to 
be highly sensitive to the cytotoxic effects of CDDP but not TDDP. They do however 
show some effects to TDDP, but at much higher concentrations (Hoy et al, 1985). This
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suggests that group 1 mutants are defective in the repair of the cytotoxic lesion formed by 
CDDP.
The repair-deficient mutants have proven a valuable tool for the isolation of 
human DNA repair genes. Initial attempts to isolate human DNA repair genes from XP 
cell lines has proved unsuccessful in that human cells are poor recipients of DNA. The 
Chinese hamster ovary mutants have therefore been used to identify human nucleotide 
excision repair genes because they have a high uptake of exogenous DNA compared to 
the human cells. One of the strategies used in their isolation, is the transfection of 
genomic DNA into these DNA repair deficient mutants, selection of repair-proficient 
transformants and retrieval of the correcting repair gene. This technique has allowed the 
isolation of genes responsible for DNA repair termed Excision Repair Complementation 
Chinese hamster repair deficiency (ERCC) genes and these are presented in Table 1.3
(review, Bootsma et al, 1988; Tanaka et al, 1989; Tanaka et al, 1990)
Tanaka, K., Satokata, I., Ogita, Z.,Uchida, T., Okada, Y. (1989) Molecular cloning of a 
mouse DNA repair gene that complements the defect of group-A xeroderma 
pigmentosum. P.N.A.S. (USA) 8 6 , 5512-5516
Tanaka, K., Miura, N., Satokata, I., Miyamoto, I., Yoshida, M.C., Satoh, Y., Kondo, S., 
Yasui, A, Okayama, H., Okada, Y. (1990) Analysis of a human DNA excision repair 
gene involved in group A xeroderma pigmentosum and containing a zinc-finger domain. 
Nature 348,73-76
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Table 1.3 Summary of cloned genes of human ERCC genes
GENE CORRECT REFERENCE
ERCC-1 Excision repair defect 
in CHO mutants of 
complementation group 1
Westerveld et al, 1984
ERCC-2 Defect in the incision step 
of excision repair of group 2  
hamster UV sensitive mutants
Weber etal, 1988
ERCC-3 Restores repair synthesis 
to XP-B complementation group
Weeda et al, 1990a
Corrects defect in CHO UV 
sensitive mutants in 
complementation group 3
Weeda et al, 1990^
Strong possibility ERCC-3 
is a DNA helicase
Weeda et al, 1990^
ERCC-5 Machines et al, 1990
ERCC- 6 Corrects the cyclobutane 
dimer repair defect in the 
moderately UV sensitive 
complementation group 6  
hamster mutants
Troelstra et al, 1990
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Analysis of the ERCC gene products have revealed that there is some amino 
acid sequence homology to other nucleotide excision repair counterparts in other 
systems. Table 1.4 briefly outlines these.
Table 1.4 Sequence homology of ERCC genes with other repair genes
GENE HOMOLOGY REFERENCE
ERCC-1 RAD 10 vanDuin et al, 1986
uvr A Hoeijmakers et al, 1986
uvrC Doolittle et al, 1986
ERCC-2 RAD 3 Weber et al, 1990
ERCC-3 None so far. 
Suggestion of 
ERCC-3 sc 
although evidence 
exists to suggest 
not homologous to 
excision repair 
genes.
Weeda et a l ^ ,  1990
ERCC-5
ERCC- 6 Nucleotide sequence yet 
to be defined.
Initial studies have suggested that the ERCC1 gene may be important in 
CDDP resistance. When the ERCC1 gene was transfected into CHO cells, the 
transfectant was demonstrated to be four fold more resistant to CDDP than the wild-type 
cell. In the same study A2780CP cells which were 13 fold more resistant to CDDP 
demonstrated higher levels of ERCC 1 expression, but these levels were variable (Reed et 
al, 1989). This study suggests that ERCC1 may be involved in CDDP resistance in 
human ovarian cancer.
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Evidence is therefore accumulating from XP cell lines and CHO mutants 
which are sensitive to CDDP that nucleotide excision repair may be an important 
pathway for removal of CDDP adducts in humans. Certain key features suggest it is 
reasonable to consider mechanisms of nucleotide excision repair in humans as having 
similarities to the that in E.coli.
(1) Human DNA repair enzymes which correct DNA base damage in 
humans such as O^-methylguanine-DNA methyl transferase, DNA glycosylase have 
similar activities to those enzymes found in E.coli (Lindahl, 1982).
(2) Damage specific incision of DNA in UV-irradiated permeabilised 
cells requires ATP (Dresler and Lieberman, 1983) as it does in E.coli.
(3) Pyrimidine dimers in human cells are excised within short 
oligonucleotides (Weinfeldet al, 1986) again as in E.coli.
(4) The DNA repair syndrome, Xeroderma Pigmentosum has various 
different complementation groups. This therefore suggests that a multi-subunit repair 
nuclease exists which is analogous to the uvr ABC in the E.coli system.
1.14 Advantages of in vitro assays
A large amount of information on DNA excision repair in mammalian cells 
has been gained by the analysis of transfecting damaged DNA into cells. Popoff and co­
workers have demonstrated the uvrB gene to be essential for the repair of CDDP induced 
DNA damage, by introduction of CDDP damaged plasmid into UV mutants of E.coli 
(Popoff et al, 1987). White and Sedgwick have also assigned a role of post-incision UV
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repair to the products of RAD 1, 4, 7 and 14 gene products by transfection experiments 
into yeast (White and Sedgwick, 1987). Problems in interpretation of results of in vivo 
assays occur. Difficulty in ensuring equivalent DNA uptake in cells therefore making 
comparisons between cell lines very hard. It is also difficult to determine the 
involvement of cellular metabolic processes in the observed outcome. In the analysis of 
repair of a damaged substrate, complications can arise if the damage itself can affect the 
uptake or integration of DNA.
Many groups have begun to unravel the pathway of excision repair in 
mammalian cells by use of in vitro assays. In vitro studies have a number of 
advantages over transfection systems. These systems are free of complications arising 
from the interaction of cellular metabolism on the system under investigation. They also 
provide a means for purification of proteins involved in specific reactions either by 
assaying protein fractions for a defined activity in a model system (Eisen et al, 1988) or 
by restoration of the relevant activity (W oodetal, 1988 • Hansson and Wood,
1989). The in vitro systems are also maniputable, in that factors such as enzyme 
inhibitors, antibodies, etc. can be added to test different hypothetical pathways.
1.15 Dissection of mammalian excision repair pathway using in vitro assays
In vitro assays have been used to either study individual steps of the excision 
repair pathway in human cells or a succession of steps leading to removal of the damage. 
The excision repair pathway can be separated into four major areas 
recognition 
removal 
resynthesis 
religation
45
In vitro assays for these steps are discussed in the next two sections of this
chapter.
1.15.1 Identification of DNA damage recognition proteins (DRPs)
If CDDP adducts are repaired by an excision repair pathway in mammalian 
cells it is reasonable to suggest that prior to incision the adducts must be recognised by a 
protein similar to that of the uvrABC complex in the E.coli nucleotide excision repair 
pathway.
Studies were stimulated in this area of research when Chu and Chang 
identified a factor which recognised adducts formed by ultra-violet radiation (Chu and 
Chang, 1988). They provided evidence that this factor was absent in an extract of cell 
line derived from complementation group E (XPE). The importance of the absence of 
this factor in XPE was later questioned by Kataoka and Fujiwara who verified the 
absence of the factor in the same XPE cell line but found it present in four other XPE 
fibroblast strains (Kataoka and Fujiwara, 1991). Chu and Chang identified another factor 
which recognised DNA damaged with CDDP (Chu and Chang, 1988), which was 
independent of the factor recognising UV damage.
In a separate study a factor which recognises the 1, 2 d(GpG) and d(ApG) 
only, has been identified (Donahue et al, 1990). These lesions have been reported to be 
the major lesions formed in vitro (Eastman, 1986). For a more extensive introduction to 
DNA damage recognition proteins refer to chapter 3, section 3.1.
Some studies have reported an increase in a damage recognition protein in 
cell lines resistant to CDDP. Chu and Chang reported that the factor they found to be 
absent in an XPE cell line was overexpressed in a Hela cell and fibrosarcoma cell line 
made resistant to CDDP in vitro (Chu and Chang, 1990). An independent study also 
reported an increase in a damage recognition protein recognising UV damage in a Hela
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cell line selected for resistance to CDDP (Chao et al, 199l a). Chao and co-workers had 
previously provided evidence for their CDDP resistant cell line to have an increased 
DNA repair capacity by plasmid reactivation (Chao et al, 1991^). A study which 
identified damage recognition proteins in A2780 cells recognising CDDP damage reports 
not to show an increase in these proteins in CDDP resistant cell lines (Andrews and 
Jones, 1991).
Evidence exists suggesting that the DRPs may be involved in a DNA repair 
pathway. Studies have shown an absence of DRPs in an XPE strain (Chu and Chang, 
1988) and also an increased expression of DDRPs in cell lines with an enhanced DNA 
repair activity (Chao et al, 199l a 'b). This however only provides circumstantial 
evidence for the involvement of the DRPs in an excision repair pathway and steps are 
being made in the direction of isolation of the protein recognising CDDP damage and 
further cloning of the gene before direct evidence can be presented as to whether this 
protein is a DNA repair protein (Toney et al, 1989).
1.15.2 Repair synthesis assay
Recently an in vitro assay for investigations of nucleotide excision repair by 
extracts from human cells has been developed (Wood and Lindahl, 1988). This assay 
basically monitors the formation of repair patches in exogenously added damaged 
plasmid DNA. This cell free system has demonstrated the repair of pyrimidine dimers, 
psoralen and CDDP adducts (Woods and Lindahl, 1988, Ullah et al, 1989). The cell free 
system has also been used in the investigation of different cell extracts. Cell extracts of 
XP complementation groups A, C, D and G were shown to be deficient in DNA repair 
synthesis in plasmid DNA treated with UV, CDDP, TDDP (Hansson et al, 1990). The 
repair synthesis assay is therefore of value in the determination of types of adducts
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repaired in an excision repair pathway in mammalian cells similar to that described for 
E.coli.
1.15.3 Study of the ligation step
The final step in the excision repair process is the formation of a 
phosphodiester bond after the removal of the damage from the DNA. The eukaryotic 
DNA ligase I has been demonstrated to play a role in both replication and repair (for 
review, Lasko et al, 1990). An altered DNA ligase I has tentatively been associated with 
the defective DNA repair syndrome known as Bloom's syndrome. DNA ligase II is 
another ligase which has been identified in eukaryotic cells although, as of yet, its' 
physiological function is unknown. In vitro assays exist which allow the measurement of 
both enzymes (Lasko et al, 1990). It would be of interest to assay the enzyme activities 
in CDDP resistant cell lines to determine if the final ligation step in the excision repair 
process is altered.
1.16 Importance of study of damage recognition step
The damage recognition step is the first step required prior to removal, 
resynthesis, religation. It is therefore an important step in that the three later stages all 
follow sequentially. If damage recognition does not occur the latter steps will not occur. 
If a protein was found which acts as a damage recognition protein, then it may prove of 
importance if its overexpression in cell lines hypersensitive to DNA damaging agents, 
allowed their return to normal DNA repair synthesis. At the opposite end of the 
spectrum, modulation of this protein may prove important in overcoming resistance to 
damage induced by agents recognised by this protein. The study of damage recognition 
proteins may therefore prove clinically relevant if they prove to be important either in
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being repair enzymes or being enzymes which recruit repair enzymes onto the site of 
damage.
1.17 Substrates for damage recognition
The DNA damage recognition proteins like the uvrABC complex in E.coli 
are more likely to recognise a range of damage rather than one specific type of damage. 
It is more economical for a cell to contain proteins which recognise classes of damage 
rather than damage induced by specific agents. Through evolutionary terms it is more 
likely proteins will not have evolved to recognise specific damage but will have evolved 
to recognise structural alterations.
CDDP is thought to bind to DNA and cause local denaturation around the 
adduct (Sundquist et al, 1986). A single-stranded binding protein, gene 32 protein, from 
bacteriophage T4 has been reported to bind more efficiently to DNA modified with 
CDDP (Toulme et al, 1983). Toulme and co-workers have suggested a role for single­
stranded binding proteins in an early step of recognition of damage due to conformational 
changes prior to recruiting other DNA repair enzymes onto the site of damage.
Recently a role for the human single-stranded binding protein (hSSB) 
involved in DNA replication has been reported in DNA excision repair (Coverley et al, 
1991) - see chapter 4, section 4.1. It was shown that monoclonal antibodies against hSSB 
caused extensive inhibition of DNA repair in a system measuring excision repair (Wood 
and Lindahl, 1988). It was also reported that upon reintroduction of purified SSB into 
the system, DNA excision repair was stimulated. It therefore may be possible that the 
identified DNA damage recognition proteins binding to CDDP adducts reported in the 
literature, may be recognising regions of single-strandedness generated by the CDDP 
adducts.
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Reports by Donahue and co-workers have identified DNA damage 
recognition proteins recognising only the 1,2 d(GpG). They have suggested that either 
this protein is involved in repair or it may impede repair by binding to this specific cross­
link and shielding it from DNA repair enzymes.
1.18 AIMS OF THE THESIS
Evidence from the literature has been presented for the involvement of a 
nucleotide excision repair pathway similar to that found in E.coli, for the removal of 
CDDP adducts in mammalian cells. The main aim of this thesis is to attempt to identify a 
protein complex in mammalian cells which recognises CDDP damaged DNA. If the 
DDRPs are found to be involved in handling damage to the DNA then they may be 
important in the generation of a CDDP resistant phenotype. A role for DDRPs in CDDP 
resistance will therefore be investigated in cell lines resistant to CDDP (their resistance 
derived in vitro). Previous reports have shown that cell lines resistant to CDDP exhibit 
increased levels of DNA damage recognition proteins recognising UV damage (Chu and 
Chang, 1990; Chao et al, 1991a). These CDDP resistant cell lines were demonstrated to 
have increased levels of DNA repair synthesis therefore the author made the tenuous link 
of the DRPs being involved in DNA repair.
In the E.coli system the uvrABC complex has been reported to recognise a 
large variety of damage. CDDP has been reported to cause areas of single-strandedness. 
Recently human single-stranded binding protein (hSSB) normally involved in DNA 
replication, has been suggested to have a role in DNA excision repair (Coverley et al, 
1991). The study of the recognition of single-stranded DNA by DDRPs will be presented 
with some evidence suggesting that the DDRPs recognising CDDP adducts may also be 
recognising regions of single-strandedness generated around the adducts.
In summary the following results chapters of this thesis will present:
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Chapter 3 The identification of damage recognition
proteins in mammalian cell extracts recognising CDDP adducts by gel mobilbity shift 
assay. The characterisation of the CDDP treatment of the substrate used in the 
identification of the DDRPs will be presented fully.
Chapter 4 The identification of DDRPs in mammalian
cell extracts by South-Western analyses and a study of their involvement in CDDP 
resistance in two ovarian tumour cell lines resistant to CDDP (resistance derived in vitro 
by multiple exposures to CDDP). Binding of the DDRPs to single-stranded 
oligonucleotides is also investigated. The DDRPs in this chapter are also examined for 
induction by pretreatment with CDDP.
Chapter 5 The isolation of CDDP resistant clones of
the A2780 ovarian tumour cell line by a single step selection with CDDP. Evidence is 
presented in this chapter to suggest that the clones are derived from a mutational origin. 
The DDRPs from the resistant clones are then analysed on a South-Western blot to 
determine if differences in binding can be detected,
51
CHAPTER 2
MATERIALS AND METHODS
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2.1 MATERIALS
Chemicals : Sigma, Biorad, Aldrich 
Enzymes & Buffers : Pharmacia 
Cisplatin: Sigma
Oswell DNA Service 
Oswell DNA Service 
Oswell DNA Service 
Oswell DNA Service
Filters : Nalgene 
Spinex Tubes: Costar
Dialysis tubing and Collodion bags : Sartorius
Autoradiography film : Kodak
Plastics: Falcon
Tissue Culture Media : NBL
Supplements for media: Gibco
Tissue Culture Plastics : Becton Dickinson
96 Microwell Plates : Nunclon
Radiochemicals: Amersham International 
Oligonucleotides aG7
2aG7
3bpMM
7bpMM
Protein molecular weight markers : BRL 
Transfer membrane: Alderman & Co .LTD 
Acrilamiderbis (30:0.8): Severn Biotech Ltd
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2.2 OLIGONUCLEOTIDES
Oligonucleotides were synthesised on an automatic DNA synthesiser by 
Oswell DNA service and HPLC purified.
2.2.1 General Buffers
TEN : lOOmM NaCl, lOmM Tris pH7.5, lOmM EDTA
TE : lOmM Tris pH7.5, ImM EDTA
TBE : 89mM Tris borate, 89mM Boric acid,
2.5mM EDTA
2.2.2 Reannealing
Complementary strands of oligonucleotides were reannealed at a 
concentration of 0.05fig/p.l by heating a mixture of both strands at 80^C for ten minutes 
in a waterbath and then allowing the waterbath to reach room temperature overnight. For 
reannealing of both strands to occur, the temperature must be lowered gradually. The 
double stranded oligonucleotides shown in table 2 .1  were reannealed in this way.
2.2.3 Cisplatin Treatment of Oligonucleotides
Both double stranded and single stranded oligonucleotides at 15ng/pl were 
incubated with various concentrations of CDDP (as described for each particular set of 
experiments) in a final reaction mixture with TEN buffer at 37 ^ C for one hour. A final 
concentration of 0.1 M NH4 HCO3  was then added and the reaction was left at 4^C for 16 
hours. This procedure allows any remaining CDDP to be inactivated. Reaction with 
CDDP initially forms monofunctionally bound platinum and then this reaction progresses
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towards the formation of bifunctional adducts. Addition of NH4 HCO3  will generate 
NH3  which will bind to the remaining coordination sites of monofunctionally bound 
CDDP. Free CDDP was then removed by precipitating the oligonucleotide with 2 V 2  
volumes of ice cold ethanol and Vjq th volume of sodium acetate at O^C for at least two 
hours. The pellet is then washed with 75% ethanol and then resuspended in TE buffer to 
a stock concentration of 0.025 |ig/ul.
2.2.4 KINASE LABELLING OF OLIGONUCLEOTIDES
Buffer: One-Phor-All Buffer Plus (Pharmacia)
(stock concentration of buffer is ten times concentrated at which the working 
concentration is used.)
lOOmM Tris-acetate 
lOOmM Magnesium acetate 
500mM Potassium acetate
Ten picomoles of oligonucleotide were incubated in One-Phor-All Buffer Plus 
with 32py ATP (specific activity lOmCi/ml), 12 units of T4 polynucleotide kinase and 
the reaction made up to 25(0.1 with sterile distilled water. The labelling of the 5' terminii 
was carried out at 37^C for 45-60 minutes.
2.2.4.1 Purification of Labelled Oligonucleotide
After the 45-60 minute incubation the labelling reaction was loaded on a
lxTBE 8 % polyacrylamide non-denaturing gel and electrophoresed for 90 minutes at a
constant voltage of 150 Volts. After electrophoresis the gel was exposed to Kodak 
XOMAT-AR autoradiography film and this was then sequentially used as a template for
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cutting out the 5' end labelled oligonucleotide. The fragment was placed in TE and 
eluted overnight at 37^C.
The following day the fragment was placed in a Spinex tube, and the TE 
from the overnight elution was used to wash out any remaining oligonucleotide from the 
fragment of acrylamide. The labelled oligonucleotide was stored in a lead pot at -20^C.
2.2.5 LIGATION OF OLIGONUCLEOTIDES
5' end labelled CDDP treated and non-CDDP treated aG7 was ligated to an 
excess of cold non-phosphorylated aG7 with 2 units of T4 Ligase in manufacturer's 
supplied ligation buffer (50mM tris-HCl, pH7.8, lOmM MgC^, ImM DTT, ImM ATP, 
100|ig/ml BSA) at 4^C for 16 hours. An excess of cold unphosphorylated aG7 was used 
in the reaction to favour the ligation of the phosphorylated aG7, both with and without 
CDDP, to the untreated aG7. After ligation the ligated products were purified on an 8 % 
polyacrylamide gel (see section 2.2.4) and eluted overnight at 37 ^ C in TE. The ligation 
products were checked on a denaturing gel (refer to section 2 .2 .6 .2 ).
2.2.6 ANALYSIS OF CDDP TREATMENT
2.2.6.1 Polyacrylamide gels - Basic Concepts
Polyacrylamide gel results from the polymerisation of acrylamide monomer 
into long chains and the cross-linking of these by bifunctional compounds such as N,N'- 
methylene bisacrylamide reacting with free functional groups at chain terminii. 
Polymerisation of acrylamide is initiated by the addition of ammonium persulphate and 
addition of N,N,N',N'-tetramethylethylenediamine (TEMED) is added as a catalyst of the 
process.
57
In the ammonium persulphate - Temed system, TEMED catalyses the 
formation of free radicals from persulphate and these in turn initiate polymerisation. 
Oxygen inhibits polymerisation and so gel mixtures are usually degassed prior to use.
Polyacrylamide gels have been used throughout this work (section 2.2.6.2, 
2.2.6.4,2.4.2).
2.2.6.2 Denaturing Polyacrylamide Gel Electrophoresis
Denaturing polyacrylamide gels were cast by mixing 45ml 30:0.8, w/w 
acrylamiderbisacrylamide with 7.5ml lOxTBE , 36g urea (7M urea). This acrylamide 
solution is then degassed. Polymerisation is aided by the addition of ammonium 
persulphate with TEMED (see section 2.2.6.1). The gel was finally cast by pouring this 
mixture between two glass plates of 55cm long separated by 0.4mm spacers and a comb 
inserted on top to allow wells to form. Once solidified the gel was placed on a vertical 
apparatus with each end submerged in a reservoir of lxTBE buffer. Gels were run at 
25mA for 3-4 hours at 55^C after which they were transferred to Whatman 3MM filter 
paper and exposed to XOMAT autoradiography film overnight
2.2.6.3 Exonuclease HI Treatment
Both CDDP and non-CDDP treated end-labelled oligonucleotides were 
incubated with six units of exonuclease III in 50mM Tris, pH 8.0, 5mM MgC^, lOmM 
B- mercaptoethanol at 37^C for 30 minutes. After the incubation period with the 
enzyme, treated oligonucleotides of 200 cps were loaded on a 25% polyacrylamide 
denaturing gel (refer to section 2 .2 .6 .1).
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2.2.6.4 Non-Denaturing Polyacrylamide Gel Electrophoresis
A lxTBE 8 % polyacrylamide was cast in a 2mm notched glass plate and 
oligonucleotides of 200cps were loaded and run at 20mA for 90 minutes in lxTBE 
buffer. The gel was then transferred to Whatmann 3MM filter paper and dried down 
under vacuum for 60 minutes at 80^C. The dried gel was then exposed to XOMAT film 
overnight with the use of an intensifying screen.
2.3 EXTRACTION OF PROTEIN FROM CELLS
2.3.1 Buffers
TMS lOmM Tris, pH 7.5 
5mMMgCl2  
0.25M sucrose
E5 0  50mM (NH4 )2 S0 4  
20mM Hepes, pH7.9 
5mMMgCl2  
O.lmM EDTA 
0.1% Brij 35
ImM DTT (add fresh each time)
2 0 % glycerol
SB 50mM NaCl
20mM Hepes, pH7.9 
5mM MgCl2  
O.lmM EDTA
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2 0 % glycerol
ImM DTT (add fresh each time)
2.3.2 Protease Inhibitors
O.lmg/ml 
0 .1  mg/ml 
50mM 
O.lmg/ml 
O.lmg/ml 
50mM
At least 1x10** cells from desired lines were harvested during exponential 
phase of growth. All the following manipulations were carried out at 4^C. The cells 
were washed with ice cold PBS and osmotically swollen with a TMS wash and lysed in 
0.25% Triton X-100. The resulting pellet of nuclei was washed three times and the DNA 
content estimated by measuring the optical density at 260nm of a small sample after 
sonication. The pellet was resuspended in TMS to a concentration of 7.5 mg/ml DNA, 
NaCl added to a final concentration of 0.3M and nuclear proteins eluted by incubation on 
ice for ten minutes. Debris was removed by a 15K spin and the supernatant clarified 
further by a 36K ultracentrifuge spin. Proteins were pelleted by incubation on ice with 
ammonium sulphate at 0.35 g/ml followed by a 10K spin. The pellet was then dissolved 
in 0 .6 ml E5 Q buffer and dialysed overnight at 4^C against one litre of storage buffer
Leupeptin
Chymostatin
Benzamidine
Aprotinin
Pepstatin
PMSF
2.3.3 Extraction Protocol
2.3.3.1 Nuclear Extract Preparation
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(SB). The following morning the solution was centrifuged in an EEC/B60 ultracentrifuge
using an SB-405 rotor at 35K for 60 minutes at 4^C and the resultant supernatant
aliquoted into eppendorf tubes and stored in liquid nitrogen. This protocol generated
protein extracts which were used in gel mobility shift assays (refer to section 2 .5 .1 ),
however it was adapted to a simplified version to give a much cruder extract which was
used in South-Western blotting. N.B. The 10K and 15K spins were carried out using a fixed angle
Sorvall GS-3 rotor, each for 30 minutes. The 36K spin was in a IEC/B60
ultracentrifuge using an SB-405 rotor for 60 minutes.
23.3.2 Cell free salt extract
106  -10? cells were harvested during exponential growth of the cells. The 
cells were washed with ice cold PBS and again osmotically swollen with a TMS wash 
and lysed in 0.5ml TMS-0.25% TX-100. After lysis NaCl was added to give a final 
concentration of 0.3M NaCl. This is then spun in a microfuge at 4^C for 15 minutes.
The supernatant is then removed and added to it 20% glycerol, 0.1% Brij 35 and ImM 
DTT (final concentration). The extract is then transferred to mini colloidan bags and 
dialysed against SB overnight at 4^C. The following morning the solution is microfuged 
at 4^C for 15 minutes and then aliquotted into eppendorf tubes and stored in liquid 
nitrogen.
2.4 QUANTIFYING PROTEIN CONCENTRATIONS IN EXTRACTS
2.4.1 Biorad Assay
Protein concentrations were estimated using the Bio-rad protein assay. The 
assay is based on the method by Bradford 1976, and is a dye binding assay based on the 
differential colour change of a Coomassie blue dye in acidic conditions to various 
concentration of protein (for detailed protocols see manufacturer's instruction manual).
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Each protein concentration was estimated in triplicate at varying amounts of the protein 
sample.
2.4.2 Discontinuous-SDS Polyacrylamide Gels
Buffers
Gel Buffer Tris 1.5M pH 8.9
SDS 10%
Tank Buffer Tris 0.05M 
Glycine 0.05M 
SDS 1%
Stack Buffer Tris 1.0M (pH6 .8 ) 
SDS 10%
Loading Buffer 0.2M Tris, pH6 .8  
SDS 8 %
EDTA 8 mM 
Glycerol 40%
Loading buffer is four times more concentrated than that of the final.
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Gradient Gel
5% 15%
Running Buffer 8 ml 8 ml
Acrylamide 2.67ml 8 ml
Polyacrylamide 1 .6 ml 1 .6 ml
Water 2.4ml 7.73ml
Sucrose / 2.25g
10% APS 30(xl 90pl
TEMED 6.5jxl 7.5(il
A Tris - SDS based resolving gel was first prepared using a concentration 
gradient of acrylamide varying between 15% at the bottom of the gel through to 5% at 
the top hence the gradient gel having a decreasing pore size. During electrophoresis in 
gradient gels, proteins migrate until the decreasing pore size inhibits further progress. 
Once the pore limit is approached the protein banding pattern does not change 
appreciably with time although migration does not stop completely. This thus ensures 
tighter bands of proteins through the gel.
To ensure easier handling of the gel 1% polyacrylamide solution was added 
to the mixture. Sucrose is also added to the 15% polyacrylamide solution to give a 
stabilising density gradient. Polymerisation was initiated by the addition of 10% APS 
and TEMED (refer to section 2.2.6.1). The gel is poured between two glass plates 
separated by 1mm spacer to about 5cm from the top and the gel overlayed with 
isobutanol. When polymerisation was complete, approximately 1 hour, the isobutanol is 
poured off. A stacking gel was then added of 5% acrylamide in a stack buffer (again
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being polymerised by the APS -TEMED system). Polymerisation of the stack occurs 
within minutes. Protein samples were loaded in the SDS loading buffer onto the gel and 
samples were run through the stack in a Tris-glycine SDS buffer at 60mA. Once the 
samples reach the resolving gel the current is turned down to 30mA and run for 2-3 hours 
at room temperature in a BIO-RAD PROTEAN II tank system. To check protein loading 
the gel is stained in 0.1% Coomassie blue stain for one hour and then destained overnight 
in destain solution, 5% methanol, 7% acetic acid.
2.5 ANALYSIS OF CISPLATIN-DNA PROTEIN INTERACTIONS
2.5.1 Gel Mobility Shift Assay
This assay is a modified version of that by Gamer and Revzin, 1981. ^ P  end 
labelled oligonucleotides (1.5ng) were incubated on ice for 35 minutes in the presence of 
2|ig poly(dI.dC):(dI.dC) with 1-2 fig nuclear extract of interest (if different amounts used 
then this is stated in the figure legend). This reaction is then incubated in a final volume 
of 20[il with storage buffer (SB) (refer to section 2.3.2).
After an incubation period the reactions were electrophoresed through a 8 % 
0.5x TBE non-denaturing polyacrylamide gel at 4^C. Following electrophoresis the gel 
was dried down under vacuum at 80^C and autoradiographed on Kodak XOMAT film.
2.5.2 South-Western Blotting
2.5.2.1 Buffers
BLOTTO 5% Carnation nonfat milk powder
50mM Tris pH7.5
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50mM Na Cl 
ImMEDTA
ImM DTT (add fresh each time)
TNE-50 lOmM Tris pH7.5
50mM NaCl 
ImMEDTA 
ImM DTT
Binding Buffer 30mM Hepes-NaOH, pH7.5 
lOmM MgCl2  
2mM MnCl2
0.25% Carnation dried milk
Wash Buffer 30mM Hepes-NaOH, pH7.5 
0.25% Carnation dried milk
2.S.2.2 Protein Blotting
The gel for proteins to be analysed by a South-Western blot is run in exactly 
the same way, under identical conditions, as that described in section 2.4.2. Once the 
samples have electrophoresed through the gel, it is then taken and proteins are transferred 
from it by the semi-dry electroblotting procedure (Kyhse-Andersen, 1984) onto a 
nitrocellulose membrane (BA852, 0.45fim; Schleicher and Schuell). After blotting the 
filters were stained with Ponceau-S stain for ten minutes and then destained in 5% acetic 
acid for a further ten minutes. This allows to check for even transfer of the proteins from 
the gel to the nitrocellulose filter where further manipulations will be carried out. The
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filters were immersed in BLOTTO for at least 1 hour at room temperature with gentle 
shaking. They were then washed twice with TNE-50 for 5 minutes for each wash. The 
filters were then taken and incubated for 60 minutes at room temperature in binding 
buffer with labelled oligonucleotide at 2x10^ cpm/ml. Included in this reaction mixture 
is poly(dI.dC):(dI.dC), 3|ig/ml, to act as a competitor for non-specific binding of 
proteins. Unbound DNA was then removed by washing at 4®C with wash buffer and 
filters left to air dry. Protein-DNA complexes were detected by autoradiography. By 
running protein molecular weight standards, estimation of the size of the detected 
proteins can be made:
Protein Standards (BRL)
Daltons
Lysozyme 15 300
B-Lactoglobulin 17 950
Carbonic anhydrase 28 500
Ovalbumin 43 750
Bovine serum albumin 70 600
Phosphorylase B 110 900
Myosin (H-chain) 206 450
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2.6 TISSUE CULTURE TECHNIQUES
2.6.1 General Cell Culture Methods
2.6.1.1 Maintenance of Cells
Cell lines were maintained as monolayers in RPMI (Rosswell Park Memorial 
Institute) medium supplemented with 10% foetal calf serum, 2mM L-Glutamine, ImM 
sodium pyruvate and sodium bicarbonate added in equilibrium with 5% CC>2 . All 
medium used had 0.05 units/ml of penicillin present. Cells were grown in a 37^C, 5% 
CC>2 dry incubator. All lines were free of mycoplasma contamination. Table 2.2 shows 
cell lines used and seeding density at which these lines were maintained at.
2.6.1.2 Storage of Cells
To reduce chances of genetic drift, all cell lines were replaced from frozen stocks 
every 3 months. Frozen stocks were maintained in liquid nitrogen in culture medium at a 
concentration of at least lxiofyml and 10% DMSO added. Cells were frozen with a 
cooling rate of approximately l^C/min to -70^C and retained at -70^C overnight before 
being transferred to liquid nitrogen. Table 2.3 shows cell lines used and descriptions.
2.6.1.3 Aseptic Technique
All aseptic manipulations were carried out in a class II microbiological safety 
cabinet with vertical air flow. All glassware was dry heat sterilised at 160^C for a 
minimum of 1 hour.
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Table 2.2 Growth conditions of cell lines
CELL LINE SEEDING DENSITY GROWTH MEDnJM
A2780 1x10^ per 75cm^flask RPMI medium
A2780CP 1x10^ per 75cm^flask RPMI medium
Ovl 1x10^ per 25cm^flask RPMI medium
Ovl DDP 2x10^ per 25cm^flask RPMI medium 
supplemented with 
CDDP at a final 
concentration of 
1 mg/ml
GM02145 1x1 0 ^ per 25cm^flask Special Liquid 
medium
Hela 1x10^ per 75cnAlask RPMI medium
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2.6.2 Clonogenic Assay
A2780 cells were plated at 2x10^ per F75cm^ flask for 5-30 (iM CDDP 
concentrations. After 24 hours the cells were treated with the various concentrations of 
CDDP for a period of 24 hours, washed twice with phosphate buffered saline, incubated 
in drug free RPMI medium for two weeks in a 37^C incubator, 5% CO2  and surviving 
colonies of more than 60 cells were counted. The A2780 cells had a plating efficiency of 
approximately 2 0 % using these conditions.
2.6.2.1 Isolation of CDDP resistant colonies by single step selection
Clonogenic assays gave a survival curve and from this a concentration of 
CDDP was chosen at which to select colonies. A concentration of CDDP at which 0-3 
colonies survived was chosen at the selecting concentration. From the surviving colonies 
a concentration of CDDP of 15jiM was used for selection of resistant colonies.
Cells were plated out as in section 2.6.2 at 2x10^ per F75cm^ flask and 
resistant colonies selected at the predetermined concentration of CDDP as described 
above. After two weeks incubation the surviving colonies were picked as separate clones 
and placed in a F25cm^ flask and grown in RPMI medium.
The frequency of resistant colonies were either calculated as surviving 
colony number per viable cell or using fluctuation analysis (Luria,S.E. & Delbruck,M.) 
based on the number of cultures containing no surviving colonies. This latter analysis 
avoids any uncertainties due to the daughter colony formation.
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2.6.2.2 Mutagen Exposure Prior to CDDP Selection
A2780 cells were seeded at 5 x1 0 ^ per F175cm^ flask. The cells were 
allowed to settle for a period of 24 hours and then treated for 2 hours with 2.5mg/ml of 
ethyl methane sulphonate (EMS) in serum free medium.
Prior to choosing this concentration of CDDP a dose response of A2780 to 
various concentrations of EMS was carried out as in section 2.6.2 (2.5mg/ml EMS was 
chosen because at this concentration the survival fraction of A2780 was 22%. At various 
times after exposure to EMS the cells were selected at 2x10^ per F75cm^ flask as 
described in section 2 .6 .2 .1 .
2.6.2.3 Pretreatment with BSO and Aphidocolin
Aphidicolin (2.5 fig/m 1 and 5 |ig/ml) was added 1 hour prior to CDDP and 
maintained during the CDDP selection as described in section 2.6.2.1. These are 
conditions previously shown to inhibit removal of DNA bound platinum in A2780 cells 
treated with CDDP (Masuda, et al 1990).
Buthionine sulfoximin (BSO) was added 24 hours prior to CDDP selection 
and maintained during the CDDP selection (selection is again as in section 2.6.2.1). 
Concentrations of BSO were used (25|iM and 50|iM) previously shown to deplete 
glutathione levels in A2780 cells and increase the sensitivity of A2780CP cells to CDDP 
in short term cell viability assays (Hamilton et al, 1985).
2.6.2.4 MTT Assay
As a rapid method of analysing the selected clones for sensitivity to CDDP 
the MTT assay was employed.
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This assay is based upon a method described by Mossman (1983) and the 
modified version by Plumb was used in this thesis presentation (Plumb et al, 1989).
The assay is dependent on the reduction of a tetrazolium dye, MTT (3-(4, 5- 
dimethylthiozoyl-2-yl, 5 diphenyl-tetrazolium bromide) to a purple formazan product by 
live but not dead cells. Cells are plated onto 96 well plates and allowed to attach and 
grow. Cells are then exposed to cytotoxic drug for a fixed period of time. Drug is 
removed and cells are allowed to recover and divide. Surviving cells are then indicated 
following incubation with MTT. Formazan production is thus an endpoint to this assay.
Cells in exponential growth were plated out at lxl(P/well in medium and left 
for two cell doubling times before drug was added. The cells were exposed to CDDP for 
24 hours and then subsequently incubated for 2-3 cell doubling times in drug free 
medium. Metabolically active cells were measured using the reduction of MTT as a 
measure of cell viability as described above.
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CHAPTER 3
GEL MOBILITY SHIFT ANALYSIS OF DNA DAMAGE 
RECOGNITION PROTEINS (DDRPs) RECOGNISING DNA 
DAMAGED WITH CDDP
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3.1 INTRODUCTION
In the search for a mammalian equivalent to the E.coli uvrABC complex, 
which recognises and excises damage from DNA, (refer to section 1.12), the gel shift 
assay has been used to identify proteins from mammalian cells binding to damaged DNA. 
The gel shift system has previously been used to identify proteins which bind to specific 
sequences involved in control of gene transcription - otherwise termed transcription 
factors (Mitchell & Tijan, 1989).
The technique is based on the observation that the movement of a DNA 
molecule through a non-denaturing polyacrylamide gel is hindered when a protein 
molecule is bound to i t  When a reaction containing nucleic acid protein complexes and 
unbound DNA molecules is subjected to gel electrophoresis, initially the free DNA will 
quickly enter the gel leaving the DNA-protein complexes behind. The highly negatively 
charged DNA will eventually pull bound proteins into the gel, but the DNA protein 
complexes are retarded in moving through the gel. The free DNA will always run much 
faster than the DNA bound protein complex, therefore allowing the two to be separated. 
With the DNA being ^2p labelled, an autoradiograph can be taken to visualise the 
complexes. In the study of transcription factors, binding of the complexes can be shown 
to be specific for a certain sequence by saturating the system with an excess of the 
specific sequence of DNA or a different sequence. Only sequences able to bind the 
transcription factor will compete in the gel shift, leading to disappearance of the 
retardation complex.
By use of the gel shift system various groups have reported factors in 
mammalian cells recognising DNA damage (Chu and Chang, 1988; Toney et al, 1989; 
Hirschfeld et al, 1990; Chao et al, 1991a; Donahue et al, 1990, Andrews and Jones,1991). 
Prior to the use of gel shift systems, proteins recognising DNA damage in mammalian 
cells were identified and partially purified using a DNA cellulose column, in which the
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substrate bound to the column was damaged by UV-irradiation (Lehmann and Kirk-Bell, 
1978; Feldberg and Grossman, 1976; Huang et al, 1975) or AAAF (Moranelli and 
Lieberman, 1980; Tsang and Kuhnlein, 1982). The proteins identified proved to be 
different from each other. The DNA binding protein characterised by Tsang binds 
efficiently to supercoiled DNA treated with UV light (Tsang and Kuhnlein, 1982) 
whereas the protein isolated by Moranelli does not recognise UV induced damage 
(Moranelli and Lieberman,1980). The protein characterised by Feldberg does recognise 
UV induced damage but it was found to elute off columns at a different salt concentration 
compared to Tsang's protein (Feldberg and Grossman, 1976). In 1988 Chu and Chang 
identified at least one nuclear factor in Hela cell extracts that binds to DNA damaged 
with ultra-violet radiation by use of the gel shift system. They reported that the factor 
was absent in an extract of a cell strain of XPE (refer to section 1.13.2 for introduction on 
XP), (Chu and Chang, 1988) and therefore called it the XPE binding factor. They 
therefore suggested that the XPE binding factor may be important in the recognition of 
damage prior to removal by DNA repair enzymes. The absence of the XPE binding 
factor in XPE cell strains was later questioned by Kataoka and Fujiwara. They verified 
the absence of the binding factor in the same XPE cell strains as Chu and Chang 
demonstrated, but found it present in other XPE cell strains (Kataoka and Fujiwara, 
1991). The uvrABC complex recognises a broad range of damage (review, vanHouten, 
1990). It has therefore been hypothesized that a DNA damage recognition protein 
complex present in mammalian cells is likely also to recognise a broad range of damage. 
In the gel shift system, as previously described, binding of the protein to a particular 
adduct can be competed for when excess of the substrate is added to the system. Cross- 
competition assays demonstrated that the binding to the XPE factor could be competed 
with an excess of CDDP damaged DNA. It was however shown that the XPE binding 
factor did not directly recognise CDDP damaged DNA (Chu and Chang, 1988). This was
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suggested to be due to the abundance of the damage recognition protein recognising 
CDDP damage, masking the binding of the XPE binding factor.
In an attempt to characterise the XPE binding factor in mammalian cells Chu 
and co-workers searched for an equivalent factor in the yeast system. It was thought that 
this approach would prove fruitful, since many proteins involved in cellular metabolism 
are conserved between yeast and humans. A factor was found in yeast which binds to 
UV damaged DNA and shares many characteristics with the XPE binding factor 
(Patterson and Chu, 1989). This factor is the photoreactivating enzyme photolyase. 
Photolyase is an enzyme which will bind to the site of a pyrimidine dimer, absorb energy 
from visible light through chromophores and reduce the cyclobutane ring in situ to 
restore DNA to its native state (review, Sancar and Sancar, 1988). In E.coli the addition 
of purified photolyase causes a two-fold stimulation in the repair of pyrimidine dimers by 
uvrA, uvrB, uvrC proteins in vitro (Sancar et al, 1984). Furthermore, genetic 
experiments in yeast suggest that expression of the PHR1 gene, the gene coding for 
photolyase, enhances excision repair by the RAD 3 epistasis group (Sancar and Smith, 
1988). These lines of evidence suggest that photolyase may be involved in excision 
repair.
Mentioned previously, the E.coli uvrABC recognises various types of DNA 
damage. CDDP is known to form intrastrand adducts that are unique to the cis 
configuration. TDDP which does not demonstrate antitumorigenic activity cannot form 
these adducts. The intrastrand adducts have therefore been reported to be the important 
lesion in the killing of tumour cells (Eastman, 1986). A factor has been identified in 
mammalian cell extracts that recognises these unique 1,2 d(GpG) and d(ApG) intrastrand 
cross-links generated by CDDP, (Donahue et al, 1990).
This CDDP recognition protein could either recognise the CDDP adduct 
itself, or more likely, recognise a change in structural conformation within the DNA. 
CDDP has been reported to bind to DNA and cause a local denaturation around the
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adduct itself, (Sundquist et al, 1986). In the bacterial system it has been found that gene 
32 from bacteriophage T4 which exhibits a high specificity for single-stranded nucleic 
acids, binds more efficiently to DNA treated with CDDP than to native DNA, (Toulme et 
al, 1983). It has been suggested that with various forms of damage which have been 
reported to cause a local melting around the adduct, (Van Houten, 1990), single stranded 
binding proteins may be important in the recognition step prior to incision of the 
damaged DNA. Recent evidence has found a role for human single stranded binding 
proteins (hSSB) in DNA excision repair. Human SSB is normally involved in replication 
of DNA by acting with T antigen and topoisomerases to unwind DNA, allowing the 
access of other DNA replication proteins, (Wold and Kelly, 1988). By making use of a 
cell free system that can cany out nucleotide excision repair in vitro , (Wood and 
Lindahl, 1988), it was found that monoclonal antibodies against hSSB caused extensive 
inhibition of DNA repair in plasmid molecules damaged by UV light or 
acetylaminofluorene. On addition of purified hSSB the repair was stimulated, (Coverley 
et al, 1991). This suggests a role for hSSB in excision repair.
In this present chapter the identification of damage recognition proteins by 
gel shift assays using CDDP modified oligonucleotides is described (these will be 
abbreviated to DDRPs). The CDDP treatment of the oligonucleotide is examined by 
denaturing gel electrophoresis and exonuclease m  treatment. Exonuclease ID is a 3'-5' 
nuclease which has previously been used to determine sites of CDDP modification, 
(Royer-Pokora et al, 1981). The adducts present in the oligonucleotide are analysed by 
ICPM spectroscopy, (Tothill et al, 1990). The involvement of single-stranded binding 
proteins are discussed in the context of DDRPs and excision repair.
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RESULTS
3.2 Choice of Oligonucleotide
Many of the groups who have identified damage recognition proteins (DRPs) 
have used DNA derived from plasmids as their substrate in the gel shift assay. 
Oligonucleotides however, can be generated with a defined sequence. They are also 
maniputable in that the sequence can be altered if need be. In the systems described in 
the next two chapters an oligonucleotide was chosen as the substrate in the detection of 
damage recognition proteins recognising CDDP adducts (DDRPs).
The choice of oligonucleotide sequence and its preparation for use in the gel 
shift assay was found to be a crucial factor in the detection of the DDRPs. It has been 
reported that CDDP binds preferentially to a sequence of guanines in DNA, (Fichtinger- 
Schepman et al, 1982). The oligonucleotide chosen had therefore to be rich in guanine 
nucleotides. A DNA sequence was chosen which had two areas of three consecutive 
guanines and had previously shown little non-specific binding to nuclear proteins, 
(Plumb et al, 1988). Preliminary experiments with oligonucleotides of random sequence 
showed high levels of non-specific protein binding. The sequence chosen, (aG7) (Table
2 .1 ), is a mutated form of a sequence which is important in binding an erythroid specific 
nuclear factor. Normally the erythroid-specific nuclear factor will bind to GATTAG 
motifs which are found to be conserved in the promoter regions and 3' enhancer regions 
of globin and non-globin genes, (Plumb et al, 1989). It is important at this point to 
emphasise that aG7 is known not to bind proteins in most cell types. HPLC purification 
after synthesis, and gel purification after radio-labelling the oligonucleotides, has shown 
to be necessary in the use of the oligonucleotides in the gel shift system in clearly 
allowing the identification of the binding factors.
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3 3  CDDP Treatment of Oligonucleotides
During the synthesis of the oligonucleotide, the crude reaction mixture 
collected at the end of each cycle contains different lengths of oligonucleotide sequence, 
depending on the efficiency of coupling of each nucleotide to the next The major 
species is the desired product There are also small quantities of premature termination 
sequences that range in size from one nucleotide to 26 nucleotides i.e one nucleotide 
shorter than the desired product Upon examination of Figure 3.1a, lane 1, one sees 
products also running at 25 and 26 nucleotides in size as well as the 27 base pair aG7. 
The smaller forms represent oligonucleotides which have not coupled completely in the 
synthesis process.
CDDP has a molecular weight of 300, this is similar to the molecular weight 
of a nucleotide which averages at 300. Therefore one CDDP adduct present on the 27 
base pair oligonucleotide was likely to increase the weight of the oligonucleotide to that 
of a 28 base pair oligonucloetide and could be observed on a denaturing gel as a shift to a 
form running at the 28 base pair size assuming there was no alteration in charge.
Treating double-stranded 27 base pair aG7 with increasing concentrations of 
CDDP produces an increase in slower migrating forms of the oligonucleotide observed 
on denaturing gels, (Figure 3.1a). Two of these forms migrate to a position consistent 
with intrastrand CDDP crosslinks or monofunctional adducts. These make up more than 
90% of the forms at the higher CDDP concentration. At the higher concentrations of 
CDDP treatment there is gradual disappearance of the 27 base pair oligonucleotide to 
slower migrating forms, so suggesting at these concentrations most of the 
oligonucleotide present contains CDDP adducts. The estimated molecular weight from 
labelled size markers of the majority of the forms would suggest they are 
oligonucleotides containing one and two CDDP adducts.
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Figure 3.1
Denaturing gel analysis of oligonucleotide treated with CDDP
A R1 2 3 4 5 6 7 d
1 2  3 4
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Panel A : Double stranded 27 base pair aG7 was treated with increasing concentrations 
of CDDP for lhr. Lanes 1-7 are aG7 treated with 0, 1, 10, 50,75, 100, 200iig/ml 
CDDP. The CDDP treated oligonucleotides were then end labelled with y^2P ATP, 
separated on a 20% denaturing polyacrylamide gel and autoradiographed. Size of the 
bands in bases were estimated from size markers.
Panel B : Exonuclease III digestion of oligonucleotide. Lanes 1 and 2 untreated aG7, 
lanes 3 and 4 aG7 treated with 200|ig/ml CDDP for 1 hr. Lanes 2 and 4, 
oligonucleotides incubated with exonuclease III prior to denaturing polyacrylamide gel 
electrophoresis.
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A smaller amount of the oligonucleotide migrates at a position consistent with interstrand 
CDDP cross-links. (Figure 3.1a, lanes 6  and 7) observed on the gel migrating between 
the 50 and 75 base pair size marker.
Exonuclease HI, a double strand specific 3-5' nuclease has previously been 
used to define the site(s) of CDDP modification, (Royer-Pokora et al, 1981). 
Exonuclease ID digestion of the oligonucleotide aG7 with or without CDDP treatment is 
shown in Figure 3.1b. Digestion of the CDDP treated oligonucleotide shows one major 
and one minor DNA fragment which are resistant to Exonuclease ID (lane 4) and are not 
present in the Exonuclease HI digested unplatinated aG7 (lane 2). This would suggest 
that the CDDP adducts are not randomly distributed in the oligonucleotide sequence, but 
rather are localised at one main site. The size of the minor nuclease resistant fragment is 
also consistent with nuclease digestion stopping at one main site in oligonucleotides 
containing interstrand crosslinks.
The larger 2aG7 oligonucleotide (54 base pairs) was analysed in the same 
way as above, by denaturing gel electrophoresis (Figure 3.2). However with the 2aG7 
being larger than the aG7, the resolution in the denaturing gel system is not as sharp and 
also the gel is overloaded. It can be seen however, that treatment of the 2aG7 with 
400|ig/ml CDDP causes a shift to a slower migrating form of the oligonucleotide. Again 
one sees that a smaller amount of the oligonucleotide (approximately 1 0 -2 0 %) migrates 
to a position consistent with interstrand crosslinks, (Figure 3.2). The exonuclease HI 
treatment of the CDDP-2aG7 produces three major fragments (marked A, B, C on figure
3.2), two of which may represent the site of major adduct formation of intrastrand 
crosslinks (sites B, C) and one which may represent nuclease digestion stopping at one 
main site in the oligonucleotide containing interstrand crosslinks (site A) as previously 
discussed.
81
Figure 3.2
Denaturing gel analysis of 2aG7
1 2 3 4
lanes 1 and 3, 2aG7. Lanes 2 and 4, 2aG7 treated with 400fig/ml CDDP for 1 hgm\ 
Prior to denaturing gel electrophoresis oligonucleotides were end labelled with y  P 
ATP. Lanes 3 and 4 treated with exonuclease III.
82
The larger platinated 2aG7 was also analysed by ICPM spectrometery, (Tothill et al, 
1990), (Figure 3.3), in collaboration with Dr.D.Bissett, Dept. Medical Oncology, 
University of Glasgow and the Scottish Universities Reactor Centre, East Kilbride. 
Nuclease digested and HPLC separated nucleotides of the CDDP treated oligonucleotides 
showed a platinum to nucleotide ratio of 8.96x10'^. (Platinum levels measured by ICPM 
spectrometry). From the trace (Figure 3.3) the major peak, peak 3 represents PtG-G 
adducts, (the peaks are compared to known standards of CDDP adducts run at the same 
time). The method cannot differentiate, however, between PtG-G intrastrand or 
interstrand adducts. However upon comparison of the denaturing gel electrophoresis, 
(Figure 3.2), 90% of the adducts prove to be migrating at a size consistent with 
intrastrand and monofunctional adducts, therefore suggesting that the major peak of the 
trace may represent PtG-G intrastrand adducts. Directly after the major peak PtGxG (x is 
any nucleotide) adducts come off. It is therefore difficult to distinguish if the major peak 
also has a population of PtGxG adducts within it. It has been reported that PtGxG 
adducts form less than 1 % of the total adducts, therefore suggesting that a small 
proportion, if any, of the major peak would represent PtGxG adducts. In the trace 
(Figure 3.3) a peak representing PtA-G cross-links is shown, (peak 2), however it was 
again not possible to distinguish between intrastrand or interstrand cross-links. As 
demonstrated in Figure 3.3 approximately 25% of the adducts are in the monofunctional 
adduct form, (peak 1). Less than 1% of adducts formed are normally of the 
monofunctional form (Eastman,1986). It has generally been accepted that in the reaction 
of CDDP with DNA monofunctional adducts are formed which will gradually react to 
form the bifunctional cross-links. The time of CDDP treatments, prior to quenching of 
the monofunctional adducts with NH4 HCO3 , may cause these differences in the amount 
of monofunctional adducts. Normal protocols for CDDP treatment of DNA follows a 18- 
24 hour treatment with drug whereas the protocol used here follows a 1 hour treatment of 
DNA with CDDP.
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Figure 3.3
Platinum detected in HPLC fractions of a 2aG7 digest
2.0
.0
0.5
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Fraction Number
2aG7 treated with 400|ig/ml CDDP, digested to the nucleotide level by treatment with 
DNAsel and Nuclease PI, HPLC purified and platinum detected within the fractions by 
ICPMS. Peaks 1, 2, 3 represent peaks at which major adducts are formed based on 
standards which have been characterised by NMR studies and obtained from Fichtinger- 
Schepman (Fichtinger-Schepman et al, 1982). Peak 1 = monofunctional adducts, Peak 2 
= PtA-G adducts, Peak 3 = PtG-G adducts. This work was carried out in collaboration 
with Dr.D.Bissett, Medical Oncology Dept., Glasgow and Scottish Universities reactor 
centre, East Kilbride.
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3.4 Identification of DDRPs by gel mobility shift assay
Use of the 27 base pair oligonucleotide, after CDDP treatment, in the gel 
shift system did not show a different pattern of binding compared to the unplatinated 
sequence (Figure 3.4, lane 9 cf. lane 12). It can be seen that retarded bands do appear in 
the unplatinated aG7, lane 9. The bands however bind both to the the platinated and 
unplatinated forms of the sequence. They therefore represent non-specific factors which 
bind to the sequence but not to CDDP adducts. It was decided to use a longer piece of 
oligonucleotide to investigate if there was a DNA length requirement for binding of 
DDRPs. The platinated aG7 after kinase labelling was ligated to a cold excess of 
untreated, unphosphorylated aG7. This was in the hope to favour the reaction of the 
platinated aG7 ligating to the unplatinated aG7, so forming a longer section of DNA, 
with one section containing the CDDP adducts. This should therefore form a more stable 
DNA duplex with CDDP present nearer the centre of the DNA. Before a ligation process 
will occur at least one end of the oligonucleotide must be phosphorylated, therefore 
ligation of the unphosphorylated, unplatinated aG7 should be an unlikely event. With 
the unplatinated form of the aG7 being in excess in the reaction, it is likely that the 
reaction will be between platinated aG7 with unplatinated aG7. After ligation monomer, 
dimer and trimer forms were separated by gel electrophoresis and isolated. To verify the 
forms isolated represented monomer, dimer and trimers, equal amounts of each fraction 
were analysed on a denaturing gel (data not shown).
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Figure 3.4
Gel mobility shift assay of monomer, dimer and trimer forms of aG7
1 2 3 4 5 6 7 8 9 10 11 12
^ B1
B2
FREE 
OLIGO
labelled non-CDDP treated aG7 and CDDP treated aG7 were ligated to an excess 
of untreated aG7. After ligation monomer, dimer and trimer forms were gel purified. 
Lanes 1-6 represent oligonucleotides incubated without extract and lanes 7-12 
oligonucleotides incubated with lpg Hela nuclear extract. Oligonucleotides in lanes 4-6 
and 10-12 were treated with 200pg CDDP prior to ligation and gel purification. The 
assay conditions are as those described in section 2.5.1. Lanes 1, 4, 7, 10 represent trimer 
forms of aG7, lanes 2, 5,8, 11 dimer forms of aG7, lanes 3, 6, 9, 12 monomer forms of 
aG7. After the ligation process the purified forms were analysed on a denaturing gel to 
check the sizes, data shown in figure 3.5. The position of unbound oligonucleotide (free 
oligo) is shown, although in the case of monomer aG7 this was electrophoresed off the 
gel.
Bands B1 and B2 represent retarded complexes.
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Figure 3.4 shows a gel mobility shift assay using the ligated substrates with nuclear 
extract from Hela cells. Two new bands are observed to bind to the CDDP-dimer 
containing fraction upon incubation with Hela extract, bands B1 and B2 (lane 11). In the 
CDDP-trimer containing fraction (lane 10), band B1 is observed much stronger than band 
B2. There is a very faint appearance of band B2 in the CDDP-trimer fraction (lane 10) 
which is totally absent in the unplatinated ligated form of the aG7 (lane 7). Bands B1 
and B2 are only observed when the aG7 has been CDDP treated prior to ligation (lanes 
10-12). ( The binding to Bands B1 and B2 is proteinase K sensitive and RNAse resistant). 
Binding of complexes to the untreated oligonucleotides are also observed, but these are 
not affected by the CDDP treatment of the oligonucleotides and represent non-specific 
binding complexes. No difference in binding of complexes to the monomer before or 
after CDDP treatment is observed. It is therefore found that DDRPs can be detected 
using a platinated oligonucleotide of 54 bases in length but not of 27 bases in length. It 
can therefore be postulated that the critical length of the platinated oligonucleotide used 
in the detection of proteins recognising CDDP adducts must be between the limits of 27 
and 54 bases in length.
To investigate the altered binding to the CDDP treated dimer and trimer 
forms of the aG7, an oligonucleotide of 54 base pairs in length containing two direct 
repeats of the aG7 sequence was synthesised. This oligonucleotide is therefore 54 base 
pairs in length. The following work described is carried out using this longer 
oligonucleotide 2aG7 unless otherwise stated.
To investigate if the protein(s) recognising the damage to the oligonucleotide, 
by CDDP treatment, are binding at saturation level in the extract, dilutions of Hela 
extract incubated with both non-CDDP and CDDP treated 2aG7 oligonucleotide were 
carried out.
Figure 3.5 shows that with increasing concentrations of Hela extract an 
increase in the binding of protein complex B 1 to the platinated 2aG7 occurs (lanes 2 , 4 , 
6 , 8 ), however only at the two lowest concentration is a difference seen with band B2 
(lanes 2, 4). If increasing concentrations of extract are incubated with unplatinated 2aG7 
(lanes 1, 3, 5, 7) there is little difference in band B l, although a slight increase may be 
seen but almost negligible in comparison to that seen with the platinated 2aG7. This 
therefore suggests that the protein represented in band Bl is limiting within the extract 
whereas the protein complex represented by band B2 is in excess at concentrations 
greater than 0.5|ig of extract The concentration of Hela extract used in the previous set 
of experiments (Figure 3.4), l|ig, therefore allowed one to detect actual changes 
occurring in the binding of proteins to the platinated oligonucleotide. This knowledge 
also allowed the following competition experiments described in the next section to be 
analysed.
3.5 Competition experiments of the DDRPs in the gel shift system.
The increased binding of complexes from Hela cells to platinated 2aG7 
compared to unplatinated 2aG7 is shown in Figure 3.6 (lanes 3  and 4). Coincubation of 
calf thymus DNA with CDDP-2aG7 and Hela extract has no effect on the binding of the 
complexes, Figure 3.6 (lanes 5-7). However coincubation with CDDP treated calf 
thymus DNA shows a dose dependant decrease in the complex represented by band 1. 
Band 2 completely disappears upon incubation with even the lowest concentration of 
CDDP treated calf thymus DNA (Figure 3.6, lanes 8-10). ICPM spectrometery of the 
CDDP adducts in calf thymus DNA, Figure 3.7, showed it to have a platinum to 
nucleotide ratio of 1.5x10"^ and for more than 80% of the population to consist of 
dinucleotide platinum crosslinks with the d(GpG) to be the main lesion.
Figure 3.5
Gel mobility shift assay of 2aG7 with increasing concentrations of Hela nuclear 
extract
1 2  3  4  5  6  7  8
FREE OLIGO
labelled non-CDDP and CDDP treated 2aG7 incubated with increasing 
concentrations of Hela nuclear extract in binding conditions as section 2.5.1. Lanes 1, 3, 
5, 7 non-CDDP 2aG7 incubated with 0.1, 0.5, 1, 2 fig Hela nuclear extract respectively. 
Lanes 2, 4, 6, 8 CDDP treated 2aG7 incubated with 0.1, 0.5, 1, 2 fig Hela nuclear extract 
Nuclear extract prepared as by section 2.3.3.1) CDDP treatment of oligonucleotide at a 
concentration of 400pg/ml CDDP. Retardation complexes represented by bands Bl and 
B2.
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Figure 3.6
Competition of binding complexes detected in gel mobility shift assay
1 2 3 4 5 6  7 8  9  10 11 12 13 14 15 16
FREE
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Coincubation of the complexes with calf thymus DNA + CDDP. ^2p labelled CDDP- 
2aG7 and untreated 2aG7 were incubated with lpg of Hela nuclear extract (binding 
conditions, nuclear extraction method and CDDP treatment as in previous figures).
Lanes 1, 3 2aG7, lanes 2,4-16 CDDP 2aG7. Lanes 3-16 incubation with l|ig  Hela 
nuclear extract, lanes 5-7 coincubation with 2.5, 7.5,12.5 |ig calf thymus DNA, lanes 8- 
10 coincubation with 2.5, 7.5, 12.5 jig CDDP treated calf thymus DNA (representing an 
excess of 1600x, 4800x, 8000x CDDP adducts).
Lanes 11-13 coincubation with 0.05, 0.15, 0.25pg 2aG7 respectively, lanes 14-16 
coincubation with 0.05, 0.15, 0.25}ig CDDP-2aG7. (representing a 1300x, 3900x, 6500x 
Molar excess). Specific retardation complexes represented by bands Bl and B2.
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Figure 3.7
Platinum detected in HPLC fractions of treated calf thymus DNA digest
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Calf thymus DNA is treated at a drug : nucleotide ratio of 0.08 with CDDP. It is then 
digested to the nucleotide level by treatment with DNAse I and Nuclease PI, HPLC 
purified and platinum detected within the fractions by ICPMS. The standards used for 
the CDDP adducts were characterised by NMR and were obtained from Fichtinger- 
Schepman. This work was done in collaboration with Dr.D.Bissett, Dept.Medical 
Oncology.
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Therefore an excess of at least 3900 fold of CDDP adducts is required to compete for 
binding to band Bl and less than a 1600 fold excess of CDDP adducts to compete for 
band B2. At most a 1300 fold Molar excess of CDDP treated oligonucleotide is required 
for competition of Band B2 whilst at least a 1300 fold Molar excess of unplatinated 
oligonucleotide competes for binding to band Bl. Thus binding of the DDRPs to the 
CDDP-2aG7 can be competed with DNA of unrelated sequence containing CDDP 
adducts, showing that the complex formation is independent of the DNA sequence used. 
Coincubation with an excess of 2aG7 competes for binding of the protein complex 
represented in band Bl but not of the protein complex represented in band B2 (lanes 11- 
13). However coincubation with a cold excess of CDDP-2aG7 competes for the binding 
in band B2 (lanes 14-16).It therefore can be concluded that binding in the complex Bl 
can be competed for with an excess of platinated calf thymus DNA, platinated 
oligonucleotide, unplatinated oligonucleotide but not with unplatinated calf thymus 
DNA. The binding in B2 can however only be competed for with platinated forms of 
calf thymus DNA or oligonucleotide.
3.6 DDRPs recognising single-stranded DNA
CDDP is known to bind to DNA and generate areas of local base pair 
disruption around the adduct. It therefore may be hypothesized that DDRPs could also 
recognise single-stranded DNA. To investigate this hypothesis, coincubation of single 
stranded M l3 with CDDP-2aG7 and Hela was carried out, (Figure 3.8). This shows 
that, upon coincubation with single stranded M l3 within the reaction, there is 
competition of band Bl, but not band B2. This therefore suggests that the protein 
complex is recognising single strands of oligonucleotide or single-stranded areas 
generated around the CDDP adduct.
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Figure 3.8
Competition of binding complexes B l and B2 with single stranded DNA
-«■ B1
\
r
32P labelled non-CDDP and CDDP 2aG7 coincubated with single-stranded DNA. Lane 
1, non-CDDP 2aG7, lanes 2, 3, 4 CDDP 2aG7. All lanes incubated with 1 \ig A2780. 
Lanes 3, 4 coincubated with 0.2|ig M l3 and 0.4fig M l3 respectively. Conditions as 
described in section 2.5.1.
1 2 3 4
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The binding of non-specific retardation complexes observed in both the unplatinated and 
platinated oligonucleotides are not competed by the CDDP treated calf thymus DNA, nor 
by the platinated 2aG7. For a further investigation and discussion of single stranded 
binding proteins as DDRPs and their involvement in excision repair refer to chapter 4.
3.7 Binding complexes are conserved across mammalian species
The gel purified trimers which were analysed by denaturing gel analysis, 
were used in gel mobility shift assays with nuclear extracts from different species, 
(Figure 3.9). CDDP-DNA binding complexes are observed after incubation with the 
CDDP treated trimer oligonucleotide with human (Hela and ovarian cell lines), murine 
(Mouse Erythroid Leukemia cells) and feline (T cell leukemia) nuclear extracts. The 
main complexes, bands Bl and B2 are seen with all extracts, however additional, less 
strongly binding complexes, are observed with some of the extracts. In the mouse 
erythroid leukemia cell extract a new complex is detected which binds to both the 
platinated and unplatinated forms of the oligonucleotide sequence. The oligonucleotide 
as described in section 3.1 is a mutated form of a sequence which is important in binding 
an erythroid specific nuclear factor. This sequence has been shown to weakly bind the 
factor (Plumb et al, 1989). The new complex observed could be a representation of the 
binding of this erythroid factor.
It therefore can be concluded that binding of complexes represented by bands 
Bl and B2 can be demonstrated in different species therefore suggesting that these 
protein complexes which recognise the CDDP damage may be important in a variety of 
different species.
3.8 Comparison of binding complexes in Hela and XPE
Chu and Chang (1988), identified two factors which represent binding to UV 
damaged DNA. Binding of both of these factors was shown to be competed for with 
CDDP damaged DNA therefore the question arises of the importance of these factors in 
recognition of CDDP damage. It was also reported by Chu and Chang that these two 
damage binding factors are both absent in Xeroderma complementation group E (XPE) 
cell extracts. To compare the damage recognition proteins detected by Chu and Chang 
with those identified in this chapter, experiments were performed using the gel mobility 
shift assay with CDDP-2aG7. Figure 3.10 shows that there is no difference in the 
binding factors B l and B2 in comparison of the Hela cell extract with the XPE cell 
extract. It therefore can be assumed that the proteins being detected in the gel shift assay 
by the platinated 2aG7 are different from those binding factors which recognise the UV 
damage, (Chu and Chang, 1988).
Figure 3.9
Detection of complexes B l and B2 across different mammalian species
1 2 3  4 5 6 7  8 9  10
*B1
- B2
■^P labelled CDDP-2aG7 and 2aG7 incubated with different mammalian extracts in 
conditions described in 2.5.1. Lanes 1, 3, 5, 7, 9 2aG7, lanes 2, 4, 6, 8, 10 CDDP-2aG7. 
Lanes 1 and 2 incubated with lfig Hela, lanes 3 and 4 lpg A2780, lanes 5 and 6 ljig 
Ovl, lanes 7 and 8 l|ig Feline T cell leukemia, lanes 9 and 10 l}ig mouse erythroid 
leukemia. All of the extracts used were prepared by the nuclear extract method as in 
section 2.3.3.1. Specific retardation complexes represented by bands Bl and B2.
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Figure 3.10
Comparison of Hela with XPE nuclear extracts by gel mobility shift assay 
1 2 3 4
P labelled 2aG7 and CDDP-2aG7 incubated with either Hela or XPE nuclear extract
(conditions as described in section 2.5.1). Lanes 1 and 3 2aG7, lanes 2 and 4 CDDP 
2aG7. Lanes 1 and 2 incubation with ljig Hela nuclear extract, lanes 3 and 4 incubation 
with lfig XPE nuclear extract. Specific retardation complexes represented by bands Bl 
and B2.
3.9 DISCUSSION
The work carried out in this chapter has attempted to illustrate the presence 
of mammalian protein(s) that binds specifically to DNA modified with the antitumour 
drug CDDP. The identification of DDRPs recognising CDDP damage in this chapter is 
by gel mobility shift assay. An oligonucleotide was chosen which has a sequence with 
two areas of three guanines. CDDP has been reported to bind to DNA forming adducts 
preferentially at N7 positions of guanine nucleotides, (Fichtinger and Schepman et al,
1985), therefore, the sequence of guanines within the oligonucleotide should provide an 
excellent target for CDDP adduct formation. The major DNA adducts of CDDP reported 
in the literature are d(GpG) and d(ApG) 1,2 intrastrand crosslinks, (Sherman and 
Lippard, 1987), representing 65% and 25% of adducts respectively. The remaining 
adducts are made up of 6 % GNG intrastrand crosslinks (N representing any base) and the 
final 4% of DNA interstrand crosslinks, DNA protein crosslinks and monofunctional 
adducts, (Eastman, 1986). In the quantification of adducts by Eastman it is observed that 
as few as 4% of the total adducts contain DNA interstrand cross-links, DNA protein 
cross-links and monofunctional adducts. However, upon comparison of these results 
with the adducts formed in the 2aG7 oligonucleotide, ICPM spectroscopy shows 
approximately 25% of the adducts are in the monofunctional form. It has been suggested 
as a model, that for the formation of CDDP cross-links the reaction must go through a 
two step process where there is a fast formation of CDDP-DNA monoadduct followed by 
slow closure to a bidentate adduct over 6-12 hours (Eastman, 1986). In Eastman's 
Protocol, CDDP treatment is for a period of 16 hours at 37^C. This time period should 
therefore give time for any monofunctional adducts being converted to bidentate adducts. 
The CDDP treatment followed in the experiments described in this chapter is a 1 hour 
CDDP treatment prior to quenching the formed adducts with NH4 HCO3 . This shorter 
period of CDDP treatment is therefore likely to result in a larger majority of adducts
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being in the monofunctional form. This could therefore explain the discrepancies in the 
amount of monoadducts reported in the literature to that observed in this chapter. The 
cell may contain DDRPs which recognise monofimctional adducts. This may be 
advantageous in the prevention of the cross-linking process which is thought to generate 
the cytotoxic lesion.
The aG7 oligonucleotide is a mutated form of the sequence which weakly 
binds an erythroid specific nuclear protein factor. As this factor is specific for erythroid 
cells it should not cause any problem in detection of the DDRPs by masking their binding 
when analysed in different cell extracts. The aG7 oligonucleotide was chosen to be used 
in the identification of the CDDP DDRP entirely for the sequence which contained a run 
of guanines and also the unplatinated form of the oligonucleotide showed little non­
specific binding in the gel shift assay. The choice of an oligonucleotide which binds an 
erythroid factor even weakly, may cause difficulties if the gel shift assay was to be 
extended into analysis of blood and tumour samples. The binding of the erythroid factor 
in these samples may mask differences in detection by the platinated oligonucleotide.
Using denaturing polyacrylamide gel electrophoresis, it can be seen that with 
increasing concentration of CDDP treatment, the 27 base pair labelled oligonucleotide 
begins to shift to slower migrating forms. These forms migrate to positions consistent 
with intrastrand cross-links. It has been suggested that 1,2 intrastrand crosslinks formed 
by CDDP may be responsible for the chemotherapeutic effectiveness, since trans-DDP 
the ineffective chemotherapeutically trans isomer, does not form this type of cross-link, 
(Pinto and Lippard, 1985). The concentration of CDDP which causes complete 
disappearance of the 27 base pair form of the oligonucleotide on a denaturing gel was 
chosen for subsequent experiments of DDRPs. In the platinated oligonucleotide 
population 90% consists of intrastrand and monofunctional adducts, whilst the remaining 
1 0 % migrates at a position consitent with interstrand cross-links.
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The type of cross-links contained within the population of platinated 
oligonucleotide have been determined in the 2aG7 oligonucleotide. ICPMS analysis of 
the platinated 54 base pair oligonucleotide 2aG7 shows the majority of adducts to be 
formed between guanine-guanine and adenine-guanine nucleotides. Previous reports 
have suggested that approximately 90% of the total platinum in the DNA is linked to N7 
atoms of the nucleobases adenine and guanine in the form of intrastrand cross-links, 
(Fichtinger-Schepman et al, 1985). By comparing the analysis of the CDDP treatment by 
the denaturing gel analysis, approximately 90% of the forms are observed to migrate to a 
position consistent with intrastrand cross-links and monofunctional adducts. It can 
therefore be postulated that although ICPM spectrometry cannot differentiate between 
PtG-G intrastrand and interstrand cross-links, the major peak represents a population 
mainly of PtG-G intrastrand cross-links. Normally upon reaction of CDDP in vitro with 
DNA, 90% of the adducts prove to be intrastrand with a small percentage being 
monofunctional in character. However as can be seen by ICPMS the CDDP treatment 
protocol used in this work leaves a larger than normal proportion of the adducts in the 
monofunctional form. Comparing the ICPMS trace of the platinated 2aG7 with that of 
the ICPMS trace of the platinated calf thymus DNA used in competition experiments, 
there is an extensive difference in the amount of monofunctional adducts formed. The 
protocol used for CDDP treatment of the calf thymus DNA was treatment for 4 hours in 
comparison to the 1 hour treatment for the 2aG7 oligonucleotide. The protocol in the 
calf thymus DNA gave a longer time for bidentate adducts to form in comparison to the 
oligonucleotide treatment. To date there is no direct evidence to which particular adduct 
forms the important cytotoxic lesion, although at present the literature favours the 1 ,2  
intrastrand crosslink.
The CDDP treated oligonucleotide (2aG7) was employed in a gel shift assay 
and differences in gel shift were seen comparing platinated 2aG7 to unplatinated 2aG7. 
At present the differences which were observed (bands B1 and B2) have not been shown
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to be specific to any one type of crosslink. Recent work has shown a protein complex 
binding to oligonucleotides which have specific 1,2 intrastrand d(GpG) and d(ApG) 
crosslinks. The proteins do not bind to 1,3 intrastrand crosslinks nor to interstrand 
crosslinks (Donahue et al, 1990). This suggests that DDRPs are present in mammalian 
cells which recognise and bind to what is presumed to be the important cytotoxic lesion 
formed by CDDP. It would be of use to take the 2aG7 sequence and generate specific 
crosslinks and then use these to characterise which type of cross-link the protein complex 
is recognising. Introduced in chapter 1, antibodies have now become available to the 
different CDDP-DNA adducts (Fichtinger-Schepman et al, 1985; Reed et al, 1982). 
These may help to provide a method of understanding, if introduced into the gel shift 
system, which adducts the DDRPs are recognising. The platinated 2aG7 sequence has 
many more monofunctional adducts than normally reported for CDDP treated DNA. The 
formation of the complexes in the gel shift assay could be due not only to the binding to 
the intrastrand cross-links but also to the monofunctional adducts prior to the formation 
of the intrastrand cross-links. Further experiments to investigate the importance of the 
monofunctional adducts would be to compare a time course of CDDP treatment prior to 
quenching the adducts in their monofunctional form. The increase in time of treatment of 
the oligonucleotide will allow more of the monofunctional forms to progress to their 
cross-link forms and so each point of time could be examined in the gel shift assay. If 
the DDRPs are involved in excision repair, the gel shift assay may be looking at a step 
occurring in the cell prior to any incision steps, where the cell detects the damage of the 
CDDP in the monofunctional form before the adduct progresses towards cross-link 
formation. This early recognition step could be beneficial to the cell as a means of 
removing any damage to the DNA before it forms cross-links which may cause more 
damage to the cell as a whole.
Studies of the DDRPs with the platinated 27 base pair aG7 did not show any 
difference in the gel shift therefore suggesting that protein complexes were not binding to
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the damaged DNA. If however the protein complexes being assayed were proteins of a 
scanning nature i.e binding to double-stranded DNA and moving its way along the DNA 
duplex until it reaches the site of damage, then it may be expected that the protein has a 
requirement for a stable duplex of DNA. CDDP being such a large bulky adduct, when 
reacted in vitro with the 27 base pair oligonucleotide will cause disruption of the duplex 
and hence if the protein present within cells is a scanning protein then it will not have a 
chance to bind to the DNA and hence recognition of the damage will not occur. This 
hypothesis was therefore tested by taking CDDP treated oligonucleotide, end label and 
ligating it to an excess of cold non-phosphorylated aG7. The different forms of the 
oligonucleotide were gel purified and used in a gel shift assay. A difference in gel shift 
patterns can only be seen in the 54 base pair and 81 base pair platinated forms of the 
oligonucleotide. No difference can be seen in binding, comparing the 27 bp unplatinated 
oligonucleotide to the 27bp platinated. This therefore suggests that the DDRPs do 
require a stable duplex of DNA for binding to occur. The size dependency of protein 
complexes binding to oligonucleotides has been reported previously, (Donahue et al, 
1990). They found that binding of their identified damage recognition protein occurred 
only to oligonucleotides 8 8  or 110 bp in length but not to probes that were 44 or 6 6  bp in 
length. Other groups who have detected CDDP damage recognition proteins have used 
DNA sequences of greater than 100 base pairs,(Chu and Chang, 1988, Chao et al, 1991a).
Competition experiments with platinated DNA of unrelated sequence were 
carried out to show that the binding of the DDRPs were independent of the platinated 
DNA sequence. It is observed that coincubation of the extract and platinated 
oligonucleotide with calf thymus DNA does not affect the binding of bands Bl and B2, 
whereas coincubation with platinated calf thymus DNA competes out the binding of band 
Bl in a dose dependant manner and competes band B2 completely at the lowest 
concentration of the platinated calf thymus DNA. This therefore suggests that the 
binding of complexes Bl and B2 is independent of DNA sequence. Although bands Bl
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and B2 are competed with platinated calf thymus DNA and not unplatinated calf thymus 
DNA, it cannot be presumed that the DDRPs are specific for CDDP damage. It is more 
likely that a cell will have evolved factor(s) which recognise different types of damage. 
It would be expected for the cell to contain repair protein(s) which will recognise specific 
classes of damage, such as a distortion in the DNA. It is therefore necessary to carry out 
cross competition experiments with DNA damaged by different agents such as ultraviolet 
radiation, mitomycin C, before any specificity of the DDRPs can be concluded.
If however, competition experiments are carried out using the sequence of 
2aG7, one sees that coincubation with unplatinated DNA competes for the binding in 
band Bl, whereas coincubation with platinated DNA competes for the binding in both Bl 
and B2. CDDP treatment of DNA has been reported to cause base pair disruption around 
the adduct and hence generate single-stranded areas around the adducts, (Sundquist et al,
1986). Competition experiments using either single-stranded 2aG7 or single-stranded 
M l3 as the competitor competes out band Bl. Therefore the competition of band Bl by 
single-stranded oligonucleotides and also by double stranded 2aG7 suggests that the 
protein complex recognises single-stranded regions, as well as having an affinity for 
double-stranded DNA. The discrepancy however in the hypothesis is if band B 1 has an 
affinity for double stranded DNA, why is it not competed out by calf thymus DNA. One 
explanation for this could be due to the number of ends present in calf thymus DNA 
compared to double stranded 2aG7. Calf thymus DNA has very large fragments of DNA 
present in its population compared to 2aG7, therefore the number of free ends within the 
calf thymus DNA will be much less than that within the 2aG7. If the protein complex 
has an affinity to bind to free ends then it is likely that it will be competed out much 
easier with 2aG7 than calf thymus DNA. It therefore can be suggested from this set of 
experiments that band B2 may represent a protein complex recognising a type of damage 
formed by CDDP, whilst band Bl may represent a single-stranded binding protein being 
detected. Evidence exists to suggest that single-stranded binding (SSB) proteins may be
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involved in the recognition of damage caused by certain DNA damaging agents. Toulme 
has suggested a role for SSB proteins in the damage recognition step on the basis of 
binding of gene 32 protein from bacteriophage T4 to DNA that has been chemically 
modified with carcinogens or antitumour agents. They found that gene 32 protein shows 
a high specificity for single-stranded DNA and binds more efficiently to DNA damaged 
with agents which cause structural changes to the duplex. The efficient binding is related 
to the formation of locally unpaired regions which are strong binding sites for the SSBs, 
(Toulme et al, 1983). Recently evidence has been presented that a mammalian DNA 
replication protein, human SSB is also involved in repair. Coverley et al (1991), showed 
that by using a cell free system that can carry out nucleotide excision repair in vitro, 
(Wood et al, 1988) ? addition of human SSB stimulated repair synthesis. Human 
SSB is a multi-subunit protein containing polypeptides of 70, 34, and 14KD. Antibodies 
to the sub-units 70 and 34KD have been isolated, (Kenny et al, 1990). Preliminary 
experiments in the gel shift system described in this chapter, with the monoclonal 
antibodies to the various subunits of the SSBs, have demonstrated that by including in the 
incubation the antibodies to the single-stranded binding proteins the binding of the 
complex represented by band Bl is abolished but no change to band B2 occurs, (personal 
communication, Dr.C.Clugston, Department of Medical Oncology, University of 
Glasgow). This is therefore strong evidence to suggest that the complex identified in 
band B1 is binding to a single-stranded form of the oligonucleotide. A further discussion 
of single-stranded binding proteins and their involvement in excision repair will be 
included in chapter 4.
Similar work in the identification of DDRPs has been carried out by several 
groups to identify proteins which bind to ultra-violet (UV) damage in DNA, (Chao et al, 
1991a, Chu and Chang, 1988, Patterson and Chu, 1989). UV as well as other agents such 
as mitomycin C (MMC) and CDDP all cause bulky adduct damage. It would therefore 
seem more economical for a cell to evolve a protein complex to deal with various types
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various types of damage. It would be of interest to test whether bands Bl and B2 which 
were detected by platinated 2aG7 are competed out with the various types of damage 
which cause bulky adduct formation. It is more likely that the damage recognition 
proteins within a cell recognises a structural conformation common to these various types 
of damage.
As discussed earlier, various groups are working on proteins recognising 
CDDP adducts. It is therefore important to compare results. Chu and Chang (1988), 
found a difference in a damage binding protein in Hela extracts in comparison to XPE 
extracts, they found their DRP to be absent in XPE cells. Cell lines derived from 
Xeroderma Pigmentosum (XP) patients are deficient in repair of DNA lesions induced by 
many types of DNA damaging agents including CDDP. XPE is simply one of, at least, 
eight complementation groups. Before any conclusions can be made about the XPE cell 
line being hypersensitive to the damaging agents because of the absence of the XPE 
binding factor, experiments in which the exogenous introduction of a single gene coding 
for this factor, corrects the DNA repair defect in intact cells, will have to be shown. The 
complexes described in these reports are detected by UV damaged probe and binding 
competed for with CDDP damaged DNA. It was therefore suggested that these proteins 
recognise both UV damage and CDDP damage. To provide evidence that retarded 
complexes represented as bands Bl and B2 in this chapter are different from Chu and 
Chang's binding factor, studies in comparing XPE cell extracts with Hela cell extracts are 
presented. It is shown that complexes Bl and B2 are present in both cell extracts, 
therefore suggesting that the proteins being detected by the CDDP treated 2aG7 are 
different from those detected by Chu and Chang.
The DDRPs if important in biological systems in the recognition of damage 
to DNA, would be expected to be present within different mammalian species. It can be 
seen in the extracts tested in this chapter that the DDRPs are present in mouse, cat and 
human extracts. However as well as bands Bl and B2 being detected other binding
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complexes are shown to bind to both the platinated and unplatinated forms of the 
oligonucleotide. These complexes generally represent non-specific binding complexes 
present in the extract. Detected within the mouse erythroleukemia extract, with both 
platinated and unplatinated oligonucleotide, is the binding factor which recognises the 
GATAAG sequence present as a mutated form in the oligonucleotide sequence. The 
DDRPs are therefore present within all the extracts tested and suggests that they may be 
ubiquitous to all mammalian cells.
In summary the experiments described in this chapter have led to the 
characterisation of mammalian cellular proteins which recognise and bind to DNA 
containing CDDP adducts. The DDRPs are shown to bind independently of sequence. 
They have also been shown to bind to various mammalian extracts hence suggesting 
that they may be ubiquitous to all mammalian extracts. It has been suggested that one of 
the protein complexes identified may represent a single-stranded binding protein and this 
is discussed with its involvement in excision repair.
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CHAPTER 4
INCREASED DAMAGE RECOGNITION PROTEINS IN AN  
OVARIAN CELL LINE RESISTANT TO CDDP - 
IDENTIFICATION BY SOUTH-WESTERN ANALYSIS
4.1 INTRODUCTION
As described in the previous chapter, proteins recognising DNA damaged by 
CDDP have been identified in different mammalian cell extracts. These proteins may be 
involved in the recognition of damage prior to recruitment of other DNA repair enzymes 
to remove the damage. They could also be involved in other aspects of DNA metabolism 
affecting toxicity of CDDP. If the DDRPs are involved in how the cell handles CDDP 
damage and since DNA repair has been implicated as a mechanism of CDDP resistance 
in vitro, it would be reasonable to examine if any changes occur in the DDRPs of CDDP 
resistant tumour cell lines.
During the progression of the work presented in this chapter, evidence was 
reported by two different groups to suggest that CDDP resistant cells express increased 
levels of a factor that recognises UV damaged DNA. By use of the gel mobility shift 
assay, it was reported that the factor which had been previously found to be deficient in 
XPE extracts, denoted as XPE binding factor, (Chu and Chang, 1988), was found to be 
increased in two independent cell lines resistant to CDDP, (Chu and Chang, 1990). In a 
separate study it was shown that a factor which recognises DNA damaged by ultra-violet 
radiation was increased in a CDDP resistant Hela cell line, (Chao et al, 1991a). Both the 
studies presented an increase in a protein present in CDDP resistant cell lines, which had 
previously shown enhanced levels of DNA repair. Both studies were carried out using 
gel shift assays. The gel shift assay has limitations in that the gel system used will detect 
protein(s) binding to a factor, but it will not differentiate between proteins binding as a 
complex to binding as a single protein species. The gel shift system allows one therefore 
to identify a factor which may represent various proteins acting within a complex to 
recognise the damaged DNA. The South-Western technique described below allows one 
to identify the specific proteins involved in the recognition of the damaged DNA.
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The South-Western technique was first defined by Bowen et al, (1980), in the 
detection of DNA-binding proteins. The method involves three steps:
(1) separation of proteins by gel electrophoresis in a SDS 
polyacrylamide gel system.
(2 ) transfer of the separated proteins to a nitrocellulose filter.
(3) analysis of the adsorbed proteins by incubating the filter with a
defined labelled probe. In the case of the work to follow in this chapter, y^2p ATP 
CDDP treated 2aG7 was used as the probe in the detection of proteins recognising 
DNA damaged with CDDP.
The oligonucleotide 2aG7 was chosen as the sequence to be used in the 
detection of the DDRPs for similar reasons to those described in detail in chapter 3:
(1 ) sequence contains guanines to which evidence has shown that 
CDDP binds preferentially to.
(2 ) the sequence shows little non-specific binding.
CDDP is known to bind to DNA and cause local denaturation around the
adducts (Sundquist et al, 1986). DDRPs recognising CDDP damage may therefore 
recognise these areas of single-strandedness. Evidence in the literature has suggested a 
role for single-stranded binding proteins, known to be involved in DNA replication, in 
excision repair (Coverley et al, 1991). Single stranded binding proteins have been 
extensively studied in replication of the adenovirus, SV40 system. SV40 has long been 
regarded as an excellent model for mammalian chromosomes since all the replication 
machinery for SV40 replication is given by the host cell i.e the mammalian cell. The 
only part of the machinery not derived from the host is the SV40 large T antigen protein.
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Initiation of SV40 DNA replication requires interaction of T-antigen with the origin of 
DNA replication, (for general review on DNA replication refer to Campbell, 1986). 
Human single stranded DNA binding protein (SSB) is found to be absolutely required for 
DNA replication. SSB is also known in the literature as RF-A and RP-A (Wold and 
Kelly, 1988, Fairman and Stillman, 1988). SSB consists of three polypeptides 70, 34, 
and 14KD. The 70KD subunit is found to bind to single-stranded DNA, whereas the 
other subunits do not. Antibodies have been generated towards the 70KD and 34KD 
subunits leading to the result that DNA unwinding and polymerase oc and 5 stimulation 
are required functions of human SSB in SV40 DNA replication, (Kenny et al, 1990).
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Recently there has been a report on the isolation of a DNA helicase that requires hSSB 
for activity (Soo Seo et al, 1991). By use of these antibodies in a cell free system that 
can carry out nucleotide excision repair, (Wood et al, 1988), extensive inhibition
of DNA repair of plasmid molecules damaged with ultraviolet light or 
acetylaminofluorene was observed, so suggesting a role for the SSB DNA replication 
protein in excision repair, (Coverley et al, 1991).
In the following chapter the identification of DDRPs recognising DNA 
damaged with CDDP are detected by South-Western analysis. Two out of the three 
identified DDRPs are found to be increased in a CDDP resistant human ovarian tumour 
cell line. Upon incubation of the South-Western blot of ovarian cell extracts, with 
single-stranded oligonucleotide 2aG7, proteins binding to the single-stranded DNA are 
observed which are of similar size to those detected with ds-CDDP-2aG7. These 
proteins were found to be increased in the CDDP resistant ovarian cell line extract, 
OvlDDP. It is therefore discussed as to whether the DDRPs increased in the CDDP 
resistant cell line extract have an affinity for both single-strand and double-strand DNA.
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4.2 RESULTS
4.2.1 Cell lines Investigated
CDDP is known to be effective in the treatment of human ovarian cancers, 
however the majority of patients with bulky ovarian cancer are not cured with standard 
CDDP regimes. The selection of subpopulations of resistant cells in the tumour has been 
suggested to account partly for chemotherapy treatment failure, (Ozols and Young, 
1984). As a way to study mechanisms of drug resistance, cell lines have been generated 
from different tumours and resistance to certain drugs have been developed in vitro. 
Although this is not an ideal situation, it allows one to study the mechanisms of 
resistance in vitro. Mechanisms of resistance to CDDP have been reported from in vitro 
studies, (see section 1.8).
To investigate if DDRPs are involved in the development of resistance to 
CDDP, two independent human ovarian cancer cell lines, both their sensitive and 
resistant sublines were analysed. A2780, (Behrens et al, 1987), Ovl originally named 
IGROV1, (Benard et al, 1985) are two independent human cell lines which were derived 
from ovarian carcinomas of two different untreated patients. CDDP resistant cell lines 
have been developed from both of these lines, denoted in this chapter as A2780CP and 
OvlDDP, by exposing them to increasing concentrations of CDDP, (Behrens et al, 1987), 
(Teyssier et al, 1989). The sensitivities to CDDP has been confirmed by MTT assay and 
Table 4.1 presents ID^q values for each cell line.
I l l
Table 4.1 id 50 OF OVARIAN TUMOUR CELL LINES
Cell line ffiso <M> Fold Resistance
A2780 2.4 x 10‘7
A2780CP 5 x 10‘6 20
Ovlp 9.5 x 10‘8
OvlDDP 4 x 10'7 4.2
4.2.2 Investigation of DDRPs in Ovl and OvlDDP by South-Western analysis
The probe used in the detection of the DDRPs is the 2aG7 oligonucleotide, 
CDDP treated, under identical conditions as that described in chapter 3. By incubating a 
South-Western blot of Ovl and OvlDDP probed with double stranded platinated 2aG7 
(ds-CDDP-2aG7), three separate factors of approximate size 25, 50 and 100KD are 
identified (Figure 4.1a). The 25KD and 100KD factors have been observed each to 
separate into two species, (data not shown). To determine if the three factors are 
recognising the damaged DNA or if they are simply binding to the oligonucleotide, a 
South-Western blot of the extracts was probed with ds-2aG7, (Figure 4.1b) . It can be 
seen that binding does not occur to the labelled ds-2aG7 using different extract 
preparations of the cells. The binding of the three factors to the damaged DNA is 
destroyed by prior incubation of the extract with proteinase K suggesting that the ds- 
CDDP-2aG7 is recognised by three different proteins. The 100KD protein recognising 
the damaged DNA is increased to levels of almost 7 fold greater in the OvlDDP resistant 
subline than in the Ovlp sensitive parental cell line (densitometry analysis).
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Figure 4.1
South-Western analysis of CDDP resistant ovarian cell line extract for DDRPs 
recognising DNA damaged with CDDP
Cell free extracts (100}ig total protein per lane) were separated on a 5-15% gradient 
SDS-polyacrylamide gel transferred to nitrocellulose and incubated with ATP 
labelled double-stranded oligonucleotide, 2aG7, both platinated and unplatinated in the 
presence of 3p.g/ml poly (dl-dC): poly (dl-dC) and 0.25% non-fat milk proteins.
Lanel : OvlDDP, Lane 2, Ovlp
Panel A : blot incubated with CDDP treated double-stranded oligonucleotide 2aG7.
Panel B : blot incubated with unplatinated oligonucleotide 2aG7.
Panel C : Coomassie Blue stain of 40|ig total protein on a SDS-PAGE gel.
Sizes in Kilodaltons estimated from molecular weight size markers.
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The 50KD protein is also increased in the OvlDDP cell line by values of 2 fold, (results 
by densitometry scan analysis).
Equivalent amounts of each protein extract from the different cell lines were 
analysed on the South-Western blot. Protein concentrations of the cell line extracts were 
estimated using the Biorad protein assay (section 2.4.1) which is based on the Bradford 
method, (Bradford, 1976). To be confident of these estimated protein concentrations a 
Coomassie Blue stained SDS-polyacrylamide gel of the cell extracts are visually 
examined to check the protein content. A Coomassie Blue stained gel is shown for 
equivalent concentrations of Ovlp and OvlDDP, (Figure 4.1c). After transfer of the 
proteins from the gel to the nitrocellulose filter, the filter is stained with Ponceau-S (data 
not shown). This procedure allows one to identify equal transfer from the gel to the 
nitrocellulose filter. The increase in both the 50 and 100KD proteins in the OvlDDP has 
consistently been found in independent prepared extracts.
4.2.3 Competition experiments of the DDRPs in the South-Western Assay
The competition for binding of the DDRPs with a cold excess of unplatinated 
and platinated DNA can help to lead to an understanding in the binding specificity of the 
DDRPs. It is more difficult, however, to show that binding is competed in a dose 
dependent manner in the South-Western system as shown in the gel mobility shift system 
(Figure 3.7). These types of experiments should provide evidence that the proteins are 
binding to damaged DNA and are independent of the sequence used in their detection.
The DDRPs identified by incubating a South-Western blot of Ovl and 
OvlDDP with CDDP-ds-2aG7 are shown in Figure 4.2a. Again the increase in the 
100KD and 50KD DDRPs is observed in the OvlDDP cell extract. This particular 
South-Western analysis shows higher levels of a 70-80KD protein(s)
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South-Western blots were carried out under identical conditions as described in figure 4.1 
and incubated with ATP labelled double-stranded CDDP treated 2aG7
oligonucleotide in the presence of 3fig/ml poly (dl-dC): poly (dl-dC) and 0.25% non-fat 
milk proteins and coincubated with :
Panel A : no competitor.
Panel B : at least 2,400 fold excess of unplatinated double-stranded 2aG7.
Panel C : at least 2,400 fold excess of platinated double-stranded 2aG7.
Panel D : 2pg calf thymus DNA.
Panel E : 2pg platinated calf thymus DNA (representing at least a 2,000 fold excess of 
platinum DNA adducts.
Lane 1 Ovlp, Lane 2 OvlDDP
Sizes in Kilodaltons estimated from molecular weight size markers.
Figure 4.2
Competition of DDRPs with double -stranded DNA, platinated and
1 2  1 2
kd
m -
unplatinated
44 "
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than usually observed. This may represent modified or degraded forms of the 100KD 
protein. Coincubation of the blot with greater than 200 fold Molar excess of cold 
unplatinated double stranded 2aG7 has little effect on the binding of the DDRPs, (Figure 
4.2b). However competition for binding to the 25, 50, and 100KD DDRPs by the CDDP- 
ds-2aG7 occurs when the blot is coincubated with unlabelled CDDP-ds-2aG7, (Figure 
4.2c) .
The binding of the CDDP-ds-2aG7 to the DDRPs cannot be competed for by 
an excess of ds-2aG7. However the binding can be competed for with an excess of 
CDDP-ds-2aG7. This suggests the identified DDRPs recognise DNA damaged with 
CDDP.
To determine if the binding of the DDRPs is independent of the sequence 
2aG7 used, competition experiments were carried out using DNA of a totally unrelated 
sequence, calf thymus DNA, as a competitor for binding. The calf thymus DNA used in 
these experiments was from the same source used for the competition experiments 
described in chapter 3 (section 3.5). Coincubation of the blot with platinated calf thymus 
DNA, representing more than a 2000 fold excess of platinum adducts, competed for 
binding of the 50KD and 100KD DDRPs, (Figure 4.2e). However coincubation with the 
same concentration of unplatinated calf thymus DNA did show some competition for 
binding to the 100KD and 50KD DDRPs, although competition for the 100KD DDRP 
was not as effective as that with platinated calf thymus DNA. Therefore, binding of 
CDDP-ds-2aG7 to the DDRPs can be competed more efficiently with CDDP treated 
DNA. Further, binding to the 50KD and 100KD proteins can be competed with an 
unrelated DNA sequence that contains platinum adducts. However the platinated calf 
thymus DNA is less efficient at competing for binding to the 25KD protein than the 
platinated 2aG7 double-stranded sequence.
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4.2.4 DDRPs in Cell Extracts of Xeroderma pigmentosum
Complementation Group E (XPE)
As introduced in chapter 3, a factor which binds to UV damaged probe DNA 
has been identified (Chu and Chang, 1988). Using gel mobility shift assays, it has been 
reported that the factor is found to be absent in cell extracts made from XPE. The factor 
is denoted XPE binding factor. The comparison was made with the XPE between Hela 
and other normal fibroblastic cell lines.
Using the same XPE cell line as used in these experiments, GM02415, the 
DDRPs of XPE cell extracts were compared to those in Hela and Ovlp and OvlDDP cell 
lines, (Figure 4.3), in a South-Western blot probed with ds-CDDP-2aG7. Three major 
DDRPs are present in the XPE cell extract of 25, 50 and 100KD. These do not appear to 
be different from those previously detected in the Ovlp and OvlDDP cell extracts except 
they occur at different intensities. Hela cell extracts show DDRPs of molecular weight 
25 and 50KD similar to the other extracts examined, but instead of a 100KD DDRP, 
factor(s) slightly larger are observed, (this result is repeatedly observed in different gels).
The deficiency of XPE binding factor in XPE cell extracts compared to Hela 
cell extracts was reported in gel shift assays. Presented in chapter 3 is the examination of 
DDRPs detected in the gel shift assay. Comparing the DDRPs binding to CDDP-ds- 
2aG7 of Hela with XPE cell extracts no detectable differences are observed, (section 3.8, 
fig-3-11)-
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Figure 4.3
South-Western analysis of DDRPs in cell extracts of XPE compared with Hela and 
ovarian tumour cell extracts
South-Western blot carried out under identical conditions as described in figure 4.1 and 
incubated with y ^ P  ATP labelled CDDP treated double-stranded 2aG7 in presence of 
3|ig/ml poly (dl.dC): poly (dl.dC) and 0.25% non-fat milk protein.
Lane 1 OvlDDP, Lane 2 Ovlp, Lane 3 XPE, Lane 4 Hela cell extracts.
Sizes in Kilodaltons estimated from molecular weight size markers.
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It therefore can be concluded that either by gel mobility shift assay or South- 
Western analysis the DDRPs detected by incubations with ds-CDDP-2aG7 may be 
different from those detected by Chu and Chang since the identified DDRPs are detected 
in extracts of XPE.
4.2.5 Examination of DDRPs in A2780 and A2780CP
CDDP resistance can occur by a number of different mechanisms. An 
increase in both a 50KD and 100KD protein has been demonstrated in the OvlDDP, in 
the previous section. The DDRPs may be involved in the CDDP resistant phenotype of 
the OvlDDP cell line. DDRPs in an independent human ovarian tumour cell line, A2780 
were examined. A2780 has various CDDP resistant sublines derived from it (Behrens et 
al, 1987). The resistant A2780CP cell line used in these South-Western analysis is 
approximately 20 fold more resistant to CDDP than the parental A2780 cell line. Under 
conditions which show an increase in the 50 and 100KD DDRPs in the OvlDDP cell 
extract, there is no detectable differences in the DDRPs of the A2780 resistant cell line, 
A2780CP when incubated with ds-CDDP-2aG7, (Figure 4 .4b). In both the A2780 cell 
lines, proteins of 25 and 50KD are detected, however the 100KD protein, which is 
detected in the OvlDDP cell extract, is not detectable in the A2780CP. No binding to the 
unplatinated labelled ds-2aG7 oligonucleotide is observed under these conditions in the 
A2780 cell extract, (Figure 4.4a). Equivalent amounts of protein from each cell line 
extract are loaded on the gel. A Coomassie Blue stained gel is shown as a check of 
protein concentrations, (Figure 4.4c).
Figure 4.4
DDRPs recognising DNA damaged with CDDP in A2780 and A2780CP, analysed by 
South-Western blots
A B C
South-Western blots were carried out under identical conditions as described in figure 4.1 
and incubated with y^2p ^TP labelled double-stranded oligonucleotide 2aG7 both 
platinated and unplatinated in the presence of 3|ig/ml poly(dl.dC): poly(dl.dC) and 
0.25% non-fat milk proteins.
Lane 1 OvlDDP, Lane 2 Ovlp, Lane 3 A2780, Lane 4 A2780CP 
Panel A : blot incubated with unplatinated oligonucleotide 2aG7.
Panel B : blot incubated with CDDP treated double-stranded 2aG7.
Panel C : Coomassie Blue stained gel of loaded protein concentrations.
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4.2.6 SUBSTRATE SPECIFICITY OF DDRPs
4.2.6.1 Binding of single-stranded oligonucleotides to protein extracts from the
human ovarian cell lines
A South-Western blot of the two independent, A2780 and Ovlp, ovarian 
extracts, both sensitive and resistant sublines, was incubated with y ^ P  ATP labelled 
single-stranded oligonucleotide 2aG7, (Figure 4.5b). Proteins of approximate molecular 
weight 50KD and 100KD were detected in these lines. Increased binding to the y-^P 
ATP single-stranded 2aG7 to the 50 and 100KD was again detected in the OvlDDP cell 
line extract. This suggests that the DDRPs detected with the ds-CDDP-2aG7, may also 
recognise regions of single-strandedness, (Figure 4.5a). A protein of approximate size 
65KD is detected with the y ^ P  ATP labelled single-stranded oligonucleotide in the 
Ovlp cell extract which is not detectable in the OvlDDP cell extract. The 25KD protein 
observed with the ds-CDDP-2aG7 was not observed using the single-stranded 2aG7. 
Therefore the 25KD DDRP recognises double stranded DNA damaged with CDDP but 
not single-stranded DNA. Experiments incubating a South-Western blot with single­
stranded oligonucleotide treated with CDDP does not show any difference in the binding 
as observed in the single-stranded probed blot, (Figure 4.5c).
It therefore may be postulated the DDRPs may be recognising regions of 
single-strandedness generated around CDDP adducts.
Figure 4.5
South-Western analysis of single-stranded binding proteins in human ovarian 
tumour cell line extracts
1 2  3 4 1 2 3 4 1 2 3 4
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South-Western analysis was as described in figure 4.1. Blots were incubated in the 
presence of 3tyg/ml poly (dl.dC): poly (dl.dC) and 0.25 % non-fat milk proteins with 
Panel A : YxiP ATP labelled CDDP treated double-stranded 2aG7.
Panel B : Y^P ATP labelled single-stranded 2aG7 oligonucleotide.
Panel C : P ATP labelled CDDP treated single-stranded 2aG7.
Lane 1 OvlDDP, Lane 2 Ovlp, Lane 3 A2780, Lane 4 A2780CP
Sizes are in Kilodaltons estimated from molecular weight size markers.
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4.2.6.2 Competition experiments with single-stranded DNA
From the previous set of experiments it has been suggested that the 50KD 
and 100KD protein detected in a ds-CDDP-2aG7 probed Western blot of Ovl and 
OvlDDP are binding to single-stranded regions in the DNA. The binding of the single­
stranded oligonucleotide (Figure 4.6a) can be competed for with at least a 2000 fold 
Molar excess of single-stranded oligonucleotide (Figure 4.6b) If the DDRPs detected 
with the platinated double-stranded 2aG7 also recognise areas of single-strandedness 
then it may be hypothesized that competition of the binding of the DDRPs will occur 
upon incubation with an excess of single-stranded oligonucleotide.
Figure 4.6b in comparison to the other figures presented in this chapter 
shows many additional bands. These bands may be due to the degradation of the extract 
although on repeated experiments using the same extract less bands are detected. These 
additional bands may also represent modified forms of the major proteins detected. The 
binding of these additional bands may more likely be due to factors present in the extract 
which have lower affinities to the single-stranded oligonucleotide and may only be 
detected if the probe used is of higher specific activities. The washing conditions in the 
South-Western system is seven minutes at 4^C, therefore any variations in the time of 
washes after incubation with the probe may cause variations in the bands detected.
Competition of DDRPs detected in Ovl and OvlDDP, with an excess of cold 
ds-CDDP-2aG7 competes well for the 50KD and 100KD DDRPs, (Figure 4.7b). 
Competition of the 25KD DDRP occurs but to a lesser extent than of the other two 
identified DDRPs. Upon coincubation of the ds-CDDP-2aG7 probed blot of Ovl and 
OvlDDP with excess of cold single-stranded 2aG7, competition for binding of the 50KD 
and 100KD protein occurs, (Figure 4.7c), but to a lesser extent than with excess of ds- 
CDDP-2aG7, (Figure 4.7b). This therefore suggests that the 50KD and 100KD DDRPs 
may have an affinity for CDDP damaged DNA as well as single-stranded DNA.
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4.2.6.3 Binding of DDRPs to mismatch oligonucleotides
It has been demonstrated in the previous section that two DDRPs of 50KD 
and 100KD are detected in the ovarian tumour cell extracts by incubation with single­
stranded DNA. These DDRPs are of similar size to those detected with platinated 
oligonucleotide. Evidence in the literature has suggested CDDP adducts in DNA to 
behave as the centre of a directed bend with generation of single-stranded regions over 
some of the DNA (Sundquist et al, 1986; Anin and Leng, 1990). Anin and Leng reported 
CDDP adducts to locally denature over 2 base pairs and distort over 4-5 base pairs. This 
therefore leads to a disruption over 6-7 base pairs of the DNA duplex.
To test whether CDDP adduct induced disruption of the duplex could be 
mimicked by mismatches in the DNA, oligonucleotides with different mismatches were 
generated. The mismatches were generated at the region of the oligonucleotide to which 
the majority of CDDP is thought normally to react i.e the sequence of guanines. 
Mismatches of 3 base pairs (3bpMM) and 7 base pairs (7bpMM) were generated in the 
2aG7 sequence (refer to table 2.1 for sequence). Figure 4.8 demonstrates that upon 
incubation under similar conditions which detects binding of DDRPs to CDDP-ds-2aG7 
(Figure 4.8a), there is no detectable binding of the mismatch oligonucleotides in the cell 
extracts of Ovl and OvlDDP (Figure 4.8b, c). However upon incubation with an excess 
of either 3 base pair mismatch or 7 base pair mismatch, there is preliminary evidence to 
suggest binding to the 25, 50, 100KD DDRPs is competed for (Figure 4.8d, e). It is 
unlikely that this competition is caused by single-stranded sequences in the 
oligonucleotide population, as binding is found not to occur to either the 3bpMM or the 
7bpMM sequence, so suggesting that the oligonucleotides are properly reannealed. It is 
not entirely clear as to whether this competition is true and these experiments would have
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Figure 4.6
Competition of single-stranded DDRPs detected in the South-Western system
1 2  1 2
_______ A B
South-Western analysis was under identical conditions as described in figure 4.1. 
DDRPs detected in all panels by incubation of the blot with y-*~P ATP single-stranded 
oligonucleotide 2aG7. The blots were coincubated with :
Panel A : no competitor.
Panel B : a 2000 fold excess of single-stranded oligonucleotide.
Lane 1 OvlDDP, Lane 2 Ovlp
Sizes are in Kilodaltons estimated from molecular weight size markers.
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Figure 4.7
Competition of DDRPs, detected with platinated double-stranded 2aG7, with both 
double-stranded CDDP treated 2aG7 and single-stranded 2aG7
1 2  1 2  1 2
South-Western analysis was as described in figure 4.1. DDRPs detected by incubating 
blots with y ^ P  ATP labelled double-stranded CDDP treated 2aG7. Blots were 
coincubated with :
Panel A : no competitor.
Panel B : at least a 2000 fold excess of CDDP treated double stranded oligonucleotide 
2aG7.
Panel C : At least a 2000 fold excess of single-stranded 2aG7 oligonucleotide.
Lane 1 OvlDDP, Lane 2 Ovlp
Sizes are in Kilodaltons estimated from molecular weight size markers.
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Figure 4.8
DDRPs binding to mismatch oligonucleotides
South-Western analysis was as described in figure 4.1. DDRPs detected by incubating 
blots with (a) y ^ P  ATP CDDP 2aG7 in panels A, D, E (b) y  ^ P ATP 3bpMM and 
7bpMM in panels B and C. Two of the panels were coincubated with a 2000 fold excess 
o f ; Panel D, 3bpMM and panel E, 7bpMM oligonucleotide.
Lane 1 = Ovlp, Lane 2 = OvlDDP
Sizes are in Kilodaltons estimated from molecular weight size markers.
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to be repeated using different extracts. It was shown previously in Figure 4.2 that 
binding was not competed for with an excess of double-stranded 2aG7.
DDRPs can therefore bind to platinated double-stranded DNA, single- 
stranded DNA, but are not detected, using similar conditions, binding to DNA containing 
mismatches. However preliminary evidence suggests that binding of the DDRPs 
detected by CDDP-ds-2aG7 can be competed for with the mismatch oligonucleotides, 
however not to as great an extent as competition with the CDDP treated DNA (Figure 
4.2).
4.2.6.4 Summary of competition experiments
The following table is a summary of the previous described competition 
experiments. It summarises the DDRPs detected by CDDP-ds-2aG7 and their 
competition either by double stranded oligonucleotide ± CDDP, by single-stranded DNA 
± CDDP or by mismatch oligonucleotides.
COMPETITOR 25 KD 50KD 100KD
ds-2cxG7 - - -
ds-CDDP-2ccG7 ++ ++ ++
Calf thy DNA +/- +/- +/-
CDDP Calf thy DNA + ++ ++
ss DNA - + +
CDDP ssDNA - + +
3bpMM +/- +/- +/-
7bpMM +/- +/- +/-
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4.2.7 DDRPs in A2780, A2780CP, Ovlp and OvlDDP - Detection by gel 
mobility shift assays
from
The gel mobility shift assay is a very different system / \  the South-Western 
technique, therefore it is very difficult to determine whether the DDRPs detected by 
South-Western analysis are different from those detected by gel mobility shift assays,
Two different groups, using gel mobility shift assays, have reported an 
increase in a binding factor recognising UV damaged DNA in CDDP resistant cells, (Chu 
and Chang, 1990, Chao et al, 1991a). Presented in the previous set of experiments there 
is found to be an increase in a 50KD and 100KD DDRP detected by South-Western 
analysis in a human ovarian cell line resistant to CDDP, OvlDDP. Both the Ovl and 
A2780 cell lines with their resistant sublines have been analysed on gel mobility shift 
assays. Under the conditions described, section 2.5.1, neither A2780CP or OvlDDP 
show any differences in the binding factors detected (B1 and B2) in the gel mobility shift 
assay, (Figure 4.9).
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Figure 4.9
Detection of DDRPs recognising DNA damaged with CDDP by gel mobility shift
assay
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y32P ATP labelled non-CDDP and CDDP treated 2aG7 incubated with two different 
human ovarian tumour cell extracts. Both CDDP sensitive and CDDP resistant 
counterparts of each line examined. Binding conditions as described in gel mobility shift 
assay, section 2.5.1.
Lanes 1, 2 A2780; Lanes 3, 4 A2780CP; Lanes 5, 6 Ovlp; Lane 7 OvlDDP. Lanes 1, 2, 
5 incubated with unplatinated 2aG7, lanes 3, 4, 6, 7 incubated with platinated 2aG7.
4.2.8 Summary of DDRPs detected by different probes
PROBE EXTRACT 25 50 65 lOOkd
DS A2780 - - - -
A2780CP - - - -
Ovl - - - -
OvlDDP - - - -
DS CDDP A2780 + + - -
A2780CP + + - -
Ovl + + - +
OvlDDP + ++ - ++
ss A2780 - + - +
A2780CP - + - +
Ovl - - + -
OvlDDP - ++ - ++
ssCDDP A2780 - + - +
A2780CP - + - +
Ovl - - + -
OvlDDP ++ — ++
4.2.9 Investigation of levels of DDRPs upon pretretment with CDDP
Many repair functions are induced de novo in damaged bacterial cells as a 
part of the SOS pathway which is believed to facilitate the recovery of bacterial cells 
from the toxic effects of DNA damaging agents (review, Little and Mount, 1982). 
Recent studies have indicated that inducible phenomena associated with DNA processing 
occur in mammalian cells exposed to carcinogens or tumour promoters (Elespuru, 1987). 
Hirschfeld and co-workers have demonstrated that upon pretreatment of primate cells 
with ultra-violet light, higher levels of DNA damage recognition proteins recognising UV 
damage can be detected (Hirschfeld et al, 1990). Another study by Glazer and co­
workers have demonstrated the inducibility of DNA binding proteins upon pretreatment 
of Hela cells with DNA damaging agents (Glazer et al, 1989) It was therefore of interest 
to examine if there was any significant change in the levels of the DDRPs recognising 
CDDP damage by pretreatment of the cells with CDDP.
After a 1 hour exposure to CDDP the cells were allowed to grow in drug free 
medium for various periods of time prior to a cell free salt extraction of the proteins. 
Figure 4.10 shows a Western blot of the A2780 and A2780CP probed with ds-CDDP- 
2aG7 with extracts made after different time periods in drug free medium. Conditions 
are identical to those detecting the change in the DDRPs of the OvlDDP cell extract 
(Figure 4.1). It can be seen however that over a time period of 24 hours for the A2780 
and 28 hours for the A2780CP after the CDDP pretreatment, there was no significant 
increase detectable in the DDRPs recognising CDDP damage. A short exposure of this 
gel did not show any significant difference in the 25KD DDRP.
Extracts from the Ovl and OvlDDP cell line were made 24 hours after a 1 
hour CDDP treatment. Figure 4.11 demonstrates that under conditions as described 
previously, there was no significant increase in the levels of the DDRPs in these cell 
extracts. It can therefore be concluded that under the conditions described, an increase in
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the levels of the DDRPs, upon pretretment with CDDP, does not occur in either of the 
ovarian cell line extracts.
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Figure 4.10
South-Western analyses of DDRPs in cell extracts of cell lines A2780 and A2780CP 
pretreated with CDDP
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South-Western analyses was as described in figure 4.1. The DDRPs were detected by 
incubation with CDDP-ds-2aG7 The extracts were made from A2780 and A2780CP 
pretreated with CDDP for 1 hour with different recovery periods prior to extraction. 
Lanes 1, 2, 3, 4 A2780, 5, 6, 7, 8, 9, 10 A2780CP. Extracts made from A2780, lanes 
l=0hours, 2=1 hour, 3=4hours, 4=24hours after the lhour CDDP treatment. Extracts 
made from A2780CP, lanes 5=0hours, 6= lhour, 7=2hours, 8=4hours, 9=24hours, 
10=28hours after the lhour CDDP treatment.
Sizes are in Kilodaltons.
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Figure 4.11
South-Western analyses of DDRPs in cell extracts of cell lines O vl and OvlDDP 
pretreated with CDDP
South-Western analyses was as described in figure 4.1. The DDRPs were detected by 
incubation with CDDP-ds-2aG7. The extracts were made from Ovl and OvlDDP 
pretreated with CDDP for 1 hour with a 24 hour recovery period. Lane 1, 2 = Ovl, lane 
3, 4= OvlDDP. Lanes 1 and 3, extracts were made directly after the lhour CDDP 
treatment, lanes 2 and 4 extracts made 24 hours after the 1 hour CDDP treatment.
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4.3 DISCUSSION
The work carried out in this chapter has attempted to identify the presence of 
mammalian proteins which bind to DNA damaged with CDDP. Unlike the previous 
chapter, chapter 3, which concentrates on the identification of DNA damage recognition 
proteins (DDRPs) by gel mobility shift assays, the South-Western technique is used.
Proteins which bind to UV damaged DNA have been detected by the gel 
mobility shift assay, (Chu and Chang, 1988; Hirschfeld et al, 1990; Chao et al, 1991a). 
The identification of proteins binding to CDDP damaged DNA have also been reported 
from gel mobility shift assays, (Donahue et al, 1990; Andrews and Jones, 1991). Little 
work has been carried out using South-Western analysis although it has been reported 
that factors of both 100KD and 28KD bind to DNA modified with either CDDP or 
Pt(en)Cl2 , (Toney et al, 1989). There is also a recent report showing South-Western data 
on the detection of proteins recognising CDDP damage present in kidney tubule cells and 
human ovarian tumour cells (Andrews and Jones, 1991).
The advantage of using the South-Western technique, is that it involves using 
an SDS polyacrylamide gel to separate the proteins. Sodium dodecyl sulphate (SDS) is 
an ionic detergent which is used in the SDS-PAGE system as an agent which will 
dissociate all proteins into their individual polypeptide subunits. The proteins which are 
identified in the South-Western blot probed with CDDP damaged DNA are individual 
proteins unlike the identified complexes in the gel mobility shift assay. The gel mobility 
shift assay uses a ’’native" gel system therefore the factors identified may represent 
complexes of proteins recognising and binding to the damaged DNA. It is therefore very 
difficult to compare results between chapter 3 and the present chapter since the gel 
systems used are very different and the binding conditions to damaged DNA have been 
optimised for each system, leading to different reaction conditions for each.
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Using the South-Western system, this chapter presents DDRPs binding to ds- 
CDDP-2aG7 oligonucleotide of 25, 50, and 100KD in human ovarian cell line extracts of 
Ovlp and A2780. The role of the DDRPs in the recognition of CDDP damage has not 
yet been defined. If they are involved in a DNA repair pathway then the question of their 
involvement in resistance to CDDP becomes a necessary one to address. Reported work 
from gel shift assays has shown an overexpression of the XPE binding factor in CDDP 
resistant Hela and HT1080 fibrosarcoma cell lines, (Chu and Chang, 1990). A separate 
group also reported overexpression of two nuclear factors that recognise UV modified 
DNA in CDDP resistant Hela cells, (Chao et al, 199 l a). It has been shown in the 
previous section that both the 50KD and 100KD DDRPs identified in the Ovlp cell line 
extract are overexpressed in the resistant subline OvlDDP. OvlDDP has been shown to 
be approximately five times more resistant to CDDP than the Ovlp cell line by the MTT 
assay. Before any correlation can be made on the observed increase in DDRPs of the 
OvlDDP cell line with pathways of DNA repair, DNA repair levels in these cell lines 
must be measured. Both the studies reported in the literature of the increase in DRPs 
demonstrated their resistant cell lines to have an enhanced repair capacity (Chu and 
Chang, 1990; Chao et al, 199 l a).
Competition for binding of the DDRPs with platinated and unplatinated 
oligonucleotide and calf thymus DNA were studied to determine the specificty of 
binding. This set of experiments showed that DDRPs in a South-Western system can be 
competed with DNA containing CDDP adducts, both with the same oligonucleotide 
2aG7 and DNA of an unrelated sequence, calf thymus DNA. Binding to double­
stranded unplatinated oligonucleotide 2aG7 does not occur under the conditions used to 
detect DDRPs binding to CDDP damaged DNA. There is no detectable competition of 
the DDRPs when incubated with an excess of double-stranded oligonucleotide. It was 
shown that binding to the 25KD is less efficiently competed for with platinated calf 
thymus DNA compared to the platinated double-stranded oligonucleotide 2aG7. This
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may be due to the number of adducts or types of adducts induced in these DNA, 
(analysis of the DNA has been described in chapter 3, sections 3.3 and 3.5). This set of 
experiments suggest that the 25, 50, and 100KD DDRPs are binding to DNA damaged 
with CDDP but are independent of sequence. Before a statement can be made about the 
type of damage the DDRPs are binding to, competition experiments would have to be 
carried out in which the DNA used as the competitor is damaged with different damaging 
agents, e.g. ultra-violet radiation , mitomycin C.
In comparison to the overexpression of the 50KD and 100KD DDRPs 
detected in the CDDP resistant subline, OvlDDP, in the South-Western study, no 
difference was observed in the gel mobility shift system under the binding conditions 
described. This therefore emphasises that comparisons between gel shift systems and 
South-Western systems should not be made because conditions both of the gels and 
binding are very different A recent study of another CDDP resistant ovarian cell line 
showed no differences in DDRPs in gel mobility shift assay but did detect proteins of 
similar size to those identified in this chapter, (Andrews and Jones, 1991). Although not 
shown in detail the South-Western analysis carried out in this separate resistant ovarian 
cell line, showed apparent differences in the DDRPs of the resistant line compared to 
those in the sensitive line.
CDDP has been shown to bind to DNA and cause a disruption of the DNA 
duplex over 4-5 base pairs, (Anin and Leng, 1990). Work using the anti-nucleoside 
antibodies in the probing for local denaturation of calf thymus DNA has shown that 
CDDP binding to DNA causes a single-stranded region around the adduct, (Sundquist et 
al, 1986). It is possible that DDRPs do not recognise specific adducts but recognise a 
distortion in the native double-stranded DNA generating areas of single-strandedness. It 
has been reported that the bacteriophage T4 gene 32 protein which is involved in DNA 
replication (Huberman et al, 1971), recombination (Kozinski and Felgenhauer, 1967) and 
repair of UV damage (Krisch and vanHoule, 1976) binds to single-stranded DNA (Jensen
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et al, 1976). Studies showed that the gene 32 protein which normally shows a low 
affinity for double-stranded DNA binds more efficiently to double-stranded DNA 
modified with CDDP (Toulme et al, 1983), therefore suggesting that CDDP may be 
causing areas of single-strandedness which are recognised by the gene 32 protein. A 
report on the absence of a single-stranded DNA binding activity in cell lines from 
xeroderma pigmentosum complementation group A, may suggest an involvement of 
single-stranded binding proteins in excision repair (Kuhnlein et al, 1983). Recent 
evidence has suggested a role for the replication protein human SSB in human DNA 
excision repair. Antibodies which have been generated towards the 70KD and 34KD 
subunits of SSB (Kenny et al, 1990) were included in a cell free system that can carry out 
nucleotide excision repair in vitro (Wood et al, 1988), It was found that on
addition of the antibodies to the system, DNA excision repair was inhibited (Coverley et 
al, 1991). On reintroduction of hSSB into the repair system, excision repair was initiated.
Results presented in this chapter have shown that proteins detected by 
incubating a South-Western blot of ovarian cell extracts with single-stranded 
oligonucleotide have identified binding proteins of approximate sizes 50KD and 100KD. 
It has been found that the proteins detected by the single-stranded oligonucleotide are 
also increased in the CDDP resistant OvlDDP cell line. The size of the DDRPs 
recognising the CDDP damaged double-stranded DNA is very similar to those detected 
with the single-stranded oligonucleotide. An increase in DDRPs of approximate sizes 
50KD and 100KD can be seen in the OvlDDP cell line both when either the platinated 
double-stranded oligonucleotide or single-stranded oligonucleotide (platinated or not) is 
used as the probe in the South-Western blot. DDRPs recognising CDDP damaged DNA 
can be competed for with single-stranded DNA although not to as great an extent than 
seen with the platinated calf thymus DNA. This may seem curious that binding to the 
single-stranded oligonucleotide only detects proteins of approximate size 50KD and 
100KD when there are many known DNA single-stranded binding proteins. Binding of
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these two proteins under the denaturing conditions used suggest that they function as a 
single species whereas as other single-stranded binding proteins will only function as part 
of a complex. Experiments using other single-stranded DNA would prove useful both in 
the competition for binding and also to detect if the same DDRPs would be detected. 
Before anything can be concluded on whether the DDRPs have an affinity for single­
stranded DNA as well as CDDP treated double-stranded DNA, experiments must be 
carried out in looking at the competition of binding of the 50 and 100KD proteins 
recognising single-stranded DNA with an excess of double-stranded DNA, both CDDP 
treated and not. The unplatinated oligonucleotide 2aG7 shows no binding of DDRPs 
therefore suggesting that in the reannealed stock of oligonucleotide prior to CDDP 
treatment, only a small amount, if any, is single-stranded. The 25KD DDRP detected by 
South-Western analysis using CDDP-ds-2aG7 shows no detectable binding to single­
stranded DNA.
It was of interest to determine whether the DDRPs which are detecting 
damage by CDDP would detect base pair mismatches in a DNA duplex. Mismatches 
generate disruptions in the DNA duplex. Binding of the DDRPs was not detected using 
the mismatch oligonucleotides however, preliminary evidence may suggest that binding 
to the 25, 50, 100KD DDRPs was competed for upon incubation with an excess of either 
the 3 base pair mismatch (3bpMM) oligonucleotide or the 7 base pair mismatch 
(7bpMM) oligonucleotide. Competition for binding to the DDRPs by the mismatch 
oligonucleotides is not as efficient as competition with CDDP treated oligonucleotide. It 
is unlikely that in the reannealed population of oligonucleotides that single-strands are a 
major problem, as there is no detection of DDRPs binding to the labelled 3bpMM or 
7bpMM. This set of experiments is very preliminary and would have to be repeated with 
different extracts before anything definitive can be said.
Proteins which bind to either UV damaged DNA or CDDP damaged DNA 
have been identified (Chu and Chang, 1988; Hirschfeld et al, 1990; Chao et al, 19913;
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Donahue et al, 1990; Andrews and Jones, 1991; Toney et al, 1989). Chu and Chang 
reported that the DRPs they identified recognising UY damaged DNA, were absent in 
cell line extracts of Xeroderma Pigmentosum Complementation Group E (XPE). They 
denoted this factor the XPE binding factor. They have suggested that because the factor 
is absent in XPE cell line extracts and recognises UV damage, it is a likely candidate to 
participate in a DNA repair system. There is a recent study that confirms the absence of 
the XPE binding factor in this particular cell line, however it shows the presence of the 
XPE binding factor in other cell lines derived from totally unrelated individuals with 
XPE (Kataoka and Fujiwara, 1991). Therefore the absence of the binding proteins is not 
always commonly observed in all the different XPE cell strains. The DDRPs discussed 
in this chapter were examined in the XPE cell strain in which a deficiency was shown 
both by Chu and Chang, and Kataoka and Fujiwara. Either by gel mobility shift assay 
(chapter 3, section 3.8, figure 3.11) or South-Western analysis, the identified DDRPs are 
present in the XPE extract. The DDRPs detected in the South-Western system in the 
XPE cell line extract are of similar size to those detected in the Ovlp cell lines. The 
presence of the DDRPs in the XPE cell extract, in both the systems described in this 
thesis, may suggest a different protein is being assayed. The differences could be due to 
the different extraction protocols used. It may also be due to the differences in the probes 
used for their detection and the binding conditions of the different assays which means 
that different factors may be detected in each of the systems.
Throughout this chapter there has been presentation of the results suggesting 
that both a 50KD and 100KD protein are increased in a CDDP resistant human ovarian 
cell line, OvlDDP. It was therefore important to include in this study another set of 
independent human ovarian cancer cell lines^ A2780 and A2780CP which are well 
studied human ovarian cancer cell lines. Work has been carried out in these cell lines 
suggesting that increased DNA repair may be an important mechanism by which the
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A2780 cells become resistant to CDDP (Lai et al, 1988). The A2780 cell lines were 
studied in the South-Western system. It was found that upon examination of the DDRPs 
only proteins of 25KD and 50KD were present under the conditions which normally 
reflect the differences in the binding to the 50KD and 100KD DDRPs in the Ovl cell 
lines. There was no detectable changes in either of the identified DDRPs in the 
A2780CP cell line extract. It may be that changes do occur in the A2780 DDRPs but 
under the binding conditions used, they are not detectable for the A2780 cell lines. It 
may however be argued that the DDRPs have no involvement in the CDDP resistant 
phenotype of the A2780CP subline and CDDP resistance may occur by some other 
mechanism.
Upon pretreatment of cells with CDDP prior to nuclear extraction, the levels 
of the DDRPs detecting CDDP damage were shown to remain constant both in the 
A2780 cell line and the Ovlp cell line. Evidence from Hirschfeld and co-workers have 
demonstrated an increase in damage recognition protein levels upon pretreatment with 
UV irradiation (Hirschfeld et al, 1990) therefore suggesting that the damage recognition 
complex identified in this study is inducible unlike the DDRPs presented in this chapter.
In summary the results presented in this chapter have identified factors 
recognising DNA damaged with CDDP of 25, 50 and 100KD. It has been found that the 
50KD and 100KD DDRPs show increased levels in a CDDP resistant ovarian cell line 
whilst the 25KD DDRP remains constant between the sensitive parental line and the 
CDDP resistant subline. A study of the DDRPs with single-stranded DNA detects DNA 
binding proteins of similar size to those identified by the platinated double-stranded 
oligonucleotide. It has also been presented that the single-stranded binding proteins are 
increased in the OvlDDP cell line. This has led to the suggestion that the DDRPs 
recognising CDDP damaged double-stranded DNA may be identifying with areas of 
single-strandedness generated around the adducts.
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CHAPTER 5
ISOLATION OF CDDP RESISTANT OVARIAN CANCER CELL 
LINES BY A SINGLE STEP SELECTION
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5.1 INTRODUCTION
It has been suggested that drug resistant tumour cells may arise during the 
development of a tumour and that they may be the reason for treatment failure during 
chemotherapy. Goldie and Coldman, (1984), have described a mathematical model for 
progression to resistance based on theoretical considerations of mutation frequencies and 
the assumption that drug resistant mutants exist or are induced in the tumour cell 
population. In this model, the mutation rate is considered as a measure of the probability 
of occurrence of a new phenotype per cell division. It is therefore obvious that the 
frequency of mutants in the tumour will be directly related to the size of the tumour 
population being considered. The larger the tumour population the greater the 
probability that a drug resistant mutant will have appeared. Conversely, within a small 
population of tumour cells there will be a significant probability that no resistant variants 
will as of yet occurred. The model is based upon the principles of the Luria-Delbruck 
fluctuation analysis, (Luria and Delbruck, 1943), which measures the probability of a 
sub-population not containing a particular mutant phenotype. Thus the fluctuation 
analysis provides a means of testing the stochastic nature of generation of a given 
phenotype.
An understanding of the mechanism of CDDP resistance is necessary for the 
development of a treatment regimen. An effective, although not perfect, way to attain 
this goal, is through studies done in a cell culture model; partly because established cell 
lines are readily demonstrated to be resistant to drugs. A variety of drug selection 
protocols have been used to examine mutations in mammalian cells, (Thacker, 1985). 
The most reliable and quantitative selection procedures have used a single step selection 
protocol that allows the identification of those rare cells that are drug resistant, 
(Thompson and Baker , 1973).
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Generally cell lines which are made resistant to CDDP in vitro have been 
derived by multiple exposures to the drug. These cell lines cannot however be used to 
quantitate mutation frequencies and factors which affect this frequency. It may also be 
expected that cells selected by multiple exposures to drug will exhibit multiple 
mechanisms of resistance. It is therefore important to derive cell lines which are resistant 
to the drug by a single step exposure to the drug. This will allow the frequency of 
variants to be calculated and may yield a range of resistant clones for analysis which may 
be more relevant to resistance ocurring in vivo.
CDDP resistant cells have previously been isolated from the human ovarian 
carcinoma cell line A2780 using repeated selection protocols, (Behrens et al, 1987). 
Three A2780 cell lines have been isolated for resistance to CDDP by this method ( the 
three sublines have an increasing resistance varying from 7.3-39 times more resistant to 
CDDP than the sensitive parental A2780 cell line , Behrens et al, 1987). CDDP resistant 
A2780 cell lines isolated by multiple exposures to CDDP are therefore available, 
however it was important to examine if CDDP resistant clones could be isolated by a 
single step selection protocol.
The choice of concentration at which the CDDP resistant clones are isolated, 
is very important. The concentration of drug is chosen upon analysis of the survival of 
the cells to a particular range of concentrations. The dose response of wild type cells to a 
selecting drug can be carried out in two ways. It can either be measured in terms of 
growth rate or plating efficiency in the presence of the drug. In most cases a plating 
assay is preferable because it allows an evaluation of population heterogeneity 
throughout the dose range. The plating efficiency measurement is also a more sensitive 
indicator of the minimum dose necessary to kill the wild-type cells and to distinguish any 
unusual resistant clones. The typical dose response curve in a plating assay with 
increasing concentration of drug in the medium can be demonstrated with the 
hypothetical survival curve shown below.
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For drug concentrations above a threshold dose of D^, the plating efficiency declines 
over a narrow window of drug concentration. For doses higher than D2 , if the curve tails 
off, as in the dashed lines "A" and "B", discrete surviving colonies may reflect the 
presence of a sub-population of cells. It is therefore important to pick a concentration of 
drug at which the colonies selected would be from area "A" or"B" but not from the 
steeper part of the curve, area "C" (represented by shaded area of the diagram). At area 
"C" of the curve, colonies selected will not ordinarily represent resistant cells; rather, 
they probably reflect the statistical nature of colony formation. We examined the dose 
response curve of A2780 to CDDP over a range of concentrations in the hope that a 
resistant sub-population of A2780 cells would be found. The resistant sub-population 
was isolated as clones of the A2780 cells picked at a specific CDDP concentration.
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One important question concerning such drug resistant variants is whether or 
not they they represent gene mutations in specific genes. In cases where the gene or 
enzyme conferring resistance is unknown, the mutational origin of drug resistance has 
been implied by mutagens inducing an increase in the frequency of resistant cells and by 
the stable retention of the resistant phenotype in the absence of selecting drug over a 
number of cell doubling times, (Thompson and Baker, 1973).
In order to provide evidence for a mutational origin of the isolated clones, the 
effect of the chemical mutagen ethyl methane sulphonate, EMS, on CDDP resistant 
variant frequency has been examined. The type of mutation which would cause cells to 
become resistant to CDDP is not known. It is therefore necessary to choose a mutagen 
which has been shown to cause various types of mutations. This will therefore increase 
the chance of the CDDP resistant phenotype being induced by pretreatment with such an 
agent.
EMS is a monofunctional ethylating agent that has been found to be 
mutagenic in a wide variety of genetic test systems from viruses to mammals, (for 
review, Sega, 1984). Genetic data obtained using microorganisms suggest that EMS may 
produce GC to AT and AT to GC transition mutations (Prakash and Sherman, 1973). 
There is also some evidence that EMS can cause base pair insertions or deletions (Huang 
and Baker, 1976) as well as more extensive intragenic deletions (Schalet, 1977). In 
higher organisms there is evidece that EMS is able to break chromosomes 
(Abbondandolo, 1982). EMS therefore seemed a good choice of mutagen for use in the 
single step selection system. The structural formula of EMS is shown below :
To further substantiate the evidence of the clones being of a mutational origin 
they were subsequently assayed for CDDP resistance after prolonged periods of growth 
in non-selective media.
Studies in the modulation of CDDP resistance are becoming an important 
area of research. In vitro studies suggest mechanisms of resistance to CDDP could 
include increased glutathione levels in tumour cells, (Waud, 1987, Hromas et al, 1987, 
Hamilton et al, 1985), and a capacity for the resistant lines to have an increase in DNA 
repair, (Masuda et al, 1990). It has therefore been the topic of many studies to modulate 
resistance by decreasing the glutathione levels or to inhibit the capacity for DNA repair. 
Buthionine sulfoximin (BSO) inhibits the y  glutamyl synthetase enzyme, an enzyme 
important in the metabolism of glutathione. BSO has been shown to decrease glutathione 
levels in cell lines resistant to CDDP resulting in increased sensitivity of the tumour cells 
to CDDP treatment, (Masuda et al 1990). As discussed in greater depth in the previous 
chapters increased DNA repair has been reported to be included in the way in which 
tumour cells can become resistant to CDDP. It has been reported that the major CDDP 
adducts 1,2 d(GpG) and 1,2 d(ApG) are removed from DNA by the nucleotide excision 
repair pathway in bacteria (Beck et al, 1985; Husain et al, 1985) and in mammalian cells 
(Fraval and Roberts, 1979). This pathway requires DNA polymerase activity for 
restoration of functional DNA. If DNA polymerases are components of a multi-enzyme 
repair complex or catalyze a rate-limiting reaction in the excision repair process, one 
might expect the inhibition of DNA polymerase activity to enhance DNA repair. 
Aphidicolin, an inhibitor of DNA polymerase a, has been shown to increase the 
cytotoxicity of CDDP in CDDP resistant A2780CP cells, (Masuda et al, 1988). These 
studies with BSO and aphidocolin have involved specific CDDP resistant lines which 
have been isolated by multiple rounds of CDDP selection. If resistance modifiers are to 
be used clinically at the time of first treatment in order to eliminate any resistant sub­
populations, then it is important to know how generally effective they are against
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resistant mutants in the tumour cell population. In order to assess this, the effect of 
aphidicolin and BSO on the frequency of cells surviving the single step selection with 
CDDP in a population of A2780 cells not previously exposed to CDDP, has been 
examined.
This chapter analyses the DDRPs from the single isolated resistant clones in 
comparison to clones of the A2780 sensitive parental cell line.
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RESULTS
5.2 SELECTION OF CDDP VARIANTS
5.2.1 Dose Response of A2780 cells to CDDP
Before CDDP resistant colonies of A2780 could be isolated by a single step 
selection, a dose response curve of the A2780 over a wide range of CDDP concentration 
had to be examined.
The surviving fraction of clonogenic cells of the human ovarian tumour cell 
line A2780 after exposure to various concentrations of CDDP ranging from 0-50 jiM is 
shown in Figure 5.1. The concentration of CDDP giving 50% survival (ID^q value) is 
0.6fiM which is comparable with the ED^q observed by others using clonogenic assays 
of A2780 cells (Behrens et al, 1987). At concentrations of CDDP between 15-30|iM, 
a surviving fraction in the range of 2-5x10“^  is observed. This appears as a tail in the 
survival curve, (Figure 5.1), suggesting that a subpopulation of cells exist which are 
resistant to this concentration of CDDP. It is therefore reasonable to choose a 
concentration between 15-30|iM for the isolation of resistant variants. Selection of the 
cells with 15JiM CDDP, the concentration chosen for the selection of the CDDP resistant 
variants, gives a spontaneous frequency of colonies survivingof 3.2 x 10'^ surviving 
colonies per viable cell (refer to Table 5.1 for figures).
A fluctuation analysis was then employed to calculate the frequencies, (Luria 
and Delbruck, 1943). This type of analysis of the data eliminates frequency values being 
affected by daughter colony formation. The equation used for the calculation was:
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Figure 5.1
Dose Response Curve for 24h CDDP Treatment in the A2780 Cell Line
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Dose response curve for 24h CDDP treatment in the A2780 cell line. Error bars shown 
are 95% confidence limits.
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m = -!nPo 
N
m = mutation frequency 
Pq= probability of no mutations 
N = number of cells
Using a fluctuation analysis, a spontaneous frequency of colonies surviving 
15|iM CDDP selection of 1.7 x 10"^ per viable cell is observed. The frequency of 
colonies surviving 15pM CDDP is comparable to known mutation frequencies of other 
mammalian drug resistant lines (Thompson and Baker, 1973).
5.2.2 Pretreatment of A2780 with EMS Prior to CDDP Selection
A large population of A2780 cells (5x10^ cells) were treated with EMS 
(section 2.6.2.2). After the EMS treatment the cells were left for various periods of time 
before the selection protocol began.
It has generally been well documented that after treatment of cells with a 
mutagen, the cells must be maintained for a period under non-selective conditions to 
permit recovery from sub-lethal damage, fixation of any mutations and expression of 
mutant genes which would lead to a drug resistant phenotype, (Thompson and Baker 
1973). Figure 5.2 shows an increase in frequency of resistant colonies between days 1 
and 3 and supports a time dependant delay in the expression of a mutatant phenotype thus 
arguing against any increase in the frequency being due to the selection of EMS resistant
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Figure 5.2
Effect of Pretreatment of the A2780 Cell Line with EMS prior to CDDP Selection
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The number of colonies per viable cell surviving selection with 15p.M CDDP when 
assayed at the time shown after exposure to 2.5mg/ml EMS. Error bars shown are 95% 
confidence limits.
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clones. After the three day period of expression there is a reduction in the frequency at 
which the variants occur. Similar reduction in mutant frequency at longer expression 
times have been observed for other drug resistant selection systems, (Thompson and 
Baker, 1973), and suggests that the CDDP resistant mutants may be selected against 
during non-selective growth conditions.
The resistant colony frequency 3 days after EMS treatment represents at least 
a ten fold increase compared to the spontaneous frequency, (Table 5.1). Thus EMS can 
induce CDDP resistant clonogenic cells, supporting a mutational basis for the resistance.
5.2.3 Maintenance of CDDP Resistant Phenotype
If the cells maintain a drug resistant phenotype in the absence of CDDP 
selection, this would also support a stable genetic alteration leading to the drug resistant 
phenotype. After at least 40 generations of growth in non-selective media, the ID^q 
values to CDDP of various clones independantly isolated after selection in 15fiM CDDP 
were assessed using a short term sensitivity assay, the MTT assay, (Mosmann, 1983). 
Six out of eight clones assayed showed a significant increase in level of resistance to 
CDDP, with up to a seven fold increase in resistance to CDDP in comparison to the 
sensitive parental A2780 cell line, (Figure 5.3). This stable retention of a drug resistant 
phenotype over a period of six months growth in non-selective media is further support 
for a mutational basis of CDDP resistance.
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Table 5.1
EMS induction of CDDP resistant mutants
Treatment Viability^ Mutant frequency^)
None 1.0 3.2x 10“6±  1.5x 10-6 (40)
EMS(C) 0.22 3.4x 10-5±  2.5x 10“5 (10)
(a) Viability is expressed as fraction of A2780 plating efficiency.
(b) The number of colonies surviving selection with 15fiM CDDP per viable cell, with 
95% confidence limits shown. Numbers in parenthesis are number of experiments.
(c) 2.5mg/ml EMS for 2 hours. Data shown are for 3 day expression time prior to CDDP 
selection.
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Figure 5.3
Sensitivity to CDDP of Randomly Selected Independant Clones Surviving 15|xM 
CDDP
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The sensitivities were measured by MTT assay. The parental A2780 cell line had an 
average I D cq  of 0.37|iM using the MTT assay. Resistance factors were calculated as the 
fold increase in the ID5 Q of the lines to CDDP compared to the parental A2780 cell line.
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5.3 Modulation of CDDP Resistance with BSO and Aphidicolin
Previous studies suggest that buthionine sulfoximin (BSO), (Hamilton et al 
1985), and aphidicolin:, (Masuda et al 1990), increase the CDDP cytotoxicity in resistant 
lines by depleting glutathione levels and inhibiting polymerase a  levels respectively. 
The CDDP resistant lines used in these studies were isolated after multiple exposures to 
CDDP hence making it unclear how representative these studies would be to all types of 
resistant mutants surviving CDDP treatment.
Table 5.2 shows the effect of pre-exposure of a population of A2780 cells to 
either BSO or aphidicolin prior to CDDP selection. Analysis of Table 5.2 shows that 
pretreatment with BSO reduces the cell viability in clonogenic assays of A2780 cells as 
has been previously reported, (Louie et al, 1985). Aphidicolin1 also markedly reduced 
the cell viability, in contrast to a previous report, (Masuda et al, 1988). Although the 
fraction of experiments with zero colonies increases in both the BSO and aphidicolin 
studies there is no significant difference in the mutant frequency, when the cell viability 
is taken into account. Both the aphidicolim prior to CDDP treatment and BSO prior to 
CDDP seem only to have a synergistic toxic effect on the cells with no difference in the 
frequency of variants surviving.
5.4 Analysis of Isolated Clones on South-Western System.
Having shown differences in an ovarian cancer cell line which is resistant to 
CDDP in damage recognition proteins, the single step selection clones were examined on 
a South - Western blot for these proteins.
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From Figure 5.4 it can be seen that from various clones isolated after CDDP 
selection, no obvious difference in the specific proteins recognising the CDDP adducts 
was seen. These clones were previously shown to be resistant to CDDP by use of the 
MTT assay (Figure 5.3).
The 100KD protein which is increased in the OvlDDP cell line, (Figure 
5.4a), is not detectable in any of the A2780 cell lines or isolated resistant clones, (Figure 
5.4b). The proteins which seems to be in common within the ovarian cell lines are the 
25KD and 50KD proteins but these do not show any difference in the lines resistant to 
CDDP so suggesting that is not the important protein involved in the mechanism of 
resistance.
A2780 was plated out in drug free medium at a low cell density and clones of 
the cell line were picked and expanded. These clones were included on the South- 
Western blot, (see Figure 5.4). It would be possible to identify clones resistant to CDDP 
by the simple method of picking the clones. If, however, the mutation rate is considered 
of a cell becoming resistant, then hypothetically a sample of 1 0 ^ clones would have to be 
examined before one drug resistant mutant would be found. The CDDP in the system is 
therefore simply acting as a selecting agent. It can be seen that there is no difference in 
the DDRPs in these picked clones.
In comparing the sensitive A2780 cell line with its resistant counterpart 
isolated by multiple exposures in the South - Western system no major differences in the 
specific DDRPs are found. Therefore the resistance phenotype of the A2780 cell lines 
selected for resistance to CDDP either by multiple exposures to the drug or by a single 
step selection is not explained in part by an increase of the DDRPs as is described in 
chapter 4 with the ovarian OvlDDP cell line.
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Figure 5.4
Identification of CDDP-DNA damage binding proteins present in A2780 clones
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South-Western analysis of individual clones of A2780 either selected by 15jiM CDDP or 
by seeding A2780 at a low cell density and picking individual clones (CDDP isolated 
clones shown to be resistant by MTT assay). Damage recognition proteins are identified 
by incubation of lOOjig protein blotted on a nitrocellulose filter with probed CDDP- 
2aG7. Panel A; Lane 1= OvlDDP, Lane 2= Ovlp. Panel B; Lane 1= A2780, Lane 2= 
A2780CP (Behrens et al 1987, Lanes 3 & 4 clones isolated from A2780 seeded out at low 
cell number; lanes 5-7 clones selected for resistance to CDDP by selection with 15p.M 
CDDP. ID^q values of CDDP selected clones examined are Lane 5 = 0.39fiM, Lane 6= 
0.97fiM, Lane 7= 2.4^M. ID50 value of A2780 = 0.37^iM (Lane 1) - ID50 values 
measured by MTT assay.
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5.5 DISCUSSION
Selection of the CDDP variants, generated variants at a frequency of 
3.2x10“^  surviving colonies per viable cell. This frequency was also calculated by the 
use of the Luria-Delbuck fluctuation analysis. A frequency of colonies surviving 15fiM 
CDDP selection of 1.7x10'^ per viable cell is observed using this analysis.
The frequency of variants surviving CDDP was calculated by two seperate 
methods. Whichever method is used to analyse the data, values are generated which are 
comparable to each other. Since the Luria-Delbruck fluctuation analysis is used in the 
data analysis, one can compare calculated frequencies knowing that there is little effect 
from the formation of satellite colonies. Values in the range of 1.7-3.2x10"^ surviving 
colonies per viable cell are observed and these values are comparable with known 
mutation frequencies of drug resistant mutants in mammalian cells, (Ling, 1982).
This leads to the question, are the cells surviving CDDP, mutants, or are they 
simply variants which will survive CDDP in a random manner without representing 
stable genetic changes.
5.5.1 Are CDDP Variants of Mutational Origin?
In the CDDP resistant cells derived in vitro, we do not as of yet know which 
gene is conferring resistance, we are therefore unable to identify a mutation in a specific 
gene. The mutational origin of drug resistance can however be inferred from 
circumstantial evidence such as known chemical mutagens inducing an increase in the 
frequency of resistant cells and by the stable retention of the resistant phenotype in the 
absence of selecting drug over a number of doubling times of the cells.
Pretreatment of A2780 cells with EMS prior to selection with CDDP causes a 
ten fold increase in CDDP resistant colonies three days after EMS exposure (Figure 5.2)
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The increase in frequency of resistant colonies between days 1 and 3 support 
a time dependant delay in the expression of a mutant phenotype and argues against the 
EMS cytotoxicity selecting for EMS resistant clones that are cross-resistant to CDDP. 
The reduction in frequency from day 5 onwards suggests that CDDP resistant mutants 
may be selected against during non-selective growth conditions. Similar reduction in 
mutant frequency at longer expression times have been observed for other drug resistant 
selection systems, (Thompson and Baker, 1973). EMS can thus induce CDDP resistant 
mutants supporting a mutational basis for resistance.
Six out of eight of the isolated clones, assayed by MTT, showed a significant 
increase in the level of resistance to CDDP. As great as seven fold difference to CDDP 
was observed on comparison to the sensitive parental A2780 cell line. The clones which 
did not show a decrease in the sensitivity may simply be representing variant cells which 
are not mutational in origin but may have occurred due to selective growth conditions at 
the time of selection. The stable retention of a drug resistant phenotype over a period of 
six months growth in non-selective media is further support for a mutational basis of 
CDDP resistance.
The isolated clones show an increase in resistance as great as seven fold, 
however upon comparison with the A2780CP derived by multiple exposures to CDDP, 
this fold resistance is not of the same magnitude, (Figure 5.3). The A2780CP cell line 
was derived in vitro by multiple rounds of exposure to CDDP over increasing 
concentrations. It is therefore likely that the "high" resistance to CDDP requires multiple 
changes since within the series of selection steps each step may yield resistant variants. 
Mutants with multiple mechanisms of resistance are highly unlikely to be selected in a 
single step using a high concentration of drug since simultaneous multiple alterations 
would be required for such a mutant to survive this selection and based on known 
mutation frequencies the probability of this occurring would decrease for each clone 
with increasing mechanisms of resistance. Since the clones have been isolated in a single
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exposure to CDDP, it is most likely that their resistance is due to a single type of 
mutation leading to a sub-population of cells which are resistant to the selecting 
concentration of CDDP. The isolated clones are therefore an ideal subpopulation to 
study the mechanism(s) of resistance to CDDP.
5.5.2 Modulation of CDDP Resistance with BSO and Aphidocolin
Studies with BSO in different cell lines have been controversial. Andrews 
and colleagues have found that depleting GSH did not change the character of CDDP 
resistance in two ovarian cancer cell line, COLO 316 and 2008 cells (Andrews et al, 
1989). Additionally depleting GSH did not overcome CDDP resistance in a human head 
and neck squamous carcinoma cell line, (Holden et al, 1985). Other studies, however 
found that GSH content was elevated in the resistant daughter cell line of A2780 and that 
depleting GSH reversed this resistance, (Hamilton et al, 1985). All of these above 
studies were carried out in cells made resistant to CDDP by multiple exposures to CDDP. 
The disagreement in the observations from each study could be due to each different cell 
line having a different mechanism(s) of resistance to CDDP.
Few studies have used single step selection protocols with chemotherapeutic 
drugs to examine the frequency of resistant mutants occurring in a cell population. 
Banranco et al, (1990), have shown that after only one exposure to an LDgg dose of 
melphalan, the surviving population in a human gastric carcinoma cell line was ten times 
more resistant to melphalan treatment one week later: this resistance eventually increased 
almost 50-fold after the cells had received the tenth weekly treatment. The initial 
resistance expressed to melphalan at the time of second treatment was preceded by a two 
fold elevation in GSH values. BSO partially reversed the expression of resistance to 
melphalan by inducing a 60% reduction in GSH content. It was therfore of interest to 
look at the effect of BSO on the frequency at which the CDDP selected variants occur.
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Pretreatment of A2780 with a concentration of BSO of 25(iM has previously 
been shown to deplete glutathione levels by 70-90% with minimal toxicity, (Louie et al, 
1985). Pretreatment with BSO at a concentration of 50pM has been shown to deplete 
GSH in a seperate ovarian cancer cell line again with little cytotoxicity, (Green et al, 
1984), and also in a gastric carcinoma cell line, (Barranco et al, 1990). Pretreatment of 
the monolayer of A2780 with seperate concentrations of 25pM and 50pM prior to CDDP 
selection of the resistant variants and maintenance of the BSO through the CDDP 
selection was presumed to deplete the GSH and keep the cells in a depleted state.
Analysis of the study with pretreatment with BSO prior to CDDP selection, 
shows that there is no significant difference in the frequency of variants surviving. On 
examining viabilities of the A2780 at both concentrations of BSO there is a toxic effect 
to the cells.
For a definitive conclusion to be drawn on the effect of depletion of GSH by 
BSO, it would be necessary to measure the GSH content to show that GSH is depleted 
and the cells are maintained in the depleted state. It has however been previously shown 
that the concentrations used, deplete GSH content in A2780 cells with minimal toxicity. 
From our studies the pretreatment with BSO and the continual exposure to BSO during 
CDDP selection has a toxic effect. At these concentrations of BSO minimal toxicity has 
been observed previously, (Hamilton et al, 1985). The difference could be due to 
pretreatment with BSO and then maintenance during the CDDP selection. The CDDP 
selection in our system is of a much higher and stringent selection, therefore BSO could 
be having a synergistic toxic effect with CDDP on the A2780 cells. This synergy could 
further be investigated by the method of Momparler, (1979), which evaluates drug 
synergy by comparing the survivng fraction produced by drugs individually, with that 
observed when both drugs are used simultaneously. Synergy is established if the 
surviving fraction for two drugs is less than the product of the surviving fractions of the 
drugs individually.
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It therefore can only be concluded that pretreatment of the A2780 cells at 
concentrations of BSO of 25|iM and 50jiM have a toxic effect on the cells and therefore 
no conclusion can be drawn on the frequency at which the variants occur with BSO 
pretreatment.
Previous investigations have suggested a role for DNA polymerase a  in the 
mechanism of resistance to CDDP. Studies have shown that pretreatment of CDDP 
resistant cells with aphidicolim have increased the cytotoxicity of these cells to CDDP. 
Work has been carried out in both the A2780 and A2780CP cell lines and it has been 
shown that aphidicolin causes an increase in the cytotoxicity of A2780CP to CDDP but 
not of the parental A2780 cell line. These reports also verify that aphidicolin is not 
cytotoxic by itself, (Masuda et al, 1988). We found treatment of A2780 cells with 
aphidicolin prior to single step selection with CDDP to have a toxic effect in synergy 
with CDDP on the cell population. We treated A2780 cells, 1 hour prior to CDDP 
selection, with either 2.5fig/ml or 5|ig/ml aphidicolin (both these concentrations have 
previously been reported to be non-toxic to A2780 cells (Masuda et al, 1988). The 1 
hour exposure to aphidicolin has been reported to show an effect on the cytotoxicity of 
A2780CP cells to CDDP, (Masuda et al, 1988), by increasing the cytotoxicity by about 
two fold.
In this work by Masuda, where there was shown to be an effect on the CDDP 
cytotoxicity in resistant cells, the experiments were carried out in the same manner as 
they did for the repair replication experiments, in which inhibition of replication was a 
major factor in the design of the protocol (Masuda et al, 1988). Cells were grown to 
heavy confluence, switched to arginine deficient medium with 2.5% bovine serum 
albumin for three days and then exposed to drug. Only after drug treatment were cells 
split and seeded into tissue culture dishes at low density in complete medium. While this 
routine enables Masuda and co-workers to perform repair replication experiments, it does 
so by imposing severe growth restraints on the cells. This near-total growth arrest may
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account for the lack of cytotoxicity of aphidocolin they observed. In quiescent cells only 
about 5% of the DNA polymerase activity is polymerase a , (Komberg and Gefter,1974). 
Cells would not be expected to be killed by a DNA polymerase a  or 8  inhibitor in the 
absence of appreciable replication or repair. If the A2780 CP cells have a higher level of 
polymerase a  (or 8 ) that is involved in repair but not required for replication, inhibition 
of polymerase activity by aphidicolini could restore the sensitivity of these cells to 
CDDP.
The studies described in this chapter, although following the 1 hour pre­
exposure to aphidicolini during CDDP selection, as above, do not inhibit replication. 
Using the concentrations of aphidicolini, as previously, seem to have a toxic effect upon 
the cells therefore analysis of the figures of variant frequency becomes very difficult.
Therefore in conclusion, both pretreatment of A2780 with either BSO or 
aphidicolin prior to CDDP selection causes a toxic effect on the cells, being in 
diasgreement with previous reports. There can therefore be no final conclusions drawn 
on the effect of reported modifiers to CDDP on the variant frequency.
5.5.3 DDRPs in single step selection clones
The single step selection clones are an ideal model for the examination of 
mechanism(s) of resistance to CDDP. Having analysed an ovarian cancer cell line which 
is resistant to CDDP in a previous chapter and shown that the 100KD DDRP was 
increased, the single step selection clones were studied on a South-Western.
The 100KD DDRP which is increased in the OvlDDP cell line, is not 
detectable in any of the A2780 cell lines or isolated resistant clones. The DDRPs which 
seems to be in common within the ovarian cell lines is the 25KD and 50KD proteins, but 
these do not show any detectable difference in the lines resistant to CDDP so suggesting 
that they are not involved in the mechanism of resistance in this line.
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A difference is observed in the 100KD DDRP in the CDDP resistant 
OvlDDP cell line but not in the A2780CP resistant line or the resistant isolated clones 
suggesting that the development of the resistant phenotype in these separate pairs of 
ovarian cancer cell lines is by different mechanisms.
After this work of the single step selection of resistant A2780 clones was in 
progress, the study of the DDRPs in various cell lines was initiated. At the time of 
choice of A2780 as a model system for the single step selection variants nothing was 
known about the DDRPs. On reflection however, since there is found to be no difference 
in the DDRPs in the CDDP resistant A2780 cell line which was derived by multiple 
exposure to CDDP but with a difference being seen in the resistant Ovl, it may have 
proved more fruitful if the single step selection system had been carried out in the Ovl 
cell line. It would be of interest to generate a single step mutant of the Ovl to examine 
the DDRPs and compare them to the increase in the DDRPs in the OvlDDP - the ovarian 
cell line derived by multiple exposures to CDDP. It is now appropriate to take these 
resistant clones and study other mechanisms of resistance as described in chapter 1 .
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CHAPTER 6
GENERAL DISCUSSION
6.1 DAMAGE RECOGNITION PROTEINS (DRPs)
The following discussion will use two abbreviations;
DRPs - Damage recognition proteins
DDRPs - CDDP damage recognition proteins
The DRPs will be used in the general context of proteins binding and 
recognising damage. The DDRPs will be used in the context of those damage 
recognition proteins identified in the work in this thesis recognising CDDP damage.
A number of studies in the literature have reported the identification of 
damage recognition proteins present in mammalian cells (Lehmann and Kirk-Bell, 1978; 
Feldberg and Grossman, 1976; Huang et al, 1975; Moranelli and Lieberman, 1980; Tsang 
and Kuhnlein, 1982; Chu and Chang, 1988; Toney et al, 1989; Hirschfeld et al, 1990; 
Chao et al, 1991a; Donahue et al, 1990; Andrews and Jones, 1990). Few of the proteins 
identified so far have been shown to direcdy recognise CDDP adducts. Introduced in 
chapter 3, various assays have been employed in the study of such proteins, including 
partial purification of DRPs by phosphocellulose column techniques, gel mobility shift 
assays and South-Western analyses. It is not entirely clear as to whether these techniques 
are identifying similar proteins or whether a broad spectrum of proteins are being 
identified. Eventual purification of these proteins will lead to characterisation of each 
individual protein and comparisons can then be made between them.
Some of the mammalian mutants which have been isolated by their 
sensitivity to UV light are shown also to be sensitive to CDDP. Both xeroderma 
pigmentosum cell lines and CHO mutants have been shown to be defective in the incision 
step of the removal of bulky adducts (Setlow et al, 1969; Thompson et al,1982). It has 
therefore been suggested that CDDP adducts in mammalian cells, may be recognised and 
removed in a similar way to UV adducts, for which evidence suggests an excision repair 
pathway.
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Few studies have presented direct evidence on damage recognition proteins 
recognising CDDP damage. Chu and Chang suggested that the DRPs they identified 
recognising UV damage, may also be important in the recognition of CDDP adducts 
(Chu and Chang, 1988). CDDP, unlike UV, forms a variety of adducts in the DNA. 
Donahue and co-workers therefore tried to identify if damage recognition proteins were 
rcognising specific adducts. They presented evidence to suggest that the recognition 
proteins they identified, bound specifically to l,2d(GpG) and l,2d(ApG) cross-links 
(Donahue et al, 1990) which have previously been demonstrated to be the main adducts 
formed upon reaction with DNA both in vitro and in vivo (Eastman, 1986), (further 
discussion in section 6.3.2). Recently, during the progress of this research, a report 
suggested the ability of damage recognition proteins, present in ovarian carcinoma and 
kidney tubule cells, to bind directly to CDDP damaged DNA (Andrews and Jones, 1991). 
Toney and co-workers have reported on the isolation of cDNAs by screening a human B- 
cell library with CDDP damaged DNA (Toney et al, 1989). Therefore reports are 
beginning to provide evidence that damage recognition proteins exist in mammalian cells 
which recognise and bind to damaged DNA.
Presented in the preceding chapters of this thesis, DDRPs recognising CDDP 
damage have been directly identified in mammalain cells, both by gel mobility shift 
assays and South-Western analyses. Evidence has been presented that these proteins are 
different to those identified in the gel mobility shift assay recognising UV damage (Chu 
and Chang, 1988). It is important to point out, that it is not clear, as to whether the 
protein complexes identified by gel mobility shift assays are the same as those identified 
by South-Western analyses. The South-Western system as described in chapter 4 detects 
damage recognition proteins under entirely different binding and gel conditions 
compared to the gel mobility shift assay. In the South-Western system the proteins are 
separated on a denaturing gel and therefore any secondary structure, as well as 
complexing of the proteins, will be altered. This therefore suggests that in detection of
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these proteins, using this system, secondary structure or complexing are not a critical 
factor. However in the gel shift system the proteins have the ability to run as a complex, 
as the gel conditions are non-denaturing. The proteins detected by this system may 
therefore be present as a complex, or the secondary structure of the proteins may prove 
important in the recognition of the damage. To try to compare the proteins detected in 
both systems some characterisation is necessary. Identification of the DNA-protein 
complex by cross-linking it with a cross-linking agent in the gel shift system will allow 
one to define the specific location of the complex. This can then be isolated and run in a 
second dimension, followed by silver staining of the proteins which will allow one to 
determine the molecular weight of the polypeptide(s). This will allow the comparison of 
the molecular weights of the polypeptides detected between the gel shift system and the 
South-Western system. In theory this may prove a fruitful approach, however in practice 
low levels of the specific factor or other factors which migrate at a similar position to the 
cross-linked DNA-complex may cause problems. An easier way perhaps, to compare the 
DDRPs in the two systems, is by purification steps. Fractionation of the protein extract 
and then analyses of each individual fraction on both the gel mobility shift assay and the 
South-Western assay may allow one to compare any differences or similarities in binding 
in each of the fractions.
6.2 ROLE OF DDRPs
If proteins are present in mammalian cells which recognise damage in the 
DNA then the question of what is the function of this recognition step becomes an issue. 
Is this step merely a signal for the initiation of other cellular processes to occur? The 
following discussion on DDRPs will concentrate mainly on speculative roles of the 
damage recognition proteins identified in this thesis recognising and binding to CDDP 
damage.
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6.2.1 Repair pathway
Evidence has been presented in the literature to suggest that an increased 
DNA repair capacity may be an important mechanism of resistance to CDDP (Andrews 
and Howell, 1991). Cell lines, resistant to CDDP, which have shown to have an increase 
in DNA repair capacity have demonstrated an increase in DNA damage recognition 
proteins (Chu and Chang, 1990; Chao et al, 1991a). A cell strain of XPE has shown the 
absence of a damage recognition protein which has been found in normal human 
fibroblasts (Chu and Chang, 1988). It is believed that CDDP adducts are removed by an 
excision repair pathway. Certain mammalian cell lines defective in an excision repair 
pathway e.g. XP and CHO mutants, are hypersensitive to the effects of both UV and 
CDDP damage. This has led to the link that the DNA damage recognition proteins may 
be repair proteins with functions analogous to the uvrABC present in E.coli. It therefore 
seems apt to propose that the DDRPs presented in this thesis, which recognise and bind 
to CDDP damage, and of which two show an increase in expression in a CDDP resistant 
cell line, may function in a repair pathway. The main criticism of this hypothesis with 
these results is that, the CDDP resistant ovarian tumour cell line which demonstrated the 
increase in the 50KD and 100KD DDRPs has not been fully characterised for its repair 
capacity. It therefore is not known as to whether the CDDP resistant OvlDDP cell line 
shows any difference in repair capacity compared to the parental CDDP sensitive cell 
line. At this stage it is therefore only speculative as to whether the DDRPs are involved 
in the repair of CDDP adducts.
Proteins involved in the excision repair pathway in E.coli have other 
functions as well as the initial recognition of the damage. The uvrABC complex will 
cause nicks at the area surrounding the bulky adducts in the presence of ATP. It 
therefore may provide further evidence for the DDRPs identified in this thesis being
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involved in repair processes, if such activities as a nicking activity in the presence of an 
energy source could be demonstrated.
At this stage it is therefore only speculative as to whether the DDRPs are 
involved in the repair of CDDP adducts They may however be as easily involved in any 
one of the following which will be discussed in turn :
(1) Protection protein
(2) Signal transduction
(3) CDDP adducts mimicking cellular structures
6.2.2 Protection protein
In the theory of evolution some mutations would lead to survival of a fitter 
species. Cells may therefore have evolved proteins which protect damage leading to 
mutations, from its own repair machinery. The protein recognising CDDP damage may 
therefore have been involved in the protection of certain mutations. Specific adducts 
formed by CDDP may therefore be recognised and protected by such proteins, allowing 
the adducts to have a killing effect on the cell. The level of DDRPs, may vary in tumour 
cells compared to normal cells providing a means for CDDP to be selective in the killing 
of tumour cells in comparison to normal cells.
6.2.3 Signal transduction
CDDP may bind to a damage recognition protein which in turn may function 
as a receptor in a signal transduction pathway which will lead to a chain of events 
eventually ending in cell death. This idea suggests that the cytotoxicity of CDDP may 
not only be due to a single event but a complex pathway of events which will eventually
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lead to cell death. The secondary pathways may include events leading to cell death via 
apoptosis or inhibition of replication. The DDRPs may act as a signal which inhibits the 
synthesis of any of the enzymes involved in replication and thus would lead to cell death. 
CDDP along with other anticancer drugs has been shown to activate apoptosis. The 
DDRPs could merely be a signal which causes the arrest of cells in G2  (comparable to 
the RAD 9 gene in Saccharomyces cerevisiae)
6.2.4 CDDP adducts mimicking cellular structures
The normal function of the damage recognition proteins may be an 
involvement in the regulation of tumour cell gene expression - the protein may be an 
example of a transcription factor. If specific CDDP adducts were to mimic natural 
regulatory sequences of genes, the titration of the recognition proteins from these 
important sequences would result in the regulation of gene expression in the tumour cell 
being destroyed. Normal cells in which such gene expression may be less critical, would 
prove to be less vulnerable to the drug. This would give the CDDP a selective killing 
mode in tumour cells compared to normal cells.
It therefore can be concluded that DDRPs recognising CDDP adducts have 
been identified in this thesis but the pathway which is followed after damage recognition 
is not clear cut. Evidence in the literature on enhanced DNA repair capacity in CDDP 
resistant cells showing an increased level of damage recognition proteins and work 
showing that a cell line deficient in excision repair demonstrating an absence in a 
recognition protein is suggestive that these reported damage recognition proteins are 
involved in repair (Chao et al, 1991a; Chu and Chang, 1990). These proteins in the 
literature all recognise UV damage, therefore a direct comparison has still to be made on 
recognition proteins recognising CDDP adducts with the cells ability for DNA repair.
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6.3 SUBSTRATE SPECIFICITY
This thesis has presented damage recognition protein(s) recognising CDDP 
damage in mammalian cells. It however should not be assumed that the DDRPs will only 
recognise CDDP damage. The protein identified by Chu and Chang recognising UV 
damage was also shown to recognise CDDP damage. The recognition protein identified 
in E.coli has been reported to have a broad range of substrates which it recognises. It is 
therefore more likely that a cell will recognise different types of damage. The following 
will discuss substrates that the DDRPs may recognise.
63.1 Single-strandedness
CDDP in binding to DNA has been reported to form regions of single- 
strandedness (Sundquist et al, 1986). Reports from work carried out in bacteriophage T4 
have suggested a protein, gene 32 protein, which normally binds to single-stranded DNA, 
to bind to double-stranded DNA modified with CDDP (Toulme et al, 1983). This 
therefore suggests that in the bacterial system at least, a protein may be present, which 
recognises areas of single-strandedness which can be caused by a local opening of 
several bases when DNA reacts with CDDP. Recent evidence has suggested the 
involvement of human single-stranded binding proteins, normally involved in eukaryotic 
DNA replication, also to be involved in excision repair (Coverley et al, 1991). The 
authors have suggested the single-stranded binding protein to either be involved in a 
recognition step of the damage or to be involved in the recruitment of DNA polymerase 
onto incised or gapped DNA. The results presented in the previous chapters suggest that 
two of the three DDRPs recognising CDDP damage may be single-stranded binding 
proteins. Antibodies have now been isolated for different subunits of the hSSBs (Kenny
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et al, 1990). Experiments using these antibodies in the gel shift system are beginning to 
provide evidence that band B1 may represent hSSB (personal communication, 
Dr.C.Clugston, Dept Medical Oncology, University of Glasgow). The generation of 
areas of single-strandedness may prove to be an important structural determinant in the 
type of damage recognised by the DDRPs.
CDDP is known to bind to DNA and generate a disruption over 4-5 base 
pairs (Anin and Leng, 1990). Presented in chapter 4, oligonucleotides with 3 base pair 
and 7 base pair mismatches were used as substrates in an attempt to define if the DDRPs 
simply bind to areas of disruption or whether it is some type of structures the CDDP 
generates which is recognised. Mismatch correction catalysed in vitro by human cell 
extracts has been reported (Glazer et al, 1987). Although the individual steps in the 
process have not been defined, proteins recognising G.T, A.C, T.T, T.C mispairs have 
been reported in human cells (Jiricny et al, 1988; Stephenson and Karran, 1989). Under 
the conditions which detects binding to the platinated oligonucleotides in the ovarian 
tumour cells, binding to the mismatch oligonucleotides does not occur. This therefore 
suggests that the DDRPs being detected in the previous chapters recognise some 
structural motif generated by the CDDP and not only areas of base pair disruption.
6.3.2 Specific adducts as substrates
Both CDDP and TDDP are known to bind to DNA and cause a spectrum of 
adducts. TDDP cannot form intra-strand cross-links between adjacent nucleotides and 
this has therefore led to the suggestion that the d(GpG) and d(ApG) adducts formed 
uniquely by CDDP are responsible for its cytotoxic activity (Pinto and Lippard, 1985). It 
has therefore been suggested that if these adducts are the important lesions, there may be 
a damage recognition protein present in mammalian cells recognising the specific type of 
adduct. Donahue and co-workers have identified a damage recognition protein
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recognising specifically 1,2 intrastrand d(GpG) and d(ApG) cross-links formed only by 
CDDP (Donahue et al, 1990). If this DDRP were involved in repair then it may be 
hypothesized that tumour cells contain lower levels of the DDRP recognising these major 
adducts than normal cells. This would allow CDDP to be selective in its mode of cell 
killing. The other adducts formed both by CDDP and TDDP will not be repaired and 
thus will be cytotoxic to both cell types. It would be important to determine therefore if 
the DDRPs identified in the previous chapters recognising CDDP damage, are 
recognising specific types of adducts or structures which are acting as a signal for the 
binding of the DDRPs.
63.3 Recognition of other damage by the DDRPs
It may be likely that the DDRPs also recognise adducts induced by UV 
irradiation, since it has been reported that cells hypersensitive to UV are also 
hypersensitive to CDDP, therefore suggesting that both these damaging agents are 
recognised by a similar pathway. Other agents which induce bulky damage or are cross­
linkers e.g mitomycin C (MMC) may also be recognised by the DDRPs. There can 
therefore be no conclusions definitively drawn on the damage the DDRPs are 
recognising. It will be necessary to carry out experiments in both the assays described in 
this thesis, to determine whether DNA damaged with other types of agents will compete 
for the binding of the DDRPs recognising the CDDP damage. From the results presented 
in this thesis it can only be said that the DDRP binds to CDDP damage. It however 
cannot be concluded that the DDRPs are specific for CDDP adducts.
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6.4 INVOLVEMENT OF DDRPs IN CDDP RESISTANCE
DNA repair has been reported to be involved in the generation of the CDDP 
resistant phenotype (refer to section 1.9). If the DDRPs are the first step in the 
recognition of damage, prior to recruitment of other repair enzymes, then it is reasonable 
to hypothesise that cell lines resistant to CDDP may exhibit increased levels of DDRPs. 
Chu and Chang have recently shown that CDDP resistant Hela and HT1080 cells have 
increased levels of DRPs recognising UV damage (Chu and Chang, 1990). Another 
report has demonstrated that a Hela cell line resistant to CDDP shows increased levels of 
DRPs recognising UV damage (Chao et al, 1991a). In both these reports the increased 
levels of DRPs have been correlated with an enhanced capacity for DNA repair in the 
CDDP resistant cell lines. Evidence therefore exists to suggest that increased levels of 
DRPs recognising UV damage are present in CDDP resistant cell lines which have shown 
to have an enhanced capacity for DNA repair.
There is however, at present no direct evidence in the literature on the 
increase of DRPs recognising CDDP damage in CDDP resistant cell lines. Presented in 
chapter 4 of this thesis, a difference is seen in the proteins binding to a CDDP damaged 
DNA probe, by South-western analyses in a CDDP resistant ovarian tumour cell line, 
OvlDDP. Little is known about this pair of cell lines, unlike the extensive research 
reported in the literature in the A2780 cell line. Before any conclusions can be drawn as 
to whether the increase in DDRPs are involved in the mechanism of repair leading to 
resistance, some studies in the examination of DNA repair would have to be undertaken 
in this pair of cell lines. For conclusive results on DDRPs being involved in DNA repair, 
the proteins would have to be cloned and reintroduced into DNA repair defective 
mutants. If the mutants returned to their wild type phenotype, then the DDRPs can be 
said to be involved in DNA repair.
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To determine if the increase in the DDRPs occurred frequently, another pair 
of ovarian tumour cell lines, A2780, sensitive and resistant counterparts, were analysed 
for the DDRPs. The results presented in this thesis on the analysis of these cell lines 
show that under the binding conditions used to detect the difference in the Ovl cell lines, 
no difference was apparent. This therefore suggests that the DDRPs do not play a role in 
the mechanism of resistance to CDDP in this ovarian tumour cell line. Many other 
mechanisms of resistance have been suggested for the way in which a tumour cell 
population becomes resistant to CDDP (see section 1.8). The A2780 cell line is therefore 
likely to express its resistance through any one of these mechanisms or a combination, 
although the work presented here demonstrates the DDRPs are unlikely to be a major 
factor in the generation of CDDP resistance in A2780 cells.
6.4.1 DDRPs in single step selection clones
Most studies on the mechanisms of resistance reported in the literature, have 
been carried out in cell lines in which their resistance was derived by multiple exposures 
to the drug. This method of isolation of CDDP resistant lines is more likely to generate 
cell lines exhibiting multiple mechanisms of resistance. These lines would therefore 
provide difficulties in the examination of independent mechanisms of resistance 
generating the CDDP resistant phenotype. It was therefore important to derive cell lines 
which were resistant to CDDP by a single-step exposure to the drug. This type of 
isolation of a CDDP resistant clone may yield a range of resistant clones for analysis 
which may be more relevant to resistance occurring in vivo.
Chapter 6 presents the isolation of such resistant clones from the A2780 
tumour cell line and the frequency at which they occur in the population. These clones 
allowed the analysis of the DDRPs in the generation of the CDDP resistant phenotype 
without the influence of other factors. Of the clones examined there was no detectable
179
difference in any of the DDRPs, under the binding conditions that demonstrate the 
difference in the 50KD and 100KD in the OvlDDP. This work on the isolation of the 
single step selection clones was initiated at the beginning of the project prior to any 
difference being shown in the DDRPs of the CDDP resistant cell line OvlDDP. On 
reflection, it may have proved more beneficial to isolate clones by single step selection to 
CDDP of the Ovlp sensitive parental cell line. The isolated resistant clones, 
although not showing any change in DDRPs, may express their resistant phenotype by 
other mechanisms of resistance and thus may provide excellent models for the 
examination of the phenotypes. The single step selection clones and the resistance 
mechanisms generated within them are more likely to be clinically relevant than the 
mechanisms of resistance to CDDP defined in cell lines made resistant to CDDP by 
multiple exposures to the drug.
6.5 CLINICAL RELEVANCE OF DDRPs
6.5.1 Use of in vitro assays for measurements in tumours
The mechanisms of resistance studies so far in the literature have all been 
reported from work carried out in cell lines. It is therefore not entirely clear as to how 
much relevance these studies have in vivo. The assays used in cell lines to study 
resistance e.g UDS, plasmid reactivation, accumulation studies cannot be applied to 
tumour material. We are therefore left with the question of whether the mechanisms of 
resistance studied in vitro have any relevance to those studied in vivo. The type of in 
vitro assays presented in this thesis can however be applied to tumour material thus 
allowing one to determine the importance of DDRPs in vivo and not just in in vitro 
derived cell lines.
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6.5.2 Involvement of DDRPs in tumorigenecity
It has been reported that CDDP may be selective in the killing of tumour 
cells by the cell's differential ability to repair certain types of adducts (Ciccarelli et al, 
1985). It has generally been hypothesized that tumour cells are less likely to be involved 
in repair mechanisms than normal cells. In the development of a cell line from a tumour 
it may be hypothesized that it has very low levels of repair, therefore if the identified 
DDRPs were involved in DNA repair, it may be suggested that tumour cells express 
lower levels of the DRPs than normal wild-type cells. The resistant OvlDDP cell line in 
these terms may be showing levels of DDRPs comparable with wild-type normal cells. 
The DDRPs may therefore per se not be involved in the development to resistance but in 
the development of tumour cells. If this hypothesis were true, then an explanation for no 
differences occurring in the DDRPs of A2780 may be in the responsiveness of the 
tumour in vivo.
6.5.3 Modulation of resistance
If tumours become resistant to chemotherapeutic drugs, modulation becomes 
an issue. Studies in cell lines resistant to CDDP have suggested modulation through the 
DNA repair pathways by agents such as aphidocolin or through the GSH pathway by 
BSO (refer to section 5.1). Problems would occur with these type of modulators in vivo. 
The aphidicolin and BSO would not only affect the tumour cells but also cause effects 
on the normal cells which could prove cytotoxic to the cells, therefore not only killing the 
tumour cells but also the normal cells. If the DDRPs are involved in a recognition step 
prior to other events occurring and are important in mechanisms of resistance to CDDP in 
vivo, they may prove a potentially important target in the modulation of CDDP resistance 
occurring in tumours. Both systems described in this thesis may prove potentially
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important in the screening of compounds for modulation of binding of the DDRPs if they 
were proven to be important in the CDDP resistant phenotype.
6.6 CONCLUSIONS AND FUTURE DIRECTIONS
This thesis has presented proteins which recognise and bind to CDDP 
damaged DNA. The role of these recognition proteins has not yet been defined. It has 
been suggested that they could be involved in a DNA repair role, however there is no 
evidence to suggest that they are not involved in protection mechanisms, signal 
transduction pathways or as regulatory proteins of tumour cell gene expression. The 
DDRPs are not likely to recognise CDDP only, but some structural motif which is 
generated by CDDP and also other damaging agents. CDDP has been reported to bind to 
DNA and generate single-stranded regions of DNA around the adducts. Evidence is 
presented to suggest that the DDRPs may be recognising these regions of single- 
strandedness.
The involvement of the DDRPs in the generation of the CDDP resistant 
phenotype in an ovarian tumour cell has been presented. If the DDRPs are important in 
vivo then they may provide a potential target for modulation.
It is necessary for the DDRPs to be isolated and characterised before any 
definitions can be made on its role both in vitro and in vivo. Once the protein has been 
characterised, antibodies can be raised which may eventually have clinical applications if 
the DDRPs are demonstrated to be important in vivo.
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Abstract
We have shown that cis diamminedichloroplatinum-(II) (DDP) resist­
ant mutants can be isolated from the human ovarian carcinoma cell line 
A2780 using a single-step selection protocol with DDP. DDP resistant 
colonies were calculated to be present at a frequency of 1.7 x 10_6/viable 
cell using a fluctuation analysis. The mutational origin of these surviving 
colonies is inferred by the fact that their frequency is increased by 
treatment of the A2780 cells with the chemical mutagen ethyl methane- 
sulfonate, with a maximum frequency observed after a 3-day expression 
time. Independently isolated clones maintain, in the absence of selection, 
a DDP resistant phenotype up to 7-fold more resistant than the parental 
A2780 cells. The resistance modifiers aphidicolin and buthionine sulfox- 
imine have no effect on the frequency of DDP resistant mutants. There­
fore neither of these drugs appears to have an effect on increasing the 
sensitivity of DDP resistant mutants existing in a cell population prior 
to DDP exposure.
Introduction
D D P 3 is an effective chemotherapeutic agent against a variety 
o f tumor types (1). However, in many cases initial response is 
followed by relapse and failure o f tumors subsequently to re­
spond to chemotherapy. This has led to the suggestion that 
cells within the tumor have acquired specific cellular resistance 
mechanisms, causing these cells to have a selective advantage 
during treatment and thus to eventually predominate in the 
tumor (2). A variety o f mechanisms o f resistance to D D P  have 
been suggested in cell lines selected in vitro for resistance (3 -  
5). M ost o f these lines have been isolated after prolonged 
exposure to D D P , leading to the possibility o f multiple mech­
anisms occurring together. It is not clear if  these resistant cell 
lines will have mechanisms relevant to clinical resistance ac­
quired during chemotherapy. Goldie and Coldman (6 ) have 
described a mathematical model for progression to resistance 
based on theoretical considerations o f mutation frequencies and 
the assumption that drug resistant mutants exist or are induced 
in the tumor cell population. Using multiple exposure selection  
protocols it is not possible to measure the frequency o f resistant 
variants in a cell population prior to D D P  exposure or factors 
affecting this frequency.
A variety o f drug selection protocols have been used to 
examine drug resistance mutations in mammalian cells (7, 8). 
The most reliable and quantitative selection procedures have 
used single step selection protocols that allow the identification 
o f those rare cells that are drug resistant (8 , 9). One important
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question concerning such drug resistant variants is whether or 
not they represent gene mutations in specific genes. In cases 
where the gene or enzyme conferring drug resistance is un­
known, the mutational origin o f drug resistance has been in­
ferred by mutagens inducing an increase in the frequency of 
resistant cells and by the stable retention o f  the resistant phe­
notype in the absence o f selection (8 , 9).
D D P  is used widely in the treatment o f ovarian cancers (10). 
D D P  resistant cells have previously been isolated from the 
human ovarian carcinoma cell line A 2780 using repeated selec­
tion protocols (11). We have used this line to assess whether 
D D P  resistant lines can be isolated using a single-step selection  
protocol. In order to provide evidence for a mutational origin, 
the effect of the chemical mutagen EM S on D D P  resistant 
variant frequency has been examined. Isolated lines surviving 
D D P  have subsequently been assayed for D D P  resistance after 
prolonged periods o f growth in nonselective media. Drugs 
which inhibit specific drug resistance mechanisms have been 
suggested as a means o f increasing response o f resistant tumors 
to chemotherapy or o f increasing the efficacy o f chemotherapy 
at first treatment (12). Aphidicolin (13) and BSO (14) have 
been suggested to increase the D D P  cytotoxicity in resistant 
lines by inhibiting polymerase a  mediated D N A  repair and 
depleting glutathione levels, respectively. The D D P  resistant 
lines used in these studies were isolated after multiple selections 
with D DP; therefore it is unclear how representative these lines 
are o f all possible resistant mutants that survive D D P  treat­
ment. If resistance modifiers are to be used clinically at the 
time o f first treatment in order to eliminate any resistant 
subpopulations, then it is important to know how generally 
effective they are against resistant mutants in the tumor popu­
lation. In order to assess this, we have examined the effect of 
aphidicolin and BSO on the frequency o f cells surviving the 
single-step selection with D D P  in A 2780 cells not previously 
exposed to D D P.
Materials and Methods
Cell Lines and Routine Culture Conditions. A2780, an ovarian carci­
noma cell line derived from an untreated patient, and A2780CP, a 
DDP resistant line produced by exposure of the A2780 line to multiple 
increasing concentrations of DDP (11), were the kind gifts o f Drs. R. 
F. Ozols and T. C. Hamilton, Fox Chase Cancer Centre, Philadelphia, 
PA. Both cell lines were maintained as monolayers in RPMI 1640, 
supplemented with 10% (v/v) fetal bovine serum and 0.005 unit/ml 
penicillin at 37°C in a 5% C 0 2-95% air atmosphere. All lines were free 
of Mycoplasma contamination.
Drug Selection. A2780 cells were plated at 2 x  106 cells/75-cm 2 flask 
for 5 -50  pM DDP concentrations or at 103 for 0 -5  yuM DDP concen­
tration. After 24 h the cells were treated with various doses of DDP for 
24 h, washed twice with phosphate-buffered saline, and incubated in 
RPMI for 2 weeks; surviving colonies of more than 100 cells were then 
counted. The A2780 cells had a plating efficiency of about 20% under 
these conditions. The frequency of resistant colonies was calculated as
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surviving colony number per viable cell or using fluctuation analysis 
(15) based on the number o f cultures containing no surviving colonies. 
This latter analysis avoids any uncertainties due to daughter colony 
formation.
Mutagen Exposure Prior to DDP Selection. Cells (5 x  106) were 
treated with 2.5 mg/ml EMS (Sigma) for 2 h in serum free medium. 
This concentration o f EMS gave 22% survival of the A2780 cells. At 
various times after the exposure to EMS the cells were selected at 2 x  
106/75-cm : flask in 15 DDP as described above.
Aphidicolin and BSO Treatment. Aphidicolin (Sigma; 2.5 and 5 gg/ 
ml) was added 1 h prior to DDP and maintained during the DDP  
selection. These are conditions previously shown to inhibit removal of 
DNA bound platinum in A2780 cells treated with DDP (13). For BSO 
treatment. BSO (Sigma) was added 24 h prior to DDP and maintained 
during the DDP selection. Concentrations o f BSO used (25 and 50 ^m) 
were previously shown to deplete glutathione levels in A2780 cells and 
increase the sensitivity of A2780CP cells to DD P in short term cell 
viability assays (14).
MTT Drug Sensitivity Assays. Cells in exponential growth were 
plated out at 103/\vell in medium in 96-well plates and incubated for 3 
days. Cells were then incubated for 24 h in medium containing 10-4 to 
6.4 x  1(T9 M D D P and subsequently for 4 days in drug free medium. 
Metabolically active cells were measured using 3-(4,5-dimethylthiazol- 
2-yl)-2,5-diphenyltetrazolium bromide reduction (Sigma) as a measure 
of cell viability as described previously (16).
Results and Discussion
Selection of D D P  Variants. The surviving fraction o f clono- 
genic cells o f  the human ovarian cell line A 2780 after exposure 
to different concentrations o f  D D P  is shown in Fig. 1. The 
DDP ID S0 was 0.6 mm which is comparable with the ID 50 
observed by others using clonogenic assays o f A 2780 cells (11, 
17). At concentrations o f  D D P  between 15 and 30 gM a surviv­
ing fraction in the range 2 to 5 x  10~6 was observed. This 
appears as a tail in the survival curve suggesting that a subpop­
ulation o f cells are resistant to this concentration o f D D P  (Fig. 
1). Selection o f the cells with 15 gM D D P  (Table 1) gives a 
frequency o f 3.2 x  10-6 surviving colonies/viable cell. U sing a 
fluctuation analysis (15) a spontaneous frequency o f colonies 
surviving 15 gM  D D P  selection o f 1.7 x  10_6/viable cells was 
observed. This is a frequency comparable with known mutation  
frequencies for drug resistant mutants in mammalian cells (18). 
This questions whether the cells surviving D D P  are mutants or 
simply variants which will survive D D P  in a stochastic manner 
but do not represent stable genetic changes.
If the cells surviving 15 gM  D D P  are mutational in origin, 
then the frequency o f  these resistant cells should be increased 
with known mutagens. The requirement for an expression time 
of cells after mutagen treatment to allow phenotypic expression  
of resistance m echanism s has been well documented (9). The 
A 2780 cells were treated with the chemical mutagen, EM S, and 
at varying times after exposure selected with 15 D D P . A 
maximum increase in D D P  resistant colonies was observed 3 
days after EM S exposure (Fig. 2). The increase in frequency of 
resistant colonies between days 1 and 3 supports a time de­
pendent delay in the expression o f  a mutant phenotype and 
argues against the EM S cytotoxicity selecting for EM S resistant 
clones that are cross-resistant to D D P . The reduced frequency 
observed at later tim e points suggests that D D P  resistant mu­
tants may be selected against during nonselective growth con­
ditions. Similar reductions in mutant frequency at longer 
expression tim es have been observed for other drug resistance 
selection systems (9). The resistant colony frequency 3 days 
after EM S treatment represents at least a 10-fold increase 
compared to the spontaneous frequency (Table 1). Thus EM S
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Fig. 1. Fraction of A2780 cells surviving 24-h exposure to the shown concen­
tration o f DDP. Bars, 95% confidence limits.
T able 1 EMS induction of DDP resistant mutants
Treatment Viability" Mutant frequency*
None 1.0 3.2 ±  1.5 x  10“6 (40)
EMS‘ 0.22 3.4 ±  2.5 x  10-5 (10)
“ Viability is expressed as fraction o f A2780 plating efficiency.
* The number of colonies surviving selection with 15 DDP per viable cell, 
with 95 % confidence limits shown. Numbers in parentheses, number of experi­
ments.
c EMS (2.5 mg/m l) for 2 h. Data shown are for 3-day expression time prior to 
DD P selection.
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Fig. 2. Number o f colonies surviving selection with 15 um DDP per viable cell 
when assayed at the time shown after 2-h exposure to 2.5 mg/ml EMS. Bars, 
95% confidence limits.
can induced D D P  resistant clonogenic cells, supporting a mu­
tational basis for the resistance.
If the cells maintain a drug resistant phenotype in the absence 
o f D D P  selection this also would support a stable genetic 
alteration leading to the drug resistant phenotype. After at least 
40 generations o f  growth in nonselective media, the IDsoS to 
D D P  o f clones independently isolated after selection in 15 /zM 
D D P  were assessed using a short-term sensitivity assay, the 3- 
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide as­
say. M ost o f the clones assayed showed a significant increase 
in level o f resistance to D D P , up to 7-fold greater than the 
parental A 2780 cells (Fig. 3). This stable retention o f a drug 
resistant phenotype is further support for a mutational basis of 
D D P  resistance. However, the clones did not show as great an 
increased resistance as the A 2780C P cell lines, which had been 
isolated by multiple rounds o f D D P  selection.
Treatment with BSO and Aphidicolin. We have shown that 
D D P  resistant colonies can be isolated from the human ovarian
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Fig. 3. Sensitivity to DDP of randomly selected independent clones surviving 
15 D D P were measured using the 3-(4,5-dimethylthiazol-2-yI)-2,5- diphenyl- 
tetrazolium bromide assay (16). The parental A2780 cell line had an average ID50 
of 0.37 hm using the 3,(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro­
mide assay. Resistance factors were calculated as the fold increase in the 1D50 of 
the lines to D D P compared to the parental A2780 cell line. ■ , A2780; El, 
A2780CP; □ , DDP selected clones. Bars, 95% confidence limits.
Table 2 Effect o f BSO and aphidicolin on DDP resistant mutant frequency
Modifier Viability"
Fraction of 
experiments 
with zero 
colonies
Mutant
frequency*
Mutant 
frequency 
using fluctuation 
analysis
None 1.0 3 4 /6 8 5 .2  x  10~6 
(1 .1  x  10“6)
1.7 x  10“6
2 .5  pg/m\ aphidicolin 0 .3 8 2 2 /3 0
tO 
£*■
£»• 
Ln
X 
X
O 
O
1 
1 2 .0  x  10~6
5 Mg/ml aphidicolin 0 .1 7 2 1 /2 3 1.3 x  10~6 
(9  x  1 0 -7)
1.3 x  10 “6
2 5  /iM BSO 0.41 2 6 /3 0 2 .6  x  10“6 
(1 .9  x  10“6)
8 .7  x  1 0 -7
5 0  pM BSO 0 .2 0 2 1 /2 5 8 .3  x  10“6 
(4 .8  x  10~6)
2.1 x  10~6
a Viability is expressed as fraction o f A2780 plating efficiency.
* The number of colonies surviving selection with 15 p\\ DDP per viable cell. 
Numbers in parentheses, SEM.
cell line A 2780 by a single exposure to D D P. The low frequency 
o f these resistant cells, their induction by treatment with the 
mutagen EM S, and the stable retention o f the drug resistant 
phenotype support their mutational origin. Subpopulations of 
cells mutated at genes conferring resistance to chemotherapeu­
tic drugs have been suggested to be the cause o f eventual 
chemotherapy treatment failure for many types o f tumors. A 
variety o f possible resistance mechanisms have been suggested 
for cells resistant to D D P  (2-5). Depletion o f intracellular GSH  
by treatment with BSO, a potent inhibitor o f 7 -glutamyl cys­
teine synthetase, has been shown to increase the sensitivity of 
D D P  resistant A 2780C P cells (13, 19). Increased D NA  repair 
levels have been shown in D D P resistant cells. Aphidicolin, an 
inhibitor o f D N A  polymerase «, has also been shown to increase 
the cytotoxicity o f D D P in D D P resistant A2780CP cells (17). 
These studies have involved specific D D P resistant lines which 
have been isolated by multiple rounds o f D D P  selection. The 
effect o f these resistance modifiers on the frequency o f D D P  
resistant cells in a population prior to D D P selection has thus 
far not been studied.
Table 2 shows the effect o f exposure o f cells to aphidicolin 
or BSO prior to D D P selection. As shown BSO reduces the 
cell viability in clonogenic assays o f the A2780 cells, as has 
previously been reported (19). Aphidicolin also markedly re­
duced the cell viability o f A2780, in contrast to a previous 
report (17). Although both the BSO and aphidicolin treatments 
increase the number o f experiments without D D P  resistant
colonies, when account is made o f  the reduction in viability 
there are no significant differences in the mutant frequencies. 
Therefore neither BSO nor aphidicolin has an effect on increas­
ing the sensitivity o f  D D P  resistant mutants existing in the cell 
population at time o f exposure to D D P , although there is a 
combined cytotoxic effect.
Few studies have used single-step selections with chem other­
apeutic drugs to examine the frequency o f  resistant mutants 
occurring in a cell population. Barranco et al. (20) have shown 
that a single exposure to melphalan (99% lethal dose) increased 
10- to 50-fold resistance to the same agent 1 week later. The 
authors suggest that this is due to increased G SH  levels in the 
cells and showed that BSO can partially reverse the resistance 
to melphalan. At present we are examining m echanism s o f  
resistance to D D P  in the single-step selection clones isolated, 
including alterations in drug accumulation, drug inactivation, 
and repair o f induced lesions. However, since BSO has no effect 
on the frequency o f D D P  resistant mutants, this would suggest 
that GSH  levels are not involved in resistance o f these lines.
Both BSO and aphidicolin have previously been reported to 
increase the sensitivity o f D D P  resistant A 2780 cells (13, 14, 
17). These cells were selected after multiple exposure to D D P  
and may represent a different mutant type than that isolated by 
the single-step procedure used in the present study or may 
represent only a small subgroup o f all possible mutant types. 
Which o f the several possible mechanisms o f D D P  resistance 
have the highest probability o f being selected for by D D P  in 
human tumors is unclear. However, the type o f single-step  
selection used in the present study will provide a means o f  
examining the efficacy o f modulators o f D D P  resistance to 
reduce the D D P  resistant mutant frequency in cells not previ­
ously exposed to D D P.
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